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Oxidative stress, lipid peroxidation, and endotoxaemia with cytokine-mediated injury 
have been implicated as factors in the pathogenesis of non-alcoholic fatty liver 
disease (NAFLD). The degree of insulin resistance together with co-existing 
inadequacies of vital antioxidant defence mechanisms may be important 
determinants of progression to fibrosis in patients with non-alcoholic steatohepatitis 
(NASH). Current therapies are targeted at improving insulin sensitivity as well as 
addressing hepatic repair including anti-inflammatory strategies. Anti-oxidants 
remedies have also been tested but the role of selenoenzymes with antioxidant action, 
namely thioredoxin reductase 1 (TR1) and glutathione peroxidase 1 (GPX1) have 
been ignored.  
 
The aim of this thesis is to investigate the role of selenium in the pathophysiology of 
NAFLD both in vitro and in vivo. The in vitro studies used cell lines representing the 
cell types involved in the disorder; hepatocytes (C3A line) and hepatic stellate cells 
(LX-2 line). In order to assess the influence of selenium status and selenoenzymes 
expression on the pathogenesis of NAFLD it was necessary to develop a culture 
system which allowed good cell viability in selenium free culture medium. This was 
achieved by the use of an insulin and transferrin (IT)-supplemented medium which 
importantly was free of any animal serum additions. Using this IT culture medium, 
selenium addition (as selenite) produced a significant increase in the expression of 
GPX1 and TR1 in both C3A and LX2 cells. TR1 and GPX1 were expressed at 
similar levels in both C3A and LX-2 cells. 
 
It was also necessary to develop an in-vitro model for fat loading C3A cells to mimic 
fatty liver pathophysiology. Two models of fat loading were investigated. One model 
used lactate, pyruvate, octanoate and ammonium (LPON). LPON has been 
previously used to increase the functionality of C3A cells but it was observed that fat 
droplets accumulated in these LPON treated cells. Dissection of the agents in the 
LPON revealed that octanoate was the factor that increased the triglyceride 
 XVI 
accumulation. Interestingly, octanoate also increased the expression of TR1 and 
GPX1, suggesting that it could induce oxidative stress leading to the induction of 
selenoenzymes to afford a protective defence mechanism. In the second model, 
oleate and/or palmitate were used to fat-load C3A cells. These cells had significantly 
higher triglyceride content than the LPON-fat-loaded cells. However, oleate and/or 
palmitate treatments did not increase the expression of either TR1 or GPX1 in C3A 
cells suggesting perhaps these cells were not under oxidative stress. LPON and 
oleate/palmitate were also capable of fat loading LX2 cells. 
 
Selenium-supplementation of C3A and LX-2 cells efficiently protected (measured by 
their lactate dehydrogenase retention) them from oxidative damage induced by t-
butylhydroperoxide. This suggests that selenium supplementation through its 
incorporation into selenoenzymes could protect the cells from the oxidative damage. 
 
The role of selenium was also investigated in the regulation of α-1 pro-collagen 
mRNA expression. In LX-2 cells, the expression of α-1 pro-collagen mRNA was 
unaffected by the selenium status of the cell. Similarly the selenium status of C3A 
cells had no effect on modifying α-1 pro-collagen mRNA of LX2 cells when co-
culture or conditioned medium experiments were performed. These results suggest 
that LX-2 cells were already largely activated and at a stage unable to be ameliorated 
by selenium treatment. In contrast, studies on C3A cells revealed that TGF-β1 
(common inducer of α-1 pro-collagen mRNA in hepatic stellate cells) dramatically 
increased the expression of α-1 pro-collagen mRNA in C3A cells to the levels 
observed in LX-2 cells. More interestingly, selenium supplementation of C3A cells 
notably decreased α-1 pro-collagen mRNA expression in response to TGF-1. 
 
In the in vivo study, plasma selenium in type 2 diabetics (high risk of developing 
NAFLD) were inversely related to the body mass index and in most patients 
selenium levels were below that required to maximally express GPX1 in red cells. 
Furthermore, type 2 diabetics had lower plasma selenium levels compared to the 
healthy control group. Collectively, this suggests that in the UK population, obesity 
 XVII 
is a risk factor for both insulin resistance and decreased selenium status leading to 
sub-optimal antioxidant protection. 
 
In conclusion, this study provides evidence that selenium through increasing the 
expression of selenoenzymes is beneficial in protecting liver cells from oxidative 
stress.  Furthermore, selenium is capable of suppressing α-1 pro-collagen mRNA 
expression in hepatocytes although not in activated hepatic stellate cells. Taken 
together these data support the view that suboptimal selenium intake in the UK may 





1 CHAPTER ONE 
 
     INTRODUCTION 
 
1.1 Non-alcoholic fatty liver disease (NAFLD) 
Patients with hepatic fibrosis are usually clinically asymptomatic but may have in 
their plasma modest elevations of liver enzymes such as ALT, AST and GGT. 
Histologically, hepatic fibrosis is characterized
 
by an increase in extracellular matrix 
constituents which are produced in response to chronic liver injury (Friedman, 2000). 
However, collagen production by the liver is also an essential physiological response 
to tissue injury that is believed to be part of the wound healing and tissue recovery 
process. It is thought that a persistent injury may provoke inflammatory processes 
which collectively form the hepatic scar found in chronic liver disease (Bataller and 
Brenner, 2005). Alcoholic fatty liver (AFLD), metabolic derangements (NAFLD), 
persistent viral and helminthic
 
infections, and hereditary metal overload are some of 
the known causes of liver fibrosis (Lotersztajn et al., 2005). In many western 
societies, NAFLD is now thought to be the most common cause of elevated liver 
enzymes (Day, 2002).  
The fatty change of the liver observed in NAFLD has different stages. It starts with 
accumulation of triglyceride but without any noticeable inflammation (NAFL). In 
some patients this quiescent state can progress to produce inflammation and become 
Non-Alcoholic SteatoHepatitis (NASH) and at this stage abnormalities in the serum 
transaminases and gamma-glutamyl transferase (GGT) may become apparent. If this 
inflammation persists and becomes chronic, approximately 20% of NASH cases may 
progress to fibrosis and ultimately cirrhosis over a 20-30 year period (Malnick et al., 
2003) (see figure 1).  
 
Historically, it was only in 1980 that the term „non-alcoholic steatohepatitis‟ (NASH) 
was first introduced. The term described a condition that appeared similar to 
 
2 
alcoholic liver disease but in which alcohol played no part in the pathogenesis. It was 













    
 
Figure 1.1: NAFLD stages of disease progression: The disease starts with mild fat 
accumulation in the liver which might present as a liver enlargement but in most of 
the cases, it is asymptomatic. Development of inflammation may then occur and the 
formation of a pathological scar is apparent. Persistent NASH can then lead to 
cirrhosis. Figure adapted from National Digestive Diseases Information 






Recognition, staging and treatment of NAFL and NASH are important to prevent or 
delay their progression into liver cirrhosis or carcinoma. Current therapies usually 
relate to improvement of insulin sensitivity including gradual weight loss, physical 
exercise and drugs to increase insulin sensitivity as well as the use of agents that 






1.1.1 Causes, epidemiology, clinical features, investigations, 




NAFLD can be either a primary or a secondary disease. The primary form of 
NAFLD is usually associated with the metabolic syndrome. Secondary NAFLD 
could arise from different causes such as starvation, or taking certain medications, 
including glucocorticoids, tamoxifen and amiodarone (Ong and Younossi, 2007). 






Table 1.1: The secondary causes of NAFLD.  
 
Secondary causes of NAFLD 
Nutritional                          Total parental nutrition, rapid weight 
                                           loss, starvation, intestinal bypass surgery 
 
Drugs                                Glucocorticoids, estrogens, tamoxifen, 
                                     methotrexate, zidovudine 
                                    Amiodarone, ASA, intravenous 
                                     tetracycline, didanosine, cocaine, 
                                   perhexilene, hypervitaminosis A, 
                                   diltiazem 
 
Toxins                         Toxic mushrooms (Amanita phalloides, 
                                     Lepiota) 
                                    Petrochemicals, phosphorus, Bacillus 
                                    cereus toxin 
 
Metabolic                     Lipodystrophy, dysbetalipoproteinemia, 
                                     Weber–Christian disease, Wolman‟s 
                                      disease 
                                       Acute fatty liver of pregnancy, Reye‟s 
                                         syndrome 
                                        Other inflammatory bowel disease, HIV 
                                       infection, small-bowel diverticulosis 
                                       with bacterial overgrowth 
 
 





With the emerging epidemic of obesity in western countries, associated hepatic 
steatosis has been found in approximately 20-30% of the population in US when 
assessed by the magnetic resonance spectroscopy (Adams et al., 2005; Kim and 
Younossi, 2008). Other studies reported that fatty liver could be detected in 
approximately 10-24% (Medina et al., 2004). Evidence suggests that the prevalence 
of fatty liver increases with age such that it is about 10 times more common in 
patients aged 40 – 60 years of age than in children (Adams et al., 2005). However, 
the prevalence of NAFLD is more frequent in diabetics (50%) and the obese (76%) 
and can be found in almost all patients who are morbidly obese (Adams et al., 2005). 
Other factors found to be associated with the prevalence of NAFLD include 
hyperlipidemia (hypertriglyceridemia, hypercholesterolemia,
 
or both) which has been 
observed in 20% to 81% of patients with NASH (Sheth et al., 1997). Although 
commonly NAFLD is associated with obesity or diabetes, NAFLD can develop in 
patients with normal body weight, normal blood sugar and normal lipid profiles 







Most of the patients with NAFLD present to clinics because of other associated 
clinical problems including obesity, diabetes or hypertriglyceridemia. Only a 
minority of patients complain of features of liver disease such as non-specific right 
upper abdominal pain and fatigue (Sheth et al., 1997). On examination, such patients 
may have enlargement of the liver but more often than not no clinical signs of 





In a case of suspected NAFLD, investigations would be requested to exclude other 
potential diagnoses. Most NAFLD patients are characterized by minor but persistent 
abnormalities in liver function tests but it remains important to exclude other 




The diagnosis of NAFLD is done by exclusion of other differential diagnoses 
including alcoholic liver disease, hepatitis C, B and other causes of fatty liver. The 
commonly used cut-off limit of alcohol intake per day to distinguish AFLD from 
NAFLD is 20g/day for females and 30g/day for males (Adams et al., 2005). 
Although, elevated liver enzymes could be an indication of NAFLD, especially an 
ALT:AST ratio > 1 in early disease, clinicians have suggested that the diagnosis of 
NAFLD relies on two parameters: 
 Exclusion of other liver diseases by conventional tests 
 At least moderate macrovesicular fatty change associated with inflammation 
on liver biopsy (Sheth et al., 1997). 
 
If bilirubin and alkaline phosphatase levels are slightly elevated, this might indicate a 
later stage of the disease (Patrick, 2002). If the RBC mean corpuscular volume 
(MCV) is raised, this might indicate alcoholic liver disease (Maruyama et al., 2001). 
The level of abnormality of liver function tests does not correlate well to the 
histological changes in the liver in NAFLD (Adams et al., 2005). Ferritin and 
autoantibodies may be elevated but are not recognized as a diagnostic feature 
(Adams et al., 2005). As a consequence it is often difficult from a clinical point of 
view to determine the severity of liver dysfunction and fibrosis in NAFLD without 
resort to liver biopsy. 
 
Other laboratory tests used to exclude other causes of liver disease include serologic 
tests for viral hepatitis, iron studies for haemochromatosis, ceruloplasmin levels for 
Wilson‟s disease and anti-mitochondrial and antinuclear antibodies for autoimmune 
hepatitis (Adams et al., 2005). 
 
Liver ultrasonography and CT shows diffuse fatty infiltration in patients with 
NAFLD (Adams et al., 2005). However, this finding is not specific to NAFLD and 
cannot be used to diagnose NASH. Since the BMI of the typical NAFLD patient is 
high, the sensitivity and the specificity of ultrasonography ability to detect any fatty 
infiltration are often compromised (Adams et al., 2005). The liver biopsy is usually 
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done to either confirm or exclude NAFLD if none of the above tests are 
conclusive(Adams et al., 2005; Sheth et al., 1997).  
 
Liver biopsy has been proposed as a diagnostic tool to determine the severity and the 
stage of the disease (Adams et al., 2005). The decision to take a liver biopsy should 
be discussed with the patient and at the same time the benefits and risks of the biopsy 
should be explained (Adams et al., 2005). Under the microscope, the histological 
changes may not always be able to distinguish alcoholic liver disease from NAFLD. 
Generally, there is a mix of macrovesicular and microvesicular droplets along with 





Cirrhosis and hepatocellular carcinoma are the main complications of NAFLD and 
more specifically NASH patients. Both of these complications lead to end stage liver 
failure, renal failure, portal hypertension, variceal haemorrhage, ascites, and 
encephalopathy. Once developed, these hepatic complications may recur after liver 
transplantation (Adams et al., 2005). 
 
 
Clinical management  
 
Weight reduction, lowering of serum lipids, exercise and medication to improve 
insulin resistance (metformin and thiazolidinediones are commonly tried) are 
currently the broad lines of treating NAFLD patients. The main aim of the treatment 
is to slow, or more preferably, prevent the disease progression by managing the 
associated clinical problems (Adams et al., 2005). Rapid weight loss should be 
avoided and the ideal weight loss should not exceed 10% of the body weight in 6 
months (Adams et al., 2005). Liver transplantation is the treatment reserved for 


















Table 1.2: Histological feature of NASH 
 
 
Histopathology of NASH 
 
• Necessary components 
- Steatosis (macro > micro) 
- Hepatocellular ballooning 
- Mixed mild lobular inflammation 
• Usually present 
- Zone 3 perisinusoidal/pericellular fibrosis 
- Zone 1 hepatocellular glycogenated nuclei 
- Small lipogranulomas, acidophil bodies, PAS-
positive Kupffer cells 
• Maybe present 
- Mallory‟s hyaline 
- Hepatocellular iron granules in zone 1 
- Megamitochondria 
• Unusual for NASH 
- Predominantly microvesicular steatosis 
- Sclerosing hyaline necrosis 
- Veno-occlusive lesions, phlebosclerosis, 
perivenular fibrosis 
- Portal changes 
- Acute/chronic cholestasis 
 
 












1.1.2 Pathogenesis of NAFLD 
 
Generally, the pathogenesis of NAFLD can be regarded as a chronic wound healing 
process with or without inflammation, characterized by increased deposition of extra-
cellular matrix (Bataller and Brenner, 2005; Friedman, 2000). At the cellular level, 
most of the literature describes the pathogenesis at NAFLD based on a two-hit 
hypothesis. The first hit is insulin resistance while the second hit is unopposed 




1.1.2.1 Two-hit hypothesis of fatty liver 
1.1.2.1.1 Insulin resistance 
 
The general physiological action of insulin is principally anabolic, i.e., to build 
energy stores and body mass. Insulin facilitates the transportation and entry of 
glucose to the cells of the various tissues. In the liver, insulin induces the synthesis of 
glycogen from glucose. Collectively, insulin targets the reduction of the blood sugar 
level, especially after heavy meals. Insulin also promotes the synthesis of fatty acids 
in the liver and inhibits the oxidation of fatty acids in the liver and adipose tissue.  
 
Insulin resistance describes a state where tissues become unresponsive to insulin. 
Insulin resistance leads to continuous secretion of insulin (hyperinsulinemia) from 
the β-cells of the pancreas to overcome the tissue resistance. Furthermore, insulin 
resistance increases the lipolysis of fatty acids from the adipose tissue leading to a 
huge influx of fatty acids from the adipose tissue to the liver. Insulin will also 
stimulate the lipogenic pathway in the liver through the sterol regulatory element-
binding protein1 (SREBP-1) (Browning and Horton, 2004; Leclercq et al., 2007). 
Moreover, insulin resistance will lead to a decrease in lipoprotein synthesis and a 
consequent reduction in the export of fat from the liver in the form of very-low-
density lipoprotein (VLDL) (Jansen, 2004). Accumulated fatty acids in the 
hepatocyte cytoplasm can activate the peroxisomal proliferator-activated receptor-α 
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(PPARα) which stimulates the peroxisomal and mitochondrial oxidation of fatty acid 
and therefore production of reactive oxygen species (ROS) (Jansen, 2004) (see figure 
1.2). These mechanisms ultimately will lead to the accumulation of fatty acids in the 
liver that may be oxidised or stored as triglycerides (fat) 
 
 
Peripheral versus hepatic insulin resistance 
 
Peripheral insulin resistance usually refers to resistance in tissues (i.e. adipose and 
muscle) other than liver. On the other hand, hepatic insulin resistance refers to the 
unresponsiveness of hepatocytes to insulin action and all the consequences resulted 
from this deranged unresponsiveness.  
 
However, peripheral insulin resistance can lead to inhibition of hormone-sensitive 
lipase and ultimately to lipolysis of fatty acids from adipose tissue. Furthermore, 
peripheral insulin resistance can lead to increased de novo synthesis of fat in the liver 
and ultimately hepatic insulin resistance (Kim et al., 2001). The activation of protein 
kinase C (PKC) and c-Jun N-terminal protein kinase 1  (JNK1) that affect insulin 
signalling could be the mechanism by which the fat accumulation leads to hepatic 
insulin resistance (Samuel et al., 2004). Furthermore, other reports suggest that an 
activated protein kinase C (PKC theta) could induce serine phosphorylation of 
insulin receptor substrate (IRS-1)  in muscle and IRS-2 in liver which in turn leads to 
defects in insulin actions in these tissues (Kim et al., 2001).  
 
However, the continuous synthesis and accumulation of fatty acids in the liver can 
worsen the peripheral insulin sensitivity by blocking insulin action and increasing the 
risk of oxidative stress by providing its substrate (fatty acids) (McAvoy et al., 2006). 
This view is supported by a study suggesting that hepatic insulin resistance worsens 
with the progression from NAFL to NASH (Sanyal et al., 2001). Moreover, 
improving insulin action through changing lifestyle and pharmacological treatment 
decreases the steatosis. This suggests that insulin resistance predisposes the liver to 
accumulate fat and not vice versa. This was supported by the demonstration that 
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hepatic hyperinsulinaemia is not the cause of insulin resistance (Pagano et al., 2002).  
Therefore, it seems possible that fat accumulation and insulin resistance are 
intimately linked having the ability to promote each other.  
 
 
Insulin resistance and inflammation 
 
It has been argued the continuous mitochondrial oxidation of fatty acids in a fatty 
liver can lead to the production of a range of oxidation by products such as ROS and 
lipid hydroperoxides (Jansen, 2004). Ultimately, these lead to mitochondrial 
dysfunction and mitochondrial damage that in turn can lead to release of 
inflammatory cytokines thereby attracting inflammatory cells such as neutrophils and 
Kupffer cells (Parkes and Templeton, 2003; Reeves and Friedman, 2002). Activated 
Kupffer cells will then in turn release various types of cytokines to recruit other 
inflammatory cells and thus initiating an inflammatory cascade (Reeves and 
Friedman, 2002). This hypothesis is supported by a study that showed fat-loaded 
hepatocytes had increased ROS production (Nardo et al., 2001).  
 
Various pro-inflammatory cytokines have been implicated in the process of liver 
fibrosis including TGF-β1, PDGF, TNF-α, IL-8 and leptin. TNF-α can induce insulin 
resistance and inflammation (Adams et al., 2005). Leptin, like adiponectin, is also 
released from the adipose tissue. Leptin has been described to be involved in 
regulating insulin resistance with regards to adiposity. Although genetically modified 
leptin-deficient mice develop less fibrotic change in their liver compared to wild type 
mice, the exact pathological role of this adipokine is not fully understood (Diehl et 
al., 2005). It has been suggested that as the fat-loaded hepatocytes become bigger 
microvascular blood flow may become impaired and thus may prevent the removal 
of the ROS and thereby exacerbating inflammation and fibrosis (Adams et al., 2005).  
 
During inflammation, significant numbers of leucocytes are recruited. Neutrophils, 
Kupffer cells, monocytes and T-lymphocytes are among the most pro-inflammatory 
of cells that migrate to the inflamed liver (Kershenobich Stal and Weissbrod, 2003). 
These attracted immune cells contribute further to the inflammatory process and 
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through the release of various inflammatory cytokines which may activate hepatic 
stellate cells (Kershenobich Stal and Weissbrod, 2003). The exact role of each 
immune cell in the processes of stellate cell activation and fibrogenesis remains 
uncertain.  
 
The duration and the severity of inflammation might be one of the important 
determining factors responsible for switching the normal wound-healing process in 
the liver to a fibrogenic process. The most important determinants of the factors 
involved in the pathogenesis of fatty liver are thought to be genetic polymorphisms 
in a range of genes including those which exhibit anti-oxidant and anti-inflammatory 
function. These genetic variations may determine the susceptibility of patients to be 







Figure 1.2: The main pathophysiological mechanism of NAFLD  
HSL:Hormone sensitive lipase, PPAR: Peroxisome proliferator-activated receptor, 
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1.1.2.1.2 Oxidative stress 
 
Oxidative stress describes the process of accumulating reactive oxygen species 
(ROS) caused by either their over-production or failure of the anti-oxidant defence 
systems to prevent their accumulation (Sies, 1997). Oxidative stress plays a major 
role in many diseases including cancer, ageing, cardiovascular diseases, diabetes 
mellitus and alcoholic liver disease (Valko et al., 2007). Many regard unopposed 
oxidative stress as being the second hit of the hypothesis for the pathogenesis of 
NAFLD described earlier in this chapter. Although ROS are primarily toxic and 
harmful to cells, they also have to a limited extent a physiological role. One 
physiological role of ROS is to kill bacteria phagocyted by monocytes and other 
leucocytes involved in immunity (Valko et al., 2007). ROS are also involved in 
various signal transduction pathways (Valko et al., 2007).  
 
Harmful effects of ROS vary from cell death through necrosis and apoptosis to less 
severe effects including modification of cell functionality and various metabolic 
processes (Valko et al., 2007). ROS can be classified according to their half lives. 
ROS with short lives have a more destructive potential than those with long half lives 
but are only capable of exerting a local effect within the cell where they are 
generated. In contrast ROS with a long half life have less destructive potential but at 
the same time can travel to other cells to produce oxidative damage (Sies, 1997). 
ROS interact with receptors which in turn may affect the binding or signal 
transduction pathways in the cell (Valko et al., 2007). In addition ROS can react with 
fatty acids and lipoproteins to generate harmful peroxyl radicals, aldehydes (e.g., 4-
hydroxynonenal) and other products of lipid peroxidation. These lipid peroxidation 
products may also affect receptor function. 4-hydroxynonenal is a strong chemo-
attractant for neutrophils (Blasig et al., 1995). 
 
The biochemical consequences of oxidative stress vary. They include not only DNA 
oxidation and mitochondria necrosis but many others (see table1.3) (Parola and 
Robino, 2001). Although ROS can arise from various cell organelles, mitochondria 
are regarded as a very important site for their production since the high metabolic 
activity of the organelle leads to large amounts of oxygen being used (Parola and 
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Robino, 2001). Oxidative phosphorylation in the mitochondria to produce ATP from 
fat and pyruvate is a complex process by which most of the ROS is produced as a by-
product. This process mainly involves the transfer of electrons from donor proteins to 
acceptor proteins. This mechanism of electron transfer can be associated with a leak 
of electrons and uncoupling of the oxidative mechanism. Recently, a study found that 
most of the ROS produced in the mitochondria is at the level of complex III because 
this complex might send ROS to the inter-membrane space where there are no 
antioxidant defence mechanisms (Chen et al., 2003). Therefore in stressed states 
where the anti-oxidant systems are exhausted, large amounts of unopposed ROS 
could be very harmful and damage mitochondria. Furthermore, the loss of 
glutathione stores has been found to be lethal in ascorbatic rats (Meister, 1995). 
 




(Reactive Oxygen species) DNA: oxidation, strand breaks, genotoxicity 
                                            Proteins: oxidation, fragmentation, formation of 
                                            carbonyls 
                                            Lipids: lipid peroxidation and degradation 
 
HAK 
(Hydroxy Alkenals)           DNA: adducts (low doses), strand breaks, genotoxicity 
                                            (high doses) 
                                            Proteins: adducts (Michael type reactions on Lys, Cys 
                                            and His residues) 
 
NO  
(Nitric Oxide)                     DNA: oxidation, strand breaks 
                                            Proteins: oxidation, nitrosation, nitration 
                                            (nytrosylation of tyrosine) 
                                            Lipids: lipid peroxidation and degradation 
 











Figure 1.3: Oxidative stress related molecules sources and consequences 






















Structurally damaged  
mitochondria Damaged DNA 
Alteration of major 
macromolecules 
 
Lipid peroxidation  
Protein peroxidation 
Affecting cell signalling and functions 
Inflammation 
Necrosis or apoptosis 
Major sources of ROS 
-Damaged hepatocytes 
-Leaking mitochondria 





Hepatic stellate cells and oxidative stress 
 
Hepatic stellate cells (HSC) constitute about 15 % of the total cell population in the 
liver (Friedman, 2008). These cells were first described by von Kupffer in 1876 as 
liver sternzellen (star-shaped cells) (Friedman, 2008; Wake, 2006). In the quiescent 
state, HSCs are perisinusoidal cells that reside in the space of Disse and contain 
numerous droplets that are packed full with retinoids (Wake, 2006). The known basic 
functions of stellate cells are to store retinoids and regulate sinusoidal blood flow 
(Friedman, 2008). In liver fibrosis, stellate cells become activated and are regarded 
as the most important source of the extracellular matrix (Friedman, 2008). For this 
reason, the mechanisms by which hepatic stellate cells become activated have been 
studied widely. 
 
The activation of stellate cells has two stages, an initiation and a perpetuation stage 
(Friedman, 2000). In the initiation phase, various factors have been implicated in the 
activation process including ROS, inflammatory cytokines and growth factors 
released from injured hepatocytes, Kupffer cells, and sinusoidal endothelial cells (see 
figure 1.4) (Friedman, 2000). Furthermore, the stellate cells express several 
transcription factors which may eventually lead to the development of a phenotypic 
transformation to activated myofibroblast-like cells. These transformed cells then 
express various cytoskeletal markers such as α-smooth muscle actin (α-SMA) and 
glial fibrillary acidic protein (GFAP) (Friedman, 2008). The activated stellate cells 
become enlarged, develop increased rough endoplasmic
 
reticulum and lose their 
vitamin A (retinoid) droplets. Whilst in vitro studies have shown that activation of 
stellate cells is accompanied by loss of these vitamin A-rich droplets, to date there is 
no clear evidence to support a direct role for these lipid droplets in cell activation in 
vivo (Friedman et al., 1993). The hepatic content of vitamin A is decreased in liver 
fibrosis but again there is no evidence to show a convincing role of vitamin A in 
stellate cell activation (Friedman, 1993). Thus, the role of retinoids in the activation 




In the perpetuation phase, stellate cells become more active, proliferative and 
contractile (Friedman, 1993). Autocrine and paracrine stimuli together with the 
activated phenotype constitute the main factors involved in the perpetuation phase. 
Although various cytokines are involved in the process of activation, TGF-β1 is 
considered the main cytokine involved in the activation process and thus 
fibrogenesis. Furthermore, platelet-derived growth factor (PDGF) is regarded as the 
most potent inducer of stellate cell proliferation (Friedman, 1993).  
 
The severity of liver fibrosis depends on the type and duration of the liver injury. In 
the case of acute injury, the regeneration process takes over the fibrogenesis process. 
On the other hand, if the injury is chronic, the regeneration process will be 










Figure 1.4: Stages of hepatic stellate cell activation: yellow droplets represents fat 
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1.1.3 The role of selenium and selenoenzymes in NAFLD 
          
Selenium (Se) is a dietary trace mineral that has powerful anti-cancer, antioxidant 
and anti-inflammatory properties. It is also able to modify immune and endocrine 




Selenium is a trace element that is essential for a number of cellular functions. 
Selenium (selen in Greek means „moon‟) was discovered by Berzelius in 1817. 
Although initially it was the toxic properties of selenium that generated scientific 
interest, Schwartz and Foltz in 1957 found that selenium could prevent hepatic 
necrosis in vitamin E-deficient rats (Schwarz and Foltz, 1957). This observation led 
to the acceptance that selenium was an essential trace element. In 1973, selenium 
was shown to be a constitutive part of cytoplasmic glutathione peroxidase (GPX1), 
an important enzymatic antioxidant. This discovery provided a plausible mechanism 
by which the trace element could exert many of its biological actions (McKenzie et 
al., 2002). Subsequently it has been found that selenium is a constituent part of a 
large number of selenoproteins which have functions other than an antioxidant role. 
The trace element, acting independently of selenoproteins, may also have biological 
actions including its ability to modify a range of cell signalling pathways including 
that of insulin (Beckett and Arthur, 2005) .  
 
 
Selenium and the diet 
Selenium exists in nature as both inorganic and organic forms. Inorganic forms 
include selenides, selenites and selenates whilst organic forms such as 
selenomethionine and selenocysteine are incorporated into proteins. Selenium enters 
the food chain by plants trapping inorganic forms of selenium from the soil and 
incorporating them into plant protein as selenomethionine and selenocyteine. There 
is wide variation in the selenium content of soil across the globe and in areas where 
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the selenium content of soil is low, populations relying on local food supplies 
become selenium deficient to varying degrees.  
  
The dose of selenium that allows the maximal expression of glutathione peroxidases 
in red blood cells is currently considered as the recommended daily allowance of 
selenium. For humans, this is in the order of ~70 µg/day (Rayman, 2000). The 
selenium intake in the UK had fallen from about 60 µg/day during the 1970s to 
currently an average of about 30 µg/day nowadays (Combs, 2001). This decrease in 
selenium intake in the UK was mostly due to a change to the sourcing of wheat from 
European counties (which have low selenium soils) instead of areas of North 
America which have high selenium content in the soil. It continues to be debated if 
this current low intake of selenium in the UK diet has adverse health consequences. 
 
Selenium is usually taken in the diet as organic selenium forms mainly from cereal 
products. However, inorganic selenium forms are commonly used in experimental 
in-vitro settings because of their speed of action. Selenium can be incorporated into 
both selenoproteins that are metabolically active and selenium-containing proteins 
that have no known biological role. Selenium is usually absorbed in the duodenum 
(Thomson, 1998). Although the various forms of selenium have different 
mechanisms of absorption, the rate of absorption is not regulated by the selenium 
level. While organic forms are actively absorbed using amino acid transporters 
(McConnell and Cho, 1965), inorganic forms can pass passively across the intestine 
(Thomson, 1998). Once selenium has been absorbed into the body, it is taken up by a 
number of cell types where it can be incorporated into selenoproteins. Selenoprotein 
P is quantitatively the main selenoprotein in plasma and is synthesised in the liver 
(Motsenbocker and Tappel, 1982). Within tissues, both the organic forms and 
inorganic forms of selenium are metabolised to a common active selenide 
intermediate. This selenide is then used to synthesise specific selenocysteine residues 
that are incorporated co-translationally into the active site of the selenoprotein. The 
main excretion pathway for selenium is through the urine, although excretion of a 





Selenium associated disorders 
Selenium deficiency has been implicated in the pathogenesis of many diseases 
including Kashin-Beck disease and Keshan disease (Chen et al., 1980; Combs, 2001; 
Levander, 1987). Keshan disease had been described in populations inhabiting 
selenium-deficient areas of China. The disease is a multifocal myocarditis affecting 
children and females. Selenium supplementation of these communities has decreased 
the incidence of this disease but has not been able to reverse the heart failure in those 
who had already contracted the disease (Chen et al., 1980). Kashin-Beck disease is 
an endemic osteoarthropy affecting children and adolescent in selenium-deficient 
areas. Furthermore, selenium deficiency had been implicated in the pathophysiology 
of cancer, cardiovascular diseases, muscular dystrophy, and a number of other 
diseases.  
 
Selenium toxicity can develop if selenium intake exceeds  800 µg/day (Kot and 
Namiesnik, 2000). The sign and symptoms of selenium toxicity include garlic-like 
breath, peripheral neuropathy, cirrhosis and traverse nail lines. However, other non-
specific symptoms like gastrointestinal disturbance and fatigue are also associated 




In normal physiology selenium regulates cellular
 
growth and death and can modulate 
signal transduction
 
in various cells  (Greeder and Milner, 1980; Kim and Stadtman, 
1997). Selenium can mimic insulin signalling restoring glycaemic control in diabetic 
mice. The exact mechanism for this action is yet fully understood. Most of the 
biological actions of selenium arise from its incorporation into the various 
selenoproteins. In addition, selenium has significant anti-inflammatory actions acting 







Selenium and NAFLD 
Selenium, acting through the synthesis of specific selenoproteins with powerful anti-
oxidant actions, is able to prevent oxidative damage to cells. Since oxidative stress 
has been postulated as being second hit in the pathogenesis of NAFLD, it is of 
concern that the selenium intake in the UK falls well below that required to allow 
maximal expression of anti-oxidant selenoenzymes. Clearly the role of selenium in 
preventing hepatic damage and fibrosis associated with NASH warrants investigation 




Selenoenzymes form an important battery of antioxidant enzymes that are extremely 
effective at preventing cellular damage that occurs through oxidative stress.   
More than twenty five selenoproteins have been identified (Moghadaszadeh and 
Beggs, 2006). When selenium is incorporated into selenocysteine, it becomes an 
essential amino acid and is incorporated into the active site of the various 
selenoenzymes. Selenocysteine (Sec) is coded for the TGA/UGA codon. This UGA 
codon may be read as a stop codon if selenium supplement is limited. Therefore, it is 




Selenocysteine (Sec) biosynthesis in mammals involves the incorporation of serine 
into SectRNA[ser]sec by seryl tRNA synthetase to yield SeryltRNA[ser]sec. The 
complex is then phosphorylated by phosphoseryl tRNA kinase. Selenium (selenide) 
is first phosphorylated by selenophosphate synthetase and then replaces the 
phosphate by the Sec synthetase. The resulting selenocysteyl-tRNA[ser]sec delivers 



















































Although the availability of Sec is essential for the translation of the UGA codon into 
a proper selenoprotein, other factor involved in the process of translation should exist 
for the process to be successful. Such factors include selenocysteine insertion 
sequence (SECIS) element, elongation factor EFSec and SECIS binding protein 2 
(SBP2) (Papp et al., 2007). Knockout of selenocysteine-t-RNA in mice has been 
shown to be lethal early in embryonic life (Bosl et al., 1997). 
 
SECIS is the secondary RNA stem –loop structure. For the proper translation of 
selenoprotein, the coded mRNA should contain a SECIS element which is located in 
the 3' of the mRNA. The SECIS has a unique structure which contain an apical loop 





The antioxidant properties of selenium are thought to be largely mediated through 
the expression of a variety of cytoprotective selenoenzymes that contain a 
selenocysteine residue in the active site. The family of glutathione peroxidases 
(GPX) and thioredoxin reductases (TR) are selenoenzymes that are considered 
particularly important for maintaining the antioxidant capacity of tissues. These 
families are represented in all tissues and the most important of these selenoenzymes 
for antioxidant function in tissue are thought to be cytoplasmic thioredoxin reductase 
(TR1), mitochondrial TR (TR2), cytoplasmic glutathione peroxidase (GPX1) and 
phospholipid hydroperoxide GPX (GPX4). The main anti-oxidant functions of these 











Table 1.5: Mammalian selenoproteins and their main proposed roles. 
 
 
Selenoprotein                                                Main role 
 
Glutathione peroxidase  
GPX1 Antioxidant in cell cytoplasm, selenium              
reservoir? 
GPX2 Antioxidant in the gastrointestinal tract 
GPX3 Antioxidant in extracellular space and 
plasma 
GPX4 Membrane antioxidant and structural protein 
in sperm  
GPX5 Unknown 
GPX6         Olfactory epithelium- and embryonic 
 tissue-specific (Lu and Holmgren, 2009) 
 
Thioredoxin reductase  Many functions including maintaing the 
redox state, detoxify peroxides and dithiol-
disulphide oxoreductase 
TR1 Cytosolic form  
TR2 Mitochondrial form 
TR3 Expressed mainly in the testes 
Iodothyronine deiodinases 
Type 1 and 2 Converts T4 (inactive) to 3,5,3' T3 (active)  
 
Type 3  Converts T4 (inactive) to 3,3,5' reverse T3 
(active)  
 
Selenoprotein P Transport of selenium, antioxidant on 
endothelium 
 
Selenoprotein W Antioxidant in cardiac and skeletal muscle? 
 
Selenophosphate synthetase (SPS2) Synthesis of selenophosphate to form 
selenoprotein 
 
15 kDa selenoprotein (Sep 15) Protects against cancer (mechanism 
unknown?) 
 
H,I,K,M,N,O,R,S,T,V Mostly unknown 
 








Figure 1.6: The role of the important selenoenzymes as anti-oxidants in oxidative 
stress. GPX1 and 4 (cytoplasmic and membrane glutathione peroxidase), TR1 and 2 
(cytoplasmic and mitochondrial thioredoxin reductase), PLHP (phospholipid 
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Glutathione is the substrate for all the GPXs and is used to reduce H2O2 and lipid 
peroxides to the corresponding alcohol (Nordberg and Arner, 2001). To date six 
GPXs have been described. GPX1 was the first selenoprotein to be discovered in the 
1970s. Although distributed throughout the body, the liver, red blood cells and 
kidney have particularly high levels of GPX1 (Mates et al., 1999). This reflects the 
need of these tissues for GPX because they are particularly metabolically active and 
thus undergoing considerable oxidative stress. GPX1 is also known as a cytoplasmic 
GPX and it consists of four identical subunits. Each subunit has a binding site for 
glutathione and an active site containing a selenocysteine residue that is located in 
the N-terminal domain. GPX1 is known for its anti-oxidant activity acting through 
the reduction of many natural-occurring harmful compounds including hydrogen 
peroxide and fatty acid hydroperoxides (Flohé, 1989).  
 
GPX 4 is the membrane-bound GPX that shares 45% homology with GPX1. It is 
monomeric and is involved in reducing the lipid hydroperoxides and cholesterol ester 
hydroperoxides within cell membranes (Mates et al., 1999). GPX2 and GPX3 are 
found mainly in the kidney and the intestines (Nordberg and Arner, 2001). GPX5 and 
6 were recently discovered with GPX5 being structurally similar to GPX3 and GPX6 




 The thioredoxin reductase family of selenoenzymes were discovered in 1996 
(Holben and Smith, 1999). The thioredoxin reductases (TR1, TR2 and TR3) are 
FAD-containing homodimeric selenoenzymes that together with thioredoxin (Trx) as 
a substrate and NADPH as a cofactor, form a powerful dithiol-disulphide 
oxidoreductase system referred to as the TR/Trx system which is important in 
sensing and regulating the redox state of the cell (Mustacich and Powis, 2000). TR1 
is found in the cell cytosol of all tissues while TR2 is found in the mitochondria 
(Kohrle et al., 2005). TR2 is considered to be important in maintaining the redox 
balance in the most important „factory‟ of ROS production, namely the mitochondria, 
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and hence the role of TR2 may be to protect the mitochondria and thereby preserve 
cell viability. These enzymes are expressed at high levels in liver, kidney and the 
heart (Kohrle et al., 2005). TR3 is a variant of TR2 but solely expressed in the testis 
(Su et al., 2005). In addition to their antioxidant roles, mammalian TRs can catalyse 
the reduction of a variety of substrates including thioredoxin, protein disulphide-
isomerase, low molecular weight disulphides such as 5,5‟-dithiobis-2-nitrobenzoic 
acid, lipoic acid, vitamin K and dehydroascorbic acid.  
 
The TR/Trx system has been associated with many diverse cellular functions 
including the regulation of cell growth, inhibition of apoptosis (Arner and Holmgren, 
2000) and regeneration of proteins inactivated by oxidative stress. In addition, TR1 
can also act directly to detoxify hydrogen peroxide and a wide variety of lipid 
hydroperoxides (Brigelius-Flohe et al., 2003). Selective inhibition studies suggest 
that TR1 may be more important than the glutathione peroxidases (GPX) in 
protecting human cells against oxidative damage. Modification of hydrogen peroxide 
signalling should be possible by manipulating the expression of GPX and TR 
through changes in selenium status.  
 
Regulation of selenoprotein expression and the hierarchy of selenoproteins 
The selenoprotein expression in cells and between tissues is highly regulated through 
a strict “hierarchy” of selenoprotein expression (Driscoll and Copeland, 2003). This 
regulation is dependent on the availability of selenium (Behne et al., 1988; Bermano 
et al., 1996; Burk and Hill, 1993; Hill et al., 1997a; Weitzel et al., 1990). However, 
this availability does not affect the transcription rate of any of the selenoprotein 
genes (Heider et al., 1992; Hirota et al., 1997; Howie et al., 1995) but it affects the 
mRNA levels which is related to mRNA translation and/or stability (Heider et al., 
1992; Howie et al., 1998). Several other factors besides selenium supply can 
influence the expression of specific selenoproteins. For example oxidative stress 
could lead to induction of TR and GPX expression (Brigelius-Flohe et al., 1997). 
Also, in a tissue specific manner, activation of second-messenger pathways could 




The availability of selenium is reflected in the differential expression of the various 
selenoproteins and changes in selenium status affect the expression of selenoproteins 
in a tissue-specific manner (Behne et al., 1988; Bermano et al., 1996; Burk and Hill, 
1993; Hill et al., 1997a; Weitzel et al., 1990). During selenium deficiency, a 
hierarchy mechanism ensures that selenium and selenoprotein expression is retained 
in some tissues at the expense of others. In addition within an individual tissue there 
is also a hierarchy of selenoprotein expression; for example in selenium deficiency 
GPX-1 expression is rapidly lost whilst TR2 expression is maintained. Examples of 
tissues that readily release their available selenium to other organs in cases of 
selenium deficiency are liver, muscle and kidney. The brain, reproductive and 
endocrine systems seem to have an essential requirement for selenium at all times so 
they have priority in accessing selenium in selenium-deficient situations (Behne et 
al., 1988; Bermano et al., 1995).   
 
TR1 expression is retained in selenium deficiency to a greater extent than GPX1 
(Berggren et al., 1999; Gasdaska et al., 1999). In vitro studies suggest that selenium 
can stabilize the mRNA of TR1 leading to increased synthesis of the active enzyme 
(Gallegos et al., 1997). Indeed some have suggested that the primary role of GPX-1 
is to act a buffer to hold a reservoir of selenium within cells that can be called upon 
to express other more important selenoproteins at times of selenium deficiency 

















1.1.4 Future Therapies  
Because the pathophysiology of liver fibrosis involves various cellular injury 
mechanisms, it has been argued that prospective therapy should be constructed to 
target all of these various mechanisms (Li and Friedman, 1999). This approach 
includes therapies that: 
1. alleviates the injurious factor 
2. inhibits the inflammatory process 
3. inhibits the activation of hepatic stellate cells 
4. lyses the matrix formed  
Alleviating the injurious factor is an appropriate way of approaching the treatment of 
any disease. Secondary NAFLD could benefit from this strategy, where the cause is 
identifiable and treatable. In the case of primary NAFLD, the complex 
interrelationship between insulin resistance, inflammation, fat-loading and oxidative 
stress in the pathogenesis of the disease means that deriving combined therapies to 
tackle each of these metabolic problems is problematic (Li and Friedman, 1999).  
As inflammation is a major contributor in the process of fibrogenesis, the use of anti-
inflammatory therapies should have potential benefit. Corticosteroids have been used 
widely to decrease inflammation in many diseases including liver fibrosis (Tanner 
and Powell, 1979). Autoimmune hepatitis has benefited from corticosteroid treatment 
more than any other type of liver fibrosis (Mathurin et al., 1996). Several other anti-
inflammatory agents had been used, including  ursodeoxycholic acid (Corpechot et 
al., 2000), captopril (Tuncer et al., 2003) and angiotensin-converting enzyme (ACE) 
inhibitors (Julie et al., 2001). All of these anti-inflammatory agents have been proven 
to decrease liver fibrosis in animal models. 
 
Because stellate cells are considered the major contributor to the fibrogenic process 
in NAFLD, inhibiting the activation of these cells would theoretically also be one 
attractive therapeutic approach to the clinical problem. Although, the relationship 
between oxidative stress and hepatic stellate cells is not yet clear, some studies claim 
that direct oxidative stress on the stellate cells could be an effective way to activate 
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them and thus contribute to fibrogenesis (Apte, 2002). However most studies support 
the view that stellate cell activation depends on factors released by nearby injured 
cells such as hepatocytes and Kupffer cells that have been damaged by chronic 
oxidative stress. These damaged cells then release various growth factors and 
inflammatory cytokines that have a major role in the activation of hepatic stellate 
cells. This proposed relationship between oxidative stress and hepatic stellate cells is 
considered by some to be the most important mechanism for stellate cell activation 
(Friedman, 1993). Clearly decreasing oxidative stress, either directly or indirectly, 
should theoretically be advantageous in preventing the activation of hepatic stellate 
cells. For this reason, many studies have investigated the ability of anti-oxidants to 
prevent stellate cells activation. 
 
A number of anti-oxidants had been investigated but whilst some studies have 
showed promising results others have failed to show a beneficial effect of 
antioxidants. The anti-oxidants studied include vitamin E (Parkkila et al., 1996), 
vitamin C (Helen and Vijayammal, 1997), silymarin (Hosny et al., 2007), and many 
others. Certainly, the antioxidants dilinoleoylphosphatidylcholine and S-
adenosylmethionine have antifibrogenic actions in LX-2 cells (Cao et al., 2006).  
 
Table 1.4: Various anti-oxidants trials used in the hepatic fibrosis treatment. 
 
 
Anti-oxidants                                                  Reference 
 
Retinoids                                                         (Okuno et al., 1990) 
 
Vitamin E                                                        (Parkkila et al., 1996)    
 
Polyenylphosphatidylcholine (PPC)               (Ma et al., 1996) 
 
Vitamin C                                                        (Helen and Vijayammal, 1997) 
 
S-adenosyl methionine                                    (Lieber, 2002) 
                                          






The role of selenium and selenoproteins as antioxidants used to treat NAFLD has not 
been addressed (see below)  
 
Various signalling cytokines have been described to play a role in the activation of 
stellate cells. Of these, the most important are PDGF and TGF-β1. Anti-sense mRNA 
of PDGF has been successful in reducing the fibrogenesis progression in an animal 
model (Borkham-Kamphorst et al., 2004). Inhibiting the signalling of TGF-β1 in 
stellate cells using different strategies was also beneficial in reducing the 
fibrogenesis process. The use of anti-sense mRNA, inhibition of TGF-β1 receptor 
phosphorylation and inhibition of intracellular Smad7 signalling pathways seems 
also to be beneficial (Liu et al., 2006).  
 
Treatments designed to promote the degradation of the scar matrix have also been 
reported. The administration of antibodies against tissue inhibitor of 
metalloproteinase-1 (TIMP-1) was effective in breaking down the fibrosis in vivo 
(rats) (Parsons et al., 2004). However, therapies designed to attack the extracellular 
matrix  should be selective to degrade the collagen laid down in fibrosis (type I and 
III), and not the “normal” physiological collagen that is essential to maintain the 
normal extracellular matrix (i.e. collagen type IV) (Friedman, 1993). Unfortunately, 
to date, no study has been able to identify an agent that distinguishes between normal 




















1.2 In-vivo and in-vitro models of NAFLD: 
 
 
A number of research methods to investigate the pathogenesis of NAFLD have been 
used. 
 
In-vivo models of NAFLD 
The use of animal in-vivo models to investigate liver fibrosis has several advantages. 
Firstly it provides a complementary picture of the pathophysiology when various 
systems such as the immunological and endocrine systems integrate in the fibrotic 
process. Animal models also often provide a good way of studying the whole picture 
of cell to cell communications. Drawbacks to animal models include ethical issues 
and technical difficulties (e.g., mice have a small blood volume) as well as concerns 
the results from such models do not necessarily accurately reflect the human 
pathophysiology.  
 
Various animal models had been used to reflect different types of fibrosis. 
Depending on the cause of fibrosis, animals have been subjected to different 
injurious agents to mimic the human cause of fibrosis. Of these models the most 
commonly used include induction of chronic injury and fibrosis by the administration 
of different toxic agents such as carbon tetrachloride (Pierce et al., 1987), 
thioacetamide (Muller et al., 1988), dimethylnitrosamine (George et al., 2001), and 
ethanol (French, 2001). The administration of heavy metals such as copper 
(Toyokuni et al., 1989) and the ligation of the common bile duct (Kountouras et al., 
1984) have been also used  to mimic Wilson‟s disease and cholestatic causes of 
human fibrosis, respectively. 
 
Recently, the administration of a methionine/choline-deficient diet was found to 
mimic the pathophysiology of NAFLD whereby fat-loading, inflammation and 
fibrosis were observed in the animal model (George et al., 2003; Rizki et al., 2006). 
In addition, several attempts to develop transgenic animal models to study the 





In-vitro models of NAFLD  
 
The commonly employed in-vitro research models are based either on the use of 




Primary cells  
Although, the use of primary cells still retaining most of their in-vivo characteristics, 
would appear ideal for the study and further dissection of the pathophysiology 
process, their availability (especially in the case of human cells), relatively short life, 
and the time required to isolate and harvest such cells make them less attractive for 
use in the research laboratory. Furthermore these primary cells can spontaneously 




Heaptocyte cells lines from primary human or rodent liver cells have been 
developed. Genetically modified cell lines have been developed by the transfection 
of the large T antigen of simian virus 40 or polyoma virus (Xu et al., 2005) into 
primary cells. Another method aimed to extend the life span of  primary cells is the 
transfection of cells with telomerase reverse transcriptase (Schnabl et al., 2002). The 
advantages of cell lines include their wide availability, their simplicity of use and 










LX-2 cell line 
All hepatic stellate cell lines that had been culture in uncoated plastic are of an 
activated phenotype (Xu et al., 2005). Recently used human stellate cells lines 
include the LX-1 and LX-2 lines which have been very well characterized (Xu et al., 
2005).  
 
Because LX-2 cell line has had a better similarity to primary activated stellate cells 
than LX-1 cell line, LX-2 cell line was chosen in our study to represent an activated 
hepatic stellate cells. 
  
The human LX-2 stellate cell line expresses key receptors regulating hepatic fibrosis, 
including
 
platelet-derived growth factor receptor  (PDGF-R),
 
obese receptor long 
form (Ob-RL), and discoidin domain receptor
 
2 (DDR2). LX-2 cells also express 
proteins involved in matrix remodelling;
 
matrix metalloproteinase (MMP)-2 and 
tissue inhibitor of matrix
 
metalloproteinase (TIMP)-2. LX-2 proliferates in response 
to TGF-β1 and express
 
mRNAs for α-1 pro-collagen and HSP47 (Xu et al., 2005). 
Transforming growth factor
 
1 gene expression was found to be induced in these 
cells. LX-2 cells have a retinoid phenotype typical of stellate cells.
 
Microarray 
analyses show there is a strong similarity in gene expression
 
between primary HSCs 
and LX-2 (98.7%),
 
with expression of multiple neuronal genes (Xu et al., 2005). LX-
2 cells are widely regarded as a suitable cell line to investigate the activation process 
and its relation to the pathophysiology of fibrosis.  
 
 
C3A cell line 
The C3A cell line is a specialized hepatocyte cell line derived from the human 
hepatoblastoma cell line HepG2. Although, there is considerable literature regarding 
HEPG2 cells as a suitable model to study hepatocyte function and its responses to 
injurious factors during liver fibrosis, the C3A cell line appears even more 





Studies on extrahepatic bioartificial liver devices have used the C3A cell line 
because of its ability to perform most of the primary hepatocyte functions including 
albumin production, detoxification of toxins via cytochrome P450 systems and 
production of urea. These functions were found to be either lost or diminished in 
HepG2 in comparison to C3A cells. The C3A cell line is found also to have a 
comparable nitrogen metabolism to perfused rat liver (ATCC). Table 1.5 illustrate 
the functions of HepG2 and C3A cell lines compared to the primary cell line. 
 
Furthermore, one study notes that C3A cells when cultured in 3-dimensional 
spheroids shows a more typical morphology of the primary hepatocyte i.e. tight 
junctions, polar cells and bile caniculi and moreover, enhanced cytochrome P450 
expression than in the conventional culturing of this cell line (Elkayam et al., 2006). 
In contrast to C3A cells, primary hepatocytes had been found to lose their metabolic 
activity and more importantly, cease proliferation relatively quickly.  
 
 One study showed further enhancement of the functionality of the C3A cell line 
through conditioning the cells with lactate/ pyruvate, octanoate and ammonium 
chloride (LPON). With this treatment, gluconeogenesis, β-oxidation and urea 
production were all increased (Filippi et al., 2004).  
 
Given the above information, we decided that the C3A cell line would be an 




C3A cell line HepG2 cell line 
Albumin production *** ** * 
Alpha fetoprotein 
production 
*** ** * 
Grow in glucose 
deficient medium 
* ** * 
Cytochrome P450 *** ** * 
Urea production *** ** * 
 
Table 1.5: Comparison of the main properties of hepatocyte primary cell to the C3A 
and HepG2 cell lines 
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1.3 Project Aims: 
 
The aims of this thesis were to address the following questions: 
 
1. Can C3A and LX-2 cell lines be cultured in a selenium-deficient medium that 
allows cell viability to be retained and allow study of the expression of the 
two main cytoplasmic selenoenzymes (TR1 and GPX1) that can perform the 
anti-oxidant action in these cells? (Chapter three) 
2. Do treatments with fatty acids lead to fat-loading of C3A and LX-2 cells?. Do 
such treatments modify the expression of TR1 and GPX1? (Chapter four) 
3. Does selenium supplementation of C3A and LX-2 cells protect them from 
oxidative damage induced by lipid hydroperoxides? (Chapter five) 
4. What is the relationship between α-1 pro-collagen mRNA expression and 
selenium status in LX-2 and C3A cells? (Chapter six) 
5. What is the selenium status of healthy subjects in the UK?. Does this differ 



























2 CHAPTER TWO         
                                          






2.1.1 Commercially available material 
2.1.1.1 Cell culture materials 
Dulbecco‟s modified Eagle‟s medium (DMEM) (4.5 g/l glucose); Hank‟s balanced 
salt saline (HBSS); phosphate-buffered saline (PBS); sodium pyruvate; L-glutamine; 
penicillin/streptomycin solution; amphotericin B solution; trypsin; fetal bovine serum 
(FBS) were purchased from Lonza Ltd. (Wokingham,, UK). 
 
2.1.1.2 Radioisotopes 
For protein iodination of TR1 and TR2, Bolton & Hunter reagent (18.5 MBq, 500 
µCi) and iodine-125 (37 MBq, 1 mCi, specific radioactivity 16 MBq/ nmol) were 
supplied by GE Healthcare, Little Chalfont, UK. 
 
2.1.1.3 Other chemicals 
Acetic acid; ethanol; ethylenediaminetetraacetic acid (EDTA); hydrochloric acid; 
methanol; microcrystalline cellulose; orthophosphoric acid; nitric acid; transforming 
growth factor β1 were supplied by MERCK, Leicester, UK. 
 
Bovine serum albumin powder (BSA); Coomassie brilliant blue (R-250 and G-250); 
5,5-dithiobis (2-nitrobenzoate) (DTNB); dithiothreitol (DTT); insulin; G-100 gel for 
gel filtration; glutathione; glutathione reductase; fatty acid-free bovine serum 
albumin; NADPH; sodium azide; sodium selenite; Sephadex G-75 gel; thioredoxin; 
t-butyl hydroperoxide, menadione, and hydrogen peroxide were supplied by Sigma 
 
37 
Aldrich Company Ltd, Poole, Dorset, UK. Lactate dehydrogenase (LDH) kits, 
Triglyceride (TG) kits and Cholesterol kits were purchased from Alpha Laboratories 
(Eastleigh, Hampshire, UK). Precinorm®U Universal control serum was supplied by 
Boehringer (Ingelheim, Germany). 
 
 Human α-1 pro-collagen primers and probe were purchased from Eurofins MWG 
operon (London, UK):  
Forward primer 5'- 
CAAGAGGAAGGCCAAGTCGAGG-3', 
Reverse primer 5'- 
CGTTGTCGCAGACGCAGAT-3' and  
Probe FAM 5'- 
CCTCAGGTACCATGACCGAGACGTGTGGAAACC-3' TAMRA.  
All materials needed for RNA extraction, cDNA and Taqman
TM
 steps were 
purchased from Applied Biosystems (Warrington, UK).  
 
Thioredoxin reductase 1 (TR1) and 2 (TR2) proteins were obtained from Lab 
Frontier (Seoul, Korea). Sheep anti-rabbit serum (secondary antibody used in TR1 
and 2 RIA) were purchased from (Fitzgerald laboratories, concord, USA). The 
Cytometric Beads Array (CBA) was purchased from BD Bioscience, San Diego, CA, 
USA. 
 
Cell culture inserts for 6-well plates (3.0 µm, translucent polyethylene terephthalate 















Figure 2.1: Illustration of the cell culture inserts (left) and its application on the well 




2.1.2 Non-commercially sourced materials 
2.1.2.1 Cell lines 
The LX-2 cell line was a kind gift from Dr Scott Friedman (Division of Liver 
Diseases, Mount Sinai School of Medicine, New York, USA). The C3A cell line was 
a gift from the Hepatology Unit, the Royal Infirmary of Edinburgh. 
 
2.1.2.2 Blood samples 
For data in chapter seven, blood samples were collected from patients with type 2 
diabetes mellitus under the supervision of Prof. Peter Hayes from both the liver unit 
and diabetic clinics. The study was approved by the Ethics committee of Edinburgh 
Royal Infirmary, NHS Lothian. 
 
2.1.2.3 Antibodies 
Antibodies to human placental thioredoxin reductase (TR1) were raised in rabbits to 
cytosolic proteins purified to homogeneity. Dr Forbes Howie, Clinical Biochemistry, 
University of Edinburgh supplied the antibodies to human TR1. TR2 antibody was 




2.2 General methods 
2.2.1 Cell culture and maintenance 




 tissue culture flasks in Dulbecco‟s 
modified Eagle‟s medium (DMEM) containing 10% fetal bovine serum (v/v), 
sodium pyruvate (1 mM), 2 mM L-glutamine,
 
100 IU penicillin, 100 mg/ml 
streptomycin and amphotericin B (0.25 µg/ml) and incubated
 
at 37 °C in a 5% CO2-
air humidified atmosphere. The medium
 
was changed 48 hr after initial plating. Cells 
were passaged every 7-10 days.  
 
2.2.2 Cell collection  
Cells were collected, unless otherwise stated as follows: Cell monolayers were 
washed twice with 2 ml HBSS, and harvested via scraping with 2 ml HBSS. 
Efficiency of harvesting was determined by light microscopic inspection. The cells 
were then pelleted by centrifugation at 500 x g for 10 min. The HBSS was aspirated, 
and the pellets frozen at - 80°C until enzyme assays were carried out. Prior to 
assessment, the cell pellets were thawed resuspended in 200 µl and lysed by 
sonication (three pulses of 10 sec using a Soniprep 150 Sonicator) on ice in 0.125 M 
potassium phosphate buffer (pH 7.4) containing 1 mM EDTA and 0.1 % Triton X-
100 (peroxide- and carbonyl-free). 
 
2.2.3 Enzyme activity assays 
2.2.3.1 Thioredoxin reductase activity assay 
This assay was performed on a Cobas-Fara centrifugal analyser (Roche Diagnostics, 
UK) by adapting the method of (Hill et al., 1997b) 
  
The assay reagent comprised of 5 mM DTNB, 0.24 mM NADPH, 10 mM EDTA, 0.2 
mg/ml BSA in 100 mM potassium phosphate/50 mM potassium chloride buffer, pH 
7.0. EDTA is necessary since mammalian Thioredoxin reductase activity is inhibited 
by heavy metal ions. Assay reagent was stored in the dark when not in use.  
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A placental cytosol preparation was used as a control: Normal 40-wk full-term 
placentas obtained within 2 hr of delivery were used, and all procedures were 
performed at 4C or on ice. The placenta (~550 g) was cut into pieces 4 cm

. 
Following removal of the umbilical cord and amniotic membrane, the pieces of 
placenta were washed with 2 L of 50 mM Tris/HCl, pH 7.4, at room temperature, 
containing 1 mM EDTA, 0.5 mM DTT (buffer A), and centrifuged at 30,000 x g for 
1 hr.  
 
Four internal controls were prepared by diluting a pooled stock solution of human 
placental cytosol with FBS at two-fold, four-fold, sixteen-fold and thirty two-fold 
dilutions. The controls were constructed to cover the range of activities given by the 
different cell types in the assay, as assessed by historical lab data (~ 0.25 to 5.0 U/g 
proteins). The controls were dispensed into 180 µl aliquots and frozen at - 80°C. 
Good linearity was demonstrated for increasing dilutions of human placental cytosol.  
 
Cell pellets were collected as described in section 2.2.2. The lysates were centrifuged 
at 500 x g, and kept on ice until assay took place.  
 
This assay is based on the conversion of the substrate DTNB (5, 5´- dithiobis 2-
nitrobenzoate) to a yellow chromophore (absorption max at 412 nm), according to 
the reaction:  
DTNB + NADPH + H
+




Thioredoxin reductase activity was measured on a Cobas-Fara centrifugal analyser 
(Roche Diagnostics, UK) using 30 µl of sample pipetted into the cuvette ring with 30 
µl diluent (distilled H2O) and 190 µl of reagent. All samples were warmed to 37°C 
prior to assay. The assay was performed on the Cobas-Fara centrifugal analyser with 
absorbance measurement at 412 nm over a period of 0.5 to 290.5 seconds. The 
absorbance was read once every 10 seconds following an initial reading at 0.5 sec, 
and the rate of absorbance change determined by kinetic analysis over the linear 
portion of the curve (100.5 to 250.5 seconds). Results were corrected for protein 








 (Holmgren and 
Bjornstedt, 1995). TR activity is expressed in units per gram protein (U/g). One unit 
of mammalian TR activity is defined as 1 mol TNB formed per minute (Holmgren 
and Bjornstedt, 1995).   
 
Intra-assay and inter-assay precision data as previously calculated by Dr Michelle 
Lewin (Lewin, 2003) using four quality control (QC) pools in one assay were 
ranging from 5-18 % and 17.1-21.4 % respectively. 
 
 
2.2.3.2 Glutathione peroxidase activity assay 
The reagent was made up of the following: 40mM NADPH, 60 mg reduced 
glutathione, 28 U glutathione reductase, 28 ml of assay buffer which is comprised of 
(0.05 M) sodium phosphate buffer (pH 7.4), 5 mM EDTA and 1 ml sodium azide 
(112.5 mM). Hydrogen peroxide reagent was prepared separately (0.077 mM). The 
reaction mix was placed in a water bath at 25C to achieve temperature equilibration. 
 
Control blood samples obtained from Blood Transfusion Unit (Royal Infirmary of 
Edinburgh) were diluted 20-fold before use.  
 
GPX1 activity was measured using an assay method adapted for use on the Cobas-
Fara centrifugal analyser. The method used was as previously described in our 
laboratory (Beckett et al., 1990), and was based on the method described by DE 
Paglia and WN Valentine (1967). Briefly, GPX1 activity is assessed by monitoring 
the rate of conversion of NADPH to NADP

 , measured as a change in absorbance at 
340 nm in the presence of the substrate hydrogen peroxide (detailed in the reaction 
equation below).   
The reaction catalysed by GPX1 and utilised for its assay is as follows:   




Glutathione reductase is added to the reaction mix to maintain a constant 
concentration of glutathione.   
 
To measure GPX1 activity on the Cobas-Fara centrifugal analyser, a 20 µl sample 
was automatically pipetted along with 40 µl diluent (distilled H2O) and 183 µl 
reaction mix into a cuvette. The blank rate with water in place of the substrate was 
also measured. The reaction was started by addition of 7 µl of the hydrogen peroxide 
substrate solution, and the subsequent reaction rate was followed for 120 sec at 340 
nm. The first reading was taken at 0.5 sec, with each subsequent reading at 5 sec 
intervals.  
 
A unit of GPX1 is defined as that which oxidises 1 µmole of NADPH per min. The 




. The blank rate was 
subtracted from the rate obtained after substrate addition.  
 
2.2.4 Lactate dehydrogenase activity assay (LDH)  
Cell viability was assessed as the percentage retention of lactate dehydrogenase 
(LDH) by the cell. This assay is based on the procedure of Gay et al (1968). Briefly, 
intracellular and extracellular LDH activities of the cell lysates and culture medium 
respectively, were determined by following the rate at which NAD

 is reduced to 
NADH measured as a decrease in absorbance at 340 nm in the presence of lactate 
using a LDH kit method (Alpha Laboratories, Eastleigh, Hampshire, UK) modified 
for use on the Cobas-Fara centrifugal analyser. The rate of decrease in absorbance at 
340 nm, measured at 37C, is directly proportional to LDH activity in the sample. 
The results were expressed as % LDH activity retained, calculated as follows: 
intracellular LDH activity/ (extracellular LDH activity + intracellular LDH activity) 
x 100. 
 
Reagents were reconstituted by the addition of 10 ml of deionized water as indicated 
on the vial. After addition of water, the vial was stoppered and mixed by gentle 
inversion several times. The vial active ingredients were: 
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Tris buffer (100 mM), NAD (7 mM), lithium lactate (50 mM) and KCl (120 mM). 
 
For cell viability studies all cells were plated into 12 well plates at a density of 1 x 
10
5




for LX-2 cells. After treatment with 
t-BuOOH, 1 ml of the culture medium was removed from the cells and placed into 
pre-labelled Eppendorf tubes. Cell pellets were collected as described in section 
2.2.2. Cell debris in the culture medium and cell lysates were removed by micro-
centrifugation of all samples at 11,000 x g for 10 min prior to assay for LDH activity. 
 
Precinorm® U (a commercially produced „universal control serum; Boehringer 
(Ingelheim, Germany)) was used for quality control for every assay run.   
 
The change in absorbance at a wavelength of 340 nm was measured in 25 µl of 
sample in a final volume of 1500 µl of the reagent. The sample and reagent were 
pipetted into the cuvettes and incubated at 37C for 30 sec. The change in absorbance 
of the reaction mixture was read at 0.5 sec, and was then read every 5 sec for a total 
of 20 readings. One unit of activity per litre was calculated as follows: 
Activity in U/l=∆ absorbance/min×factor 
where the factor = total reaction volume (ml)×1000/6.3×sample volume (ml)×cuvette 
pathlength (cm) 
The LDH activity was expressed as units per litre (U/l) as determined by kinetic 
analysis.  
 
The LDH activity was also measured in culture medium that had not been in contact 
with cells as a measure of endogenous LDH in the culture medium, as well as after 
addition of Triton X-100 and PBS (lysis conditions). These blank values were 
subsequently subtracted from each extracellular and intracellular LDH measurement. 
The LDH activities in both the media and cell lysates were then calculated as 
described above. 
 
According to the manufacturer, the inter-assay CV (%) is 3.2 and the intra-assay CV 
(%) is 2.3. 
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2.2.5 Bradford assay for protein measurements 
Protein measurements were carried out utilising the dye-binding assay of Bradford 
(Bradford, 1976) adapted for use on the Cobas-Fara centrifugal analyser.   
 
The Bradford reagent was prepared by dissolving 100 mg Coomassie Brilliant Blue 
G-250 in 50 ml 95% ethanol. Then, 100 ml 85 % (w/v) phosphoric acid was added, 
and the mixture stirred for 30 min. The resulting solution was diluted with distilled 
H2O to a final volume of 1000 ml, filtered through Whatman grade 1 filter paper and 
stored at room temperature in a closed bottle. 
 
A standard curve was constructed using bovine serum albumin (BSA) as standard, 
and distilled water as the diluent, covering the range 0 to 100 mg/l.  
 
Bradford reagent (256 µl) was added to each cuvette, which was incubated for 100 
sec at 37C prior to sample addition, with an initial absorbance reading (595 nm) 
taken at 95 sec. Following the addition of 25 µl of sample plus 50 µl distilled H2O 
(diluent) to the cuvettes, a further incubation took place for 180 sec at 37C. A final 
absorbance was then read at 595 nm. The difference between the final and initial 
absorbencies was calculated, and a standard curve plotted. 
 
The protein concentrations of samples were interpolated from the standard curve. 
Samples were diluted with distilled water to fall in the middle portion of the standard 
curve and a quality control (QC) was run with every rotor to assess the 
reproducibility of the results.  
 





2.2.6 Triglyceride measurements 
Triglyceride measurements were made using a commercial kit adapted for use on the 
Cobas-Fara centrifugal analyser. The triglyceride assay is based on the method of 
Wako and the modifications by (McGowan et al., 1983) and P Fossati et al. (1982). 
The assay runs according to the following reactions: 
TG + H2O   Glycerol + free fatty acids 
Glycerol + ATP  Glycerol -3 phosphate + ADP 
Glycerol-3-phosphate + O2   DAP + H2O2 
H2O2  + 4-AAP + 3,5 DHBS Quinone-imine dye + 2H2O  
 
In reaction (a), triglycerides are converted to glycerol and fatty acids in the presence 
of water (H2O); in reaction (b), glycerol in the presence of adenosine triphosphate 
(ATP) is converted to glycerol -3 phosphate and adenosine diphosphate (ADP) while 
In reaction (c), glycerol -3 phosphate is oxidised by oxygen (O2) to form 
dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H2O2). In the final step 
(d), the hydrogen peroxide (H2O2), 4-aminoantipyrine (4-AAP) and 3,5-dichloro-2-
hydroxybenzene sulfonate (DHBS) are converted to a red coloured dye. The 
concentrations of triglycerides are proportional to the dye absorbance.               
 
The ready-to-use reagent contained the following ingredients: 
ATP (2.5 mM), Mg acetate (2.5 mM), 4-aminoantipyrine (0.8 mM), DHBS (1 mM), 
glycerol phosphate oxidase (GPO) (microbial) (>3000U/l), glycerol kinase 
(microbial) (>100 U/l), lipoprotein lipase (microbial) (>2000 U/l), horseradish 
peroxidase (>300 U/l), buffer (53 mM, pH 7).  
 
Cell pellets were treated as described in section 2.2.2. Cell debris in the cell lysates 
were removed by micro-centrifugation of all samples at 11,000 x g for 10 min prior 
to assay for triglyceride measurement. 
 
Precinorm® U was again used for quality control for every assay run.  
Samples (100 µl) were transferred into Cobas cups for triglyceride measurement. The 
change in absorbance at a wavelength of 500 nm was measured in 3 µl of sample in a 
 
46 
final volume of 303 µl (300 µl reagent and 3 µl sample). The sample and the reagent 
were pipetted into the cuvettes and incubated at 37C for 300 sec. The triglyceride 
concentration was expressed as mM as determined by kinetic analysis. 
 




2.2.7 Cholesterol measurements 
Cholesterol measurements were accomplished by using a commercial kit adapted for 
use on the Cobas-Fara centrifugal analyser. The cholesterol assay is based on 
enzymatic oxidation of cholesterol using cholesterol oxidase after hydrolysis of 
cholesterol esters. The formulation was based on the method of (Allain et al., 1974) 
as modified by (Roeschlau et al., 1974). 
 
The assay proceeds according to the following reactions: 
Cholesterol esters    Cholesterol + Fatty acids 
Cholesterol + O2     Cholest-4-en-3-one + H2O2  
2H2O2 + Hydroxybenzoic acid + 4-aminoantipyrine    Quinoneimine Dye +4 H2O 
The concentrations of cholesterol are proportional to the dye absorbance.  
 
The reagent was obtained ready to use and contained the following ingredients: 
Cholesterol oxidase (>200 U/l), cholesterol esterase (>500 U/l), horseradish 
peroxidase (>300 U/l), 4-aminoantipyrine (0.25 mM), hydroxybenzoic acid (10 mM), 
buffer (50 mM, pH 6.7) and surfactants.         
  
Cell pellets were collected as described in section 2.2.2.  
 




Samples (100 µl) were transferred into Cobas cups for cholesterol measurement. The 
change in absorbance at the wavelength of 500 nm was measured in 3 µl of sample in 
a final volume of 303 µl (300 µl reagent and 3 µl sample). The sample and the 
reagent were pipetted into the cuvettes and incubated at 37C for 300 sec. The 
cholesterol concentration was expressed as mM as determined by kinetic analysis. 
 
 

























2.2.8 Thioredoxin reductase 1 radioimmunoassay (RIA) 
2.2.8.1    Introduction 
 Thioredoxin reductase1 (TR1) was measured using an „in-house‟ radioimmunoassay 
developed in this laboratory by Dr. Forbes Howie, and has been described previously 
(Lewin et al., 2001; Miller et al., 2001). 
 
2.2.8.2     Preparation of antibody 
Primary antibody was raised in rabbits to an immunogen of human TR1 purified 
from placenta. The pre-precipitated secondary antibody was prepared by adding 25 
ml of sheep anti-rabbit serum to 1.5 ml normal rabbit serum and mixing overnight at 
room temperature to precipitate out the immunoglobulins. Following centrifugation 
(230 x g, 5 min), the supernatant was discarded and the precipitate washed four times 
with 0.05 M phosphate buffer (pH 7.4) containing 0.1 % BSA and 0.02 % sodium 
azide. After the final wash the supernatant was removed and the pellet was 
resuspended in the same 0.05 M phosphate buffer as described above, to give a final 
volume of 100 ml. 
 
2.2.8.3    Preparation of the assay diluent 
The assay was performed using a diluent of 25 mM potassium phosphate buffer, pH 
7.5, containing BSA 1 g/l, NaN3 0.2 g/l, and 10 mM dithiothreitol. This diluent was 
used for both the antibody and the tracer. 
2.2.8.4     Preparation of 125I-TR tracer 
Purified human placental TR1 was iodinated by Dr Forbes Howie using the Bolton-
Hunter iodination procedure (Bolton and Hunter, 1973). Briefly, the benzene from 
the Bolton Hunter reagent was dried off by directing a gentle stream of dry nitrogen 
into the vial (fume hood). Pure TR1 (5 g) in borate buffer was then added. Then the 
mixture was vortexed and spun down briefly. After incubation on ice for 60 min, 0.3 
ml borate/glycine buffer was added to stop the reaction. The tube then left for 10 min 
on ice. After that, 0.3 ml phosphate/BSA buffer was added and mixed. The mixture 
was then applied to a Packed 10 ml glass column of swollen Sephadex G-75 gel, 
with H2O plus 0.02% sodium azide and equilibrated with phosphate buffer, pH 7.4. 
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The column was then washed with 0.5 ml of Phosphate buffer before connecting a 
wash reservoir. After that, Every 1 ml fraction was collected separately until 25 ml 
were available. 
Radioactivity of these fractions was measured and fractions in the first peak were 
pooled. The 
125
I-TR tracer was immediately diluted 1:2 with FBS and stored at -20C 
for up to three months. For use in the radioimmunoassay the 
125
I-TR tracer was 
diluted with assay diluent so that approximately 10,000 cpm was added to each tube 
(mass approximately 50-100 pg TR/ tube). 
2.2.8.5     Preparation of standards, controls and samples 
Standards were prepared by diluting a stock solution of purified placental human 
TR1 (1 mg TR/l) with FBS to give the following concentrations: 0.5, 1, 2, 5, 10, 25, 
50 µg TR/l. Three controls were made by diluting a stock solution of human 
placental cytosol with FBS to give values of approximately 2.5, 5 and 25 µg TR/l. 
Both standards and controls were dispensed into aliquots and frozen at - 80C. 
 
Cell pellets were stored at - 80C immediately following harvesting. Prior to assay, 
samples were removed from the freezer, thawed, lysed by sonication, centrifuged and 
kept on ice until assay took place. Each sample was diluted with radioimmunoassay 
buffer between 1:10 and 1:25. 
 
2.2.8.6     TR1 radioimmunoassay 
Antibodies, tracer, standards, controls and samples were all warmed to room 
temperature prior to setting up of the assay. All samples, standards and controls were 
assayed in duplicate. For the assay 100 µl of 
125
I-TR tracer (~15,000 cpm) was 
pipetted together with 100 µl standard, control or sample. Primary anti-TR1 antibody 
(100 µl; final dilution 1: 30,000) was then added to all tubes (with the exception of 
the total counts) which were vortexed and incubated at 4°C overnight.  
 
The following day, pre-precipitated second antibody (donkey anti-rabbit serum) 
prepared as described above (section 2.2.8.2) was added to each tube (except the 
total counts), vortexed, and incubated at room temperature with shaking for 1 hour. 
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Following this, 1.5 ml wash solution (0.05 % v/v Brij 35 and 0.001 % w/v 
microcrystalline cellulose) was added (except to the total counts tubes) and the tubes 
centrifuged at 3000 x g for 30 min at 4C. The supernatant was decanted and the 
precipitate was washed with a further 1.5 ml of wash solution. 
125
I radioactivity in 
the precipitate was counted in a multi-well 1261 MULTIGAMMA Gamma Counter 
(Wallac, Gaithersburg, MD, USA). The standard curve was plotted and results 
interpolated using a MultiCalc data processsing package (LKB 1224-RIACalc RIA 
evaluation program) (Wallac, Gaithersburg, MD, USA). 
 
Results were corrected for protein measured by the Bradford method (section 2.2.5). 
Intra-assay and inter-assay precision data as previously calculated by Dr Michelle 
Lewin (Lewin, 2003) using 9 replicates of each pool (5 and 25 µg TR/ l) were read 
from a single standard curve. The intra-assay CVs (%) were 14.4 and 3.9 for 5 and 
25 µg TR/ l respectively. The inter-assay CV (%) was determined by running the 
controls in each assay for 12 consecutive assays. They were 8 and 11.1 for 5 and 25 
µg TR/ l respectively. 
 
The minimum detection limit of the TR RIA was 1.50 µg TR/l. The working 
concentration range of this assay was 3.50 - 50.0 µg TR/l and was defined as the 
concentration range which had a CV of less than 10 %. These data were calculated 
by Dr Lewin (Lewin, 2003) from 9 assays. 
 
 
2.2.9 Thioredoxin reductase 2  
The assay was performed as for TR1 (see section 2.2.8). 
Standards were prepared by diluting a stock solution of purified human TR2 (1 mg 
TR/l) with FBS to give the following concentrations: 0.78, 1.56, 3.12, 6.25, 12.5, 25, 
50 µg TR/l. Two controls were made by diluting a stock solution of human placental 
cytosol with FBS to give values of approximately 9 and 30 µg TR/l. Both standards 
and controls were dispensed into aliquots and frozen at - 80C. 
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2.2.10  Taqman Real-Time PCR  
2.2.10.1       Primers and probe concentrations 
The relative expression of α-1 pro-collagen mRNA was assessed using Quantitative 
Taqman Real-Time PCR. The primers and probes used were of the following 
concentrations: 
The forward primer concentration was 13 pmole/µl, 
The reverse primer concentration was 22 pmole/µl and  
The probe concentration was 36 pmole/µl. 
 
These stocks were diluted using RNA-free water into intermediate stocks from where 
it can be diluted 25 times in the reaction mix of the taq-man plate. Final 
concentrations were 250 nM/250 nM/100 nM (For/Rev/Probe). 
2.2.10.2       RNA extraction and mRNA measurement 
To extract the RNA of harvested cells, the cells were collected and resuspended in 
lysis buffer (RLT buffer, Qiagen,West Sussex, UK). Then the RNA was extracted 
with the RNeasy mini-kit (Qiagen, Qiagen,West Sussex, UK) following the 
manufacturer‟s protocol. The quantity and the quality were assessed using a 
Nanodrop spectrophotometer (ND-1000, Nanodrop Technologies Inc, Wilmington, 
DE, USA). 
 
The Quantitative Taqman Real-Time PCR was the method used to assess the 
expression of α-1 pro-collagen mRNA. The protocols of the manufacturer were 
followed and ABI Prism 7900 Sequence Detector (Applied Biosystems) was used to 









2.2.11  Oil-red O staining 
 
This method was used to stain the fat droplets accumulated in the cells. The method 
used was previously described by Green and Kehinde (1975). The cells were stained 
kindly by Dr Forbes Howie as follows: 
 
0.2 g of oil red O was dissolved in 200 ml of isopropanol. The solution was warmed 
to 56 
o
C for at least 1hr and then cooled and stored at room temperature. Working 
solution was then prepared immediately before use by adding 4 parts of distilled 
water to 6 parts stock solution. The working solution was then vortexed and left for 
10 min. Finally it was filtered through a fine filter paper (No. 42 Whatman). 
 
Cells were cultured on cover slips for the purpose of staining. After completion of 
the experiment, cells were fixed with 10% formalin for 10 mins and washed in 60% 
isopropanol for 30 seconds. Oil red O staining was conducted for 10 minutes. The 
cells then washed in 60 % isopropanol for 5 seconds. After that, they washed in 
distilled water and Mayer‟s haematoxylin solution (1 ml) was then added for 30 secs. 
Washing was repeated with distilled water. Cells were then counter stained with 
sodium phosphate for 5 min and air-dried. Finally they were mounted using a water-
based preservative.  
 
2.2.12  Selenium measurements in blood samples  
Selenium was assessed by Mr.Gordon Marr using atomic absorption 
spectrophotometry.  
 
A Perkin Elmer AA800 graphite furnace with Zeeman-effect background correction 
(Perkin Elmer Life and Analytical Sciences, Norwalk, Connecticut, USA) was used 
to assess selenium concentrations in the collected EDTA plasma samples. 
 
Samples were taken in EDTA tubes and plasma separated. Plasma samples were 
diluted two-fold in 0.2% HNO3. A Pd/Mg in HNO3 matrix modifier was used to 
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stabilise the selenium. The method of additions calibration was used to cancel out 
any matrix effects in the sample. Frozen human EDTA was spiked to produce a 
calibration curve.  
 
For the selenium measurements, a palladium matrix modifier was used because of its 
higher pyrolysis temperature and therefore a reduction in interference. This produced 
a more sensitive assay for serum. 
  
Zeeman-effect background correction 
Despite using a matrix modifier and high atomisation temperatures, other elements 
such as phosphate and iron can still interfere with the selenium measurement.. To 
decrease interference from these elements the Zeeman-effect background correction 
system was used on the AA 800. Basically, atomic lines subjected to a strong 
magnetic field are split into three or more parts. The extra lines occur when the 
magnet splits the electron energy levels in the atoms. The three lines include one at 
the original wavelength and two either side, at the simplest split. The higher the 
magnetism the greater the split. This allows atomic species to be split from non-
atomic species and the difference being noted. Using the Zeeman-effect background 
correction can stop interference from phosphate and iron at levels of 50mg/l 
 
The lower detection limit for selenium in this method was 0.54 μg/l. This high 
sensitivity of the method was achieved by using the electrode-less discharge lamp 
(EDL) lamp.  
 
Pool samples were used to indicate the precision of the method. The inter-assay and 
intra-assay variations were 9.8 % CV and 6.6 % CV, respectively.  
 
The bias (accuracy) calculated by measuring known selenium concentrations from 





2.2.13  Cytokine measurements 
The concentrations of six cytokines were kindly measured by Dr Suzanne Mackenzie 
using the commercially available BD Cytometric Beads Array (CBA). These 
cytokines were interleukin-8 (IL-8), interleukin-1β (IL-1β), interleukin-6 (IL-6), 
interleukin-10 (IL-10), tumour necrosis factor- (TNF) and interleukin-12p70 (IL-
12p70). This kit basically can assess multiple analytes in a single sample and with 
combination of flow cytometry, the method could attain a sensitivity ranging from 
1.9 pg/ml for IL-12 up to 7.2 pg/ml for IL-1β with no cross reactivity between the 
assessed analytes.  
 
2.2.14  Statistical analysis and computer programmes used 
One-way ANOVA with Tukey post-test (comparing each column to others) was used 
as the statistical test unless otherwise mentioned. Graph-Pad Prism 4.00 software 
(Graph-Pad Software Inc., San Diego, USA) was used to create the figures. Two-way 



























3 CHAPTER THREE        
                                                  
THE EFFECT OF SELENIUM DEPLETION AND 
REPLETION ON SELENOENZYME EXPRESSION OF 
C3A AND LX-2 CELLS 
3.1 Introduction: 
 
One of the primary hypotheses of this thesis is that selenium deficiency in 
hepatocytes and stellate cells leads to unopposed oxidative stress giving rise to an 
inflammatory response which in turn activates fibrogenesis in the stellate cells. 
Selenium is a trace element necessary for the expression of selenoenzymes including 
the family of thioredoxin reductases and glutathione peroxidases (Allan et al., 1999; 
McKenzie et al., 2002). Selenium is required in sufficient amount in tissues to ensure 
that the selenoenzymes are maximally expressed (McKenzie et al., 2002) and this 
promotes optimal anti-oxidant protection. When selenium availability is inadequate, 
sub-optimal expression of selenoenzymes occurs leaving cells vulnerable to 
oxidative damage (McKenzie et al., 2002). To be able to investigate the induction of 
selenoenzymes by selenium supplementation, there is a need to develop a culture 
system that is selenium-deficient but allows at the same time maintenance of 
adequate cell viability. 
 
The selenium content of basal culture media vary; for example, basal DMEM for 
mouse hybridomas contains 1 nM of selenium, but RPMI 1640 medium used to 
culture human hepatoma cells contains 30 nM selenium (Freshney, 1992). The 
DMEM basal medium used previously in our laboratory had a very low selenium 
concentration of 0.35 nM (Lewin, 2001), and is classified as selenium-deficient 
medium. Various medium supplements also have different selenium concentrations; 
for example, the selenium content of FBS may vary, with values ranging from 
undetectable to 200 nM (Leist et al., 1996), 480 nM (Fujiwara et al., 1999), and  160-
180 nM (Geiger et al., 1993). Selenium found in FBS and other protein supplements 
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is exclusively incorporated covalently into the proteins of the serum supplements. As 
such many believe that selenium in these selenoproteins is neither bioavailable nor 
readily accessible by cells in culture (Brigelius-Flohé et al., 1995; Marcocci et al., 
1997). For this reason experiments concerning the effect of selenium 
supplementation on promoting the synthesis of selenoproteins in cells require 
selenium to be added as either sodium selenite or selenomethionine. These 
compounds can readily enter the cell and exert a biological action through being 
converted to active selenide moieties that can be used to synthesize a selenocysteine 
residue at the active site of selenoenzymes (Baker et al., 1998; Brigelius-Flohé et al., 
1995).  Sodium selenite can prove toxic in doses in excess of 1µM but at the 
concentration used to supplement cells (5-200 nM) no such toxicity is observed. 
 
It is well established that cell culture is a useful tool to investigate in-vitro various 
metabolic disorders. One of the aims of this study was to produce an in-vitro liver 
cell model that comprised cells grown in a wide range of selenium environments. 
The concentration ranges of selenium studied should cover the range from markedly 
selenium deficient to levels of selenium in excess of those required to maximally 
express selenoenzymes without being toxic. This range would encompass the 
selenium  status of the UK population who is regarded as having only approximately 
40% of the Selenium intake required to optimise the expression of GPX in red cells 
(Brown et al., 2000). In order to develop these models of human liver, C3A and LX-
2 cells were used to represent human hepatocytes and human hepatic stellate cells, 
respectively. Culture conditions that would allow these cells to remain viable in 
selenium-deficient medium were required and, furthermore, it was important to 
confirm that these cell lines would respond to selenium supplementation added as 
sodium selenite by up-regulating the expression of the TR and GPX selenoenzymes. 
 
The aims of this chapter were to establish culture conditions that allowed the 
following: 
1. Maintenance of cell viability under selenium-deficient and replete conditions 
for C3A and LX-2 cells. 
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2. Induction of thioredoxin reductase 1 and glutathione peroxidase 1 expression 
after selenium-supplementation.  
3.2 Methods  
 
General protocols: 
For experiments in this chapter, C3A and LX-2 cells were seeded and maintained in 
DMEM containing 10 % FBS as described in section 2.2.1. The cells were passaged 
and re-plated into two 6-well (35 mm) or 12 well plates for each cell type. After 24 
hr incubation (i.e. at confluence) treatments were started as described below. 
 
Protocol 3.2.1: Sodium selenite was added at increasing doses, 0, 5, 10, 40, 50, 100 
or 200 nM. Cells were then incubated for a further 72 hours, a time that allows a new 
steady state for selenoproteins expression. Following this incubation period, the cells 
were harvested (section 2.2.2). Thioredoxin reductase activity was measured 
according to the method described in section 2.2.3.1. TR1 content was measured by 
RIA as described in section 2.2.7. 
 
Protocol 3.2.2: The medium was changed to the one of the following media for a 
further 72 hours: DMEM medium with added IT (10 µg/ml Insulin /5 µg/ml 
Transferrin, DMEM medium with IT (10 µg/ml insulin/5 µg/ml transferrin) plus 
selenium (100 nM), 10 % FBS-supplemented DMEM medium, 10 % FBS-
supplemented DMEM medium plus selenium (100 nM). LDH levels in cells and 
media were then assessed as described earlier.  
 
Protocol 3.2.3: The medium was changed to IT-supplemented medium, (insulin [10 
µg/ml] / transferrin [5 µg/ml]). After further incubation for 24 hours, sodium selenite 
was added at increasing concentrations, 0, 5, 10, 50, 100, 200 nM. Cells were then 
incubated for a further 72 hours. Following the incubation, the cells were harvested 
and TR activity, TR1 content and GPX1 activity assays were conducted. 
 
Protocol 3.2.4: The medium was changed to IT-supplemented medium. After a 
further 24 hours of culture, sodium selenite (100 nM) was added to the cells for 72 
hours. Cells then were exposed to IT (10 µg/ml (I) /5 µg/ml (T)) supplemented 
medium (i.e. no selenium present). Cells were collected at 0, 24, 48, 72, 96 hours 
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after commencement of selenium depletion. Harvested cells were stored at - 80°C 
until enzyme assays were carried out for both TR1 protein content and GPX1 
activity. Collection and assessment of the TR1 and GPX1 activity in these cells has 
been described in section 2.2.2 and 2.2.7 and 2.2.3.2 respectively. 
 
Protocol 3.2.5: The medium was changed to IT-supplemented medium. After a 
further 24 hours of culture, sodium selenite (100 nM) was added to the cells for 72 
hours. Following the incubation, the cells were harvested and TR2 assay was 






























3.3.1 Optimization experiments 
 
3.3.1.1 Thioredoxin reductase 1(TR1) expression and activity response of C3A 
and LX-2 cells to increasing selenium supplementation: 
 
The intracellular expression of TR1 in cultured C3A cells was compared to that in 
cultured LX-2 cells using defined culture conditions. Experiments in this section 
were done according to protocol 3.2.1. 
 
It was important to demonstrate that these cells expressed significant levels of TR1 
and furthermore that the expression of TR1 is responsive to increasing doses of 
selenium. Culture medium supplemented with 10% FBS was chosen in the first 
instance to allow cell plating and viability assessment as FBS is frequently a 
component of many typical cell culture media. It was hoped that this 10 % FBS-
supplemented medium might serve as selenium-deficient medium allowing 
selenoenzyme expression to increase in response to addition of selenium. If this 
occurred then the medium would be suitable for further studies into the effect of 
selenium supplementation.  
 
As shown in figure 3.1A, C3A cells grown in 10 % FBS responded to additional 
selenium supplementation by increasing levels of TR1 activity. TR1 content showed 
a similar response (figure 3.1B) to increasing selenium supplementation suggesting 
that the increased thioredoxin reductase activity largely reflects changes in TR1 
expression. Selenite addition achieved approximately a 2-fold increase in TR1 





























































Figure 3.1: (A) TR activity and (B) TR1 protein level in C3A cells.  
The response of (A) TR activity and (B) TR1 protein levels to selenium 
supplementation is shown. The cells were treated with increasing selenium 
concentrations (as sodium selenite) for 72 hours. TR activity and TR1 levels on 
harvested cells were assessed as described in 2.2.3.1 and 2.2.7 respectively. 
Measured activity represents both cytoplasmic and mitochondrial thioredoxin 
reductases. Data represent the mean ± standard error (± SEM). (A) n=3 and (B) n=4 
experiments, each data point analysed in triplicate within each experiment.  * 




























Interestingly, as shown in figure 3.2, the hepatic stellate LX-2 cells behaved 
differently to C3A cells. Both TR activity and TR1 content were not induced by 
selenium supplementation of 10% FBS culture medium, even at doses of selenium as 
high as 200 nM.  
 
To investigate the possibility that LX-2 cells were not responsive because of the 
potential bioavailability of selenium contained in the 10% FBS culture medium, the 
experiment was repeated under conditions where FBS was absent from the culture 
medium. However, the cells failed to survive over the 72 hours incubation period of 
the experiment (results not shown). At this point of the study, it was necessary to 
identify a medium which allowed maintenance of LX-2 cell viability in the absence 
of FBS and selenium.  
 
FBS-free medium is commonly supplemented with BSA to help maintain a protein 
balance for tissue culture. For that purpose BSA of various concentrations (0-0.75%) 
was used to serve as a selenium deficient medium but it also failed to maintain cell 
viability (see appendices A.3.2.1). 
 
Subsequent experiments (detailed in appendices A.3.2.2) established that cell 
viability for LX2 cells was possible in basal medium supplemented with insulin and 


















































   
























Figure 3.2: (A) TR activity and (B) TR1 protein level in LX-2 cells.  
The response of (A) TR activity and (B) TR1 protein expression to selenium 
supplementation over the selenium range 0 to 200 nM for 72 hours. Cells then were 
collected and assessed at 72 hours. TR activity represents total TR, including 
cytoplasmic and mitochondrial TR. The graph shown represents the mean ± standard 
error (± SEM) for (A) n=3 and (B) n=4 experiments, each data point analysed in 




























3.3.1.2 Comparison of insulin/transferrin supplemented medium with FBS-
supplemented medium on TR1 and GPX1 response to selenium 
supplementation of C3A and LX-2 cells: 
 
To illustrate further the utility of IT-supplemented DMEM medium as compared to 
10 % FBS supplemented medium, experiments were conducted as described in 
protocol 3.2.2. 
 
Figure 3.3 confirms that selenium supplementation of IT medium significantly 
increases the level of TR1 in C3A and LX-2 cells compared to that in cells treated 
with selenium-deficient IT medium. TR1 content is at a similar level to cells grown 
in FBS-supplemented medium. Furthermore, as before, LX2 cells grown in FBS-
supplemented medium were unable to show TR1 responsiveness to added selenium  
 
Glutathione peroxidase 1, like TR1, is a major selenoenzyme that is thought to 
contribute to cell protection from oxidative damage. Glutathione peroxidase 1 is the 
isoenzyme found in cytosol and thus protects the same cellular compartment from 
oxidative damage as TR1. Moreover, glutathione peroxidase 1, like TR1, responds to 
selenium supplementation (McKenzie et al., 2002).  
 
As shown in figure 3.4, GPX1 activity measured in both C3A and LX-2 cells 
cultured in the IT-supplemented medium plus or minus selenium was responsive to 
selenium supplementation.  
 
LX-2 cells grown in FBS had significantly (p<0.001) higher GPX1 activity than cells 
grown in IT, again suggesting that a selenium source in FBS was available to the 
cells to promote selenoenzyme synthesis (figure 3.4B). In C3A cells selenite 
(100nM) stimulated GPX1 activity in cells grown in IT media to the same level as 


































































Figure 3.3: Effect on selenium supplementation of various media on TR1 protein 
level of (A) C3A and (B) LX-2 cells. 
Both C3A and LX-2 were plated in DMEM medium containing 10 % FBS. After 24 
hours, the medium was removed and the different supplements as shown were added 
for 72 hours. Cells were then collected and assessed for TR1 levels. The selenium 
concentration was 100 nM. These experiments were done in triplicate in three 
different experiments. The graph shown represents the mean ± standard error 
































































































Figure 3.4: Glutathione peroxidase 1 activity in (A) C3A and (B) LX-2 cells after 
selenium (100nM) supplementation.  
Both (A) C3A and (B) LX-2 were plated in DMEM medium containing 10 % FBS. 
After 24 hours, the medium was changed to IT-supplemented medium or 10 % FBS- 
supplemented medium for 24 hours. 24 hours later, sodium selenite (100 nM) was 
added for a further 72 hours. The graph shown represents the mean ± standard error 
(±SEM) of 3 experiments. Each experiment was done using triplicate wells for each 










3.3.2 Hypothesis driven experiments 
 
 
3.3.2.1 Dose response of selenium supplementation on TR1 content 
and GPX1 activity of C3A and LX-2 cells: 
  
The purpose of this experiment was to confirm that cells grown in IT-supplemented 
medium were  responsive to increasing doses of selenium and to determine levels of 
selenium supplementation that allowed maximal expression of TR and GPX (see 
protocol 3.2.3). 
 
As seen from figure 3.5 and 3.6, both TR1 and GPX1 increased in response to 
increasing amounts of selenium supplements. Optimal expression of TR1 and GPX1 
was achieved at a selenite dose of 50 –100nM. While TR1 increased 2-fold, GPX1 


















































































Figure 3.5: Glutathione peroxidase 1 activity response to selenium supplementation 
when grown in IT-supplemented medium in (A) C3A and (B) LX-2. 
Both C3A cells and LX-2 cells were plated and grown in DMEM medium 
containing 10 % FBS. After 24 hours cells were placed in IT-supplemented medium 
for 24 hours. After a further 24 hours, selenium at the concentrations shown was 
then added for a further 72 hours. This graph represents mean ± standard error 
(±SEM) for 3 different experiments. Each data point was analysed using triplicate 
























































Figure 3.6: Response of TR1 protein levels to selenium supplementation (IT-
supplemented medium) in (A) C3A and (B) LX-2 cells. Both C3A cells and LX-2 
cells were plated and grown in DMEM medium containing 10 % FBS. After 24 hours 
cells were placed in IT-supplemented medium for a further 24 hours. Selenium at the 
concentrations shown was then added for a further 72 hours. Cells were then 
harvested and TR1 content assessed. This graph represents mean ± standard error 
(±SEM) of three independent experiments where each data point within an 
experiment was analysed using triplicate wells. * p<0.05, ** p<0.01, *** p<0.001 







3.3.2.2 Hierarchy study of TR1 and GPX1 profile in C3A and LX-2 cells in 
selenium-deficient medium: 
 
To assess the hierarchy of retained selenoprotein expression in selenium deficiency 
experiments were conducted according to protocol 3.2.4. 
 
Figure 3.7 A illustrates that GPX1 activity was quickly lost from C3A and LX-2 cells 
when cells that had been exposed to optimal doses of selenite were switched to 
selenium-deficient medium. After 72 hours in selenium deficient media, the GPX 
activity remaining in C3A and LX-2 cells was only 25% and 10% respectively of 
that found at time zero (figure 3.7A). In contrast, TR1 showed only a modest fall in 
content over this time period decreasing to 63% of content in C3A cells and 71% of 




















































































Figure 3.7: The effect of selenium depletion on (A) GPX1 activity and (B) TR1 
content of C3A and LX-2 cells: 
Both (A) glutathione peroxidase 1 activities and (B) thioredoxin reductase 1 protein 
levels were assessed. C3A and LX-2 cells were plated in DMEM medium containing 
10 % FBS. After 24 hours, the medium was changed to IT-supplemented medium. 
Selenium (100 nM) was then added for a further 72 hours. Cells then were exposed 
to selenium-deficient IT (10 µg/ml (I) /5 µg/ml (T)) supplemented medium. Cells 
were collected at 0, 24, 48, 72, 96 hours after commencement of selenium depletion 
and the GPX activity and TR1 protein expression measured. The data represent mean 
± standard error (±SEM) of three independent experiments with each data point 
analysed in triplicate within each experiment. * p<0.05, ** p<0.01, *** p<0.001 







3.3.2.3 The level of thioredoxin reductase 2 is not affected by 
selenium status: 
 
Thioredoxin reductase 2 is an important selenoenzyme that is expressed mainly in 
the mitochondrial compartment of the cell. The experiment in this section was done 
according to protocol 3.2.5. 
 
Figure 3.8 illustrates that thioredoxin reducatse2 did not respond to added selenium 














































Figure 3.8: The response of TR2 to addition of an optimal selenium concentration 
[100 nM]: The medium was changed to IT-supplemented medium after 24 hours of 
plating. After a further 24 hours of culture, sodium selenite (100 nM) was added to 
the cells for 72 hours. Following the incubation, the cells were harvested and TR2 
assay was conducted as described in section 2.2.8. The data represent mean ± 
standard error (±SEM) of three independent experiments with each data point 








3.4 Conclusion and Discussion: 
 
Conclusions: 
1. IT was identified as an appropriate supplement to be used for future studies in 
this thesis, meeting all the criteria mentioned at the beginning of this chapter 
(i.e. allowing good cell viability in a medium that is deficient in selenium and 
alleviating a requirement for FBS). 
2. Both C3A and LX2 cells demonstrate increased expression of GPX and TR1 
in IT medium supplemented with selenium. The selenium dependency is 
dose-dependent, reaching maximal expression by 50 – 100 nM Se. 
3. Subsequent selenium depletion, following maximal expression of GPX and 
TR1 in selenium-containing IT, demonstrated that GPX activity falls more 
sharply than TR1 activity, consistent with the hypothesis of a hierarchy of 
selenoenzyme retention under conditions of selenium restriction. 




The results in this chapter establish that both C3A and LX-2 cells are capable of 
expressing similar levels of GPX1 and TR1.When C3A and LX-2 cells were grown 
and plated in 10% FBS-supplemented medium, LX-2 cells appeared to have access 
to selenium (most likely present in FBS covalently bound) and were thus able to 
maximally express both TR1 and GPX1. There are two possible explanations for this 
high expression of TR1. Firstly, higher levels of TR1 are associated with oxidative 
stress (McKenzie et al., 2002; Moon et al., 2005; Rundlof et al., 2007) and this might 
apply to LX-2 cells as these cells are partially activated cells and therefore also could 
be considered as partially injured or undergoing oxidative stress (Xu et al., 2005). 
Secondly, TR1 may be maximally expressed in LX-2 cells if these cells are able to 
access an adequate supply of selenium present in FBS. This latter explanation is 
supported by the low TR1 content when cells were grown in selenium-deficient 
medium (Allan et al., 1999). Furthermore, TR1 was unable to be further induced in 
LX-2 cells in FBS-supplemented medium containing additional selenium as sodium 
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selenite. The results support the hypothesis that LX-2 cells may have access to 
sufficient selenium in the FBS-supplement to allow maximal expression of TR1.  
 
In contrast to LX-2, C3A cells showed a good response to selenium supplementation 
of FBS-supplemented medium with sodium selenite. Although, several studies have 
been able to induce selenoenzymes when selenite is added to 10 % FBS-
supplemented medium in other cell-types (Campbell et al., 2007; Miller et al., 2002) 
FBS-supplemented medium was not used in any of our subsequent experiments for 
the following reasons: 
  
a)  The observation in this chapter indicated that LX-2 cells were capable of 
accessing the selenium supply incorporated into FBS whilst C3A were unable to 
achieve this (figure 3.2 vs 3.1). Thus it was necessary to culture both cell types in a 
culture medium that allowed controlled access of selenium supply to each cell type. 
 
b)  There was a clear evidence that cell viability, as assessed by the percentage LDH 
retention was achieved when the cells were cultured in IT medium.  
 
Further studies were conducted to confirm the practicality of IT-supplemented 
medium in achieving selenium depletion of cells to allow a reproducible 
demonstration of selenium-dependent increases in selenoenzyme expression. The 
results reported in this chapter confirmed that IT medium is able to meet these 
requirements. Moreover, the selenoenzymes GPX1 showed lower levels of basal 
expression in IT-supplemented medium compared to FBS-supplemented medium 
and could be induced by selenium supplementation. Thus, IT-supplemented medium 
is a suitable choice to maintain cell viability when serum-free conditions are to be 
used and provides an environment where selenoenzyme expression can be induced 
by selenium supplementation. 
 
TR1 showed the same level of protein expression in IT medium supplemented with 
selenium compared to FBS-supplemented medium. Furthermore, it was clear from 
experiments shown in figures 3.5 and 3.6 that the induction of GPX by addition of 
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selenium to selenium-deficient medium was more marked than that of TR1. This is 
explicable through the “Hierarchy hypothesis” concerning selenoenzymes. This 
hypothesis states that, under conditions of selenium deficiency, the expression of 
those selenoenzymes with more critical biological action is retained at the expense of 
less biologically important selenoenzymes. Thus, in selenium deficiency, TR1 
expression is preferentially retained whilst GPX activity is lost earlier. Figure 3.7 
shows that whilst GPX1 activity in LX-2 cells decreases comparatively quickly over 
time, TR1 largely maintains its expression over the same time course. According to 
the hypothesis, therefore, this difference reflects a greater hierarchical importance in 
diverting selenium to TR1, as opposed to GPX1 in LX-2. This observation is 
confirmed by several reports in other situations of selenium depletion (McKenzie et 
al., 2002). Although, both enzymes were decreased over time in C3A cells, GPX1 
was again depleted faster than TR1 in the same cells. Moreover, in selenium-replete 
conditions the GPX1 response was more profound than TR1 in C3A and LX-2 cells. 
This might suggest that GPX1 is more important anti-oxidant in cases of selenium-
replete tissue. Since the UK population as a whole has suboptimal expression of 
selenoproteins because of the suboptimal intake of selenium (Brown et al., 2000), 
TR1 may be more important than GPX1 as an antioxidant when selenium availability 
is limited by dietary supply, as is reported for the UK. 
 
Several studies indicate that the mitochondrial thioredoxin reductase (TR2) knockout 
mouse is embryologically lethal and hence it is assumed that the TR2 selenoprotein 
is at the top of the hierarchy of selenoproteins when selenium supply is deficient or 
limited (Nonn et al., 2003). This would be consistent with the essential role that TR2 
is known to have in mitochondrial function. In my experiments TR2 was not 
responsive to selenium depletion or repletion states in either C3A or LX-2 cells 
(figure 3.8). A similar maintenance of TR2 in selenium-deficient human vascular 
endothelial cells has been observed in our laboratory (Dr Beckett personal 
communication). Thus these data support the essential role of TR2 in the 
mitochondria of C3A and LX-2 cells, though TR2 was not subjected to further 





4 CHAPTER FOUR 
 







The pathogenesis of non alcoholic steatohepatitis (NASH) is commonly explained by 
the two-hit hypothesis (Day and James, 1998), where insulin resistance with fat 
accumulation in the hepatocyte represents the first hit. However, with prolonged 
exposure to fatty acid flux, the liver undergoes marked oxidative stress and it is this 
that is regarded as the second hit.  
 
Development of an in-vitro model of NAFLD has been challenging since the model 
of the disorder, as described by the two-hit hypothesis, requires not only fat-loaded 
cells (and/or displaying insulin resistance) in culture but also cells that are 
undergoing oxidative stress. 
 
In this chapter, LPON medium, a combination of Lactate [20 mM], Pyruvate [2 
mM], Octanoate [4 mM] and NH4Cl [4 mM] was chosen as one culture medium to 
fat load C3A and LX-2 cells. LPON-treated C3A cells  accumulate fat vacuoles 
which can be observed by electron microscopy (Filippi et al., 2004). The primary 
rational for using the various agents in LPON is as follows: Lactate/Pyruvate 
promotes lactate elimination, Octanoate  enhances β-oxidation, and NH4Cl  promotes 
ammonia elimination (Filippi et al., 2004). LPON proved to be a good model to 
induce insulin resistance and triglyceride accumulation (Celine Filippi, personal 
communications). This suggests that LPON could be used as a basis from which to 
develop a NAFLD in-vitro model since it leads to fat accumulation and produces 




Other studies have examined the ability of cultured hepatocytes (Hep G2 cells) to be 
fat-loaded with the common dietary long chain fatty acids, either oleate or palmitate 
or both combined, analysing their effect on fat accumulation and apoptosis. These 
studies  concluded that palmitate predisposes to more acute injury to the liver cells, 
while oleate appeared to promote a more chronic type of  injury (Gomez-Lechon et 
al., 2007; Wei et al., 2006). Thus a second model of fat loading was studied in this 
chapter, involving oleate and/or palmitate  
 
Although, NAFLD is a complicated disease where many factors are involved, this 
chapter will explore the development of an in-vitro model of NAFLD that exhibits 
triglyceride accumulation and more importantly, insulin resistance and/or oxidative 
stress leading to cellular damage.  
 
Hepatic stellate cells in the quiescent state contain fat droplets, mainly composed of 
vitamin A. These fat droplets release their vitamin A in the activation process. The 
ability of these cells to release vitamin A has been tested in one study using 
conditioned medium from macrophages (Friedman et al., 1993) which concluded that 
conditioned medium contains some activation factors which contribute to the 
depletion of fat droplets in these stellate cells. No other studies since then have 
explored the activation process of these stellate cells and its relationship to vitamin A 
release. 
 
The aims of this chapter were to assess fat-loaded hepatocyte and hepatic stellate cell 
models in terms of: 
1. The degree of triglyceride accumulation. 
2. Selenoenzyme expression in response to fat-loading which might reflect 








4.2 Methods  
 
General protocols 
For the purpose of experiments in this chapter, C3A and LX-2 cells were seeded and 
maintained in DMEM containing 10 % FBS as described in sections 2.2.1. The C3A 
and LX-2 cells were passaged and re-plated into 6-well plates at densities of 100 and 
50 x 10
3
 cells per well, respectively. After 24 hr incubation (i.e. at confluence) 
treatments were started as described below. Protein concentrations were measured as 
described in section 2.2.5. The triglyceride content was assessed as described in 
section 2.2.6.  
 
Protocol 4.2.1: The cells were washed twice with HBSS and then treated with 
Lactate [20 mM], Pyruvate [1 mM], Octanoate [4 mM], NH4CL [4 mM] or LPON 
for 48 hours. The final pyruvate concentration was 2 mM because DMEM medium 
already contained 1 mM sodium pyruvate.  
 
Protocol 4.2.2: The cells were cultured in IT-supplemented medium after 24 hours 
of plating. After 24 hours, cells were washed twice with HBSS before treatment with 
oleate at [0.25 mM] or [0.5 mM] or palmitate at [0.125 mM] or [0.25 mM] contained 
in IT-supplemented medium for 24 hours.  
 
Protocol 4.2.3: TR1 concentrations were assessed in LPON-loaded versus oleate or 
palmitate-loaded C3A and LX-2 cells as described in protocols 4.2.1 and 4.2.2 
respectively. The intracellular TR1 levels of C3A cells were compared to those of 
LX-2 cells as described in section 2.2.8.  
 
Protocol 4.2.4: The cells were washed twice with HBSS and then treated with lactate 
[20 mM], or pyruvate [1 mM], or octanoate [4 mM] or NH4CL [4 mM] or LPON for 
48 hours. TR1 and GPX1 levels were measured as described in sections 2.2.8 and 







4.3.1 Hypothesis driven experiments 
 
Two models of fat loading C3A and LX-2 cells were explored, namely the LPON 
and oleate/palmitate models. 
 
4.3.1.1 LPON versus oleate/palmitate as a fat loading model: 
 
The intracellular triglyceride accumulation in C3A cells was compared to that in LX-
2 cells using two different models to fat load them. 
 
For LPON-treated cells, the incubation time (48 hours) was chosen based upon 
preliminary experiments showing that 48 hours incubation was optimal to allow 
triglyceride accumulation without affecting cell viability (data not shown). LPON-
treated cells were treated as described in protocol 4.2.1. 
 
Oleate and palmitate were chosen because of their common use as dietary fatty acids. 
Preliminary experiments were done to determine the optimal concentration (see 
appendix (A4.1.1) and incubation period (see appendix A4.1.2) of oleate and 
palmitate. Oleate- and palmitate-treated cells were treated as described in protocol 
4.2.2. 
 
As shown in figure 4.1, the triglyceride level increased in LPON-treated C3A and 
LX-2 cells. While C3A cell triglyceride levels increased by 50 %, LX-2 cells showed 
an approximately 200% increase in triglyceride content. The triglyceride level of 
both C3A and LX-2 cells increased with oleate or palmitate supplementation over 24 
hours. Interestingly, the triglyceride level of palmitate-loaded cells [0.125 mM] was 
significantly (p< 0.001) lower than that of oleate-treated cells [0.25 mM] in both cell 
types.  
 
Although, cells treated with 0.5 mM oleate or palmitate were able to accumulate 
more triglyceride than cells treated with 0.25 mM fatty acid (Fig 4.1), cells showed 
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compromised viability at [0.5 mM] of oleate or palmitate. Since it was necessary to 
maintain a balance of good viability versus fat-loading for these cells it was decided 
to use 0.25 mM oleate and 0.125 mM palmitate in subsequent experiments. 
 
Figure 4.2 shows triglyceride accumulation using the oil red O method where red 
pigment concentrates in the fat droplets. 
 
Further experiments were conducted to show the effect of combined treatments of 
oleate and palmitate. The results indicated that, when various combinations of fatty 
acids were used, triglyceride accumulation was similar to that shown in fig 4.1 (see 
appendix A4.1.3).  
 
 
Further preliminary experiments had shown that C3A and LX-2 cells accumulated 
similar levels of triglyceride after LPON treatment when incubated in IT-
supplemented medium in contrast to 10 %FBS-supplemented medium i.e. in this 
























































































































































Figure 4.1: Triglyceride accumulation in LPON, oleate or palmitate-treated (A) C3A 
and (B) LX-2 cells  C3A and LX-2 cells were incubated for  48 hours in cells treated 
with LPON and 24 hours  in cells treated with oleate or palmitate at the 
concentrations shown. Triglyceride content was measured as described in section 
2.2.6. Data are the mean ± standard error (± SEM) n=3 for both A and B, each 
experiment done in triplicate. * p<0.05, ** p<0.01, *** p<0.001 compared to control 




























Figure 4.2: Fat accumulation in LPON-treated C3A cells  
Oil red O staining of C3A cells treated with LPON for 48 hours was accomplished 
according to the method described in section 2.2.11. Red dots in panel (B) represent 









































4.3.1.2 The effect of LPON, oleate or palmitate treatment on the expression of 
thioredoxin reductase1 (TR1)  
 
The effects of LPON, oleate or palmitate on selenoenzyme expression were 
investigated as described in protocol 4.2.3.   
 
 
As shown in figure 4.3, LPON-loaded C3A and LX-2 cells demonstrated increased 
expression of TR1 concentrations. Clearly, one or more of the LPON components 
may have been responsible for the induction of TR1 (see next section). TR1 levels 
































































































































































Figure 4.3: The effect of LPON, oleate or palmitate treatments on TR1 levels in (A) 
C3A and (B) LX-2 cells. C3A and LX-2 cells were incubated for 48 hours with 
LPON and for 24 hours with either oleate or palmitate at the indicated 
concentrations. Cells were then collected and TR1 levels were assessed as described 
in section 2.2.8. Data represent the mean ± standard error (± SEM) for (A) n=3 and 



















4.3.1.3 The effect of individual LPON components on triglyceride, TR1 level 
and GPX1 activity 
 
To assess which component of LPON was responsible for the triglyceride 
accumulation and TR1 induction protocol 4.2.4 was followed.  
 
As illustrated in figures 4.4, 4.5 and 4.6 octanoate appeared to be the single 
component of LPON responsible for the increased triglyceride concentration, TR1 
concentration and GPX1 activity in both C3A and LX-2 cells. The other components 
individually had little if any effect on triglyceride levels or selenoenzyme expression. 
 
LX-2 cells showed the highest levels of triglyceride accumulation, reaching 125 ± 20 
nmol/mg protein compared to C3A cells which only reached about 90 ± 10 nmol/mg 
protein when treated with LPON. This difference was also observed with octanoate 
treatment. Other components of LPON treatment showed comparable results, with 
little or no effect on triglyceride accumulation.  
 
LX-2 cells showed a different response to C3A cells when TR1 levels were 
compared. However, it was anticipated that the control cells would have higher 
levels of TR1 in LX-2 cells based upon earlier experiments reported in section 3.2.1. 
Higher levels of TR1 were also observed in LX-2 cells treated with LPON (200% of 
the control) compared to C3A cells (only 150% of the control). The same trend 
towards higher TR1 levels in LX2 cells was also observed in octanoate treated cells. 
Other components of LPON appeared to have no effect on TR-1 expression in both 
C3A and LX-2 cells. 
 
Although, higher levels of GPX1 activity were observed in control LX-2 cells 30 ± 2 
mU/mg protein compared to C3A cells 25 ± 2 mU/mg protein, the same percentage 
increase (about 160 % of control cells) was obtained in response to LPON or 
octanoate in both C3A and LX-2 cells. Other components of LPON again did not 
significantly affect the expression of GPX-1 in both C3A and LX-2 cells. 
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Since colleagues in the hepatology research group at Edinburgh Royal Infirmary had 
previously shown that the complete LPON formulation induces insulin resistance (Dr 
Filippi, personal communication), it was decided to continue further experiments 


















































































Figure 4.4: The effect of LPON and its various components on triglyceride content of 
(A) C3A and (B) LX-2. C3A and LX-2 cells were incubated for 48 hours with LPON 
or separately its various components. Cells were then collected and triglyceride 
content assessed as described in section 2.2.6. L=Lactate, P=Pyruvate, O=Octanoate, 
N= ammonium chloride (NH4Cl). Data represent the mean ± standard error (± SEM), 
n=3 for both A and B, each experiment done in triplicate.  * p<0.05, ** p<0.01, 











































































Figure 4.5: The effect of LPON and its various components on TR1 concentrations in 
(A) C3A and (B) LX-2. C3A and LX-2 cells were incubated for 48 hours with LPON 
or its various individual components. Cells were then collected and TR1 assessed as 
described in section 2.2.8. L=Lactate, P=Pyruvate, O=Octanoate, N= NH4Cl). Data 
represent the mean ± standard error (± SEM), n=3 for both A and B, each experiment 





























































































Figure 4.6: The effect of LPON and its various components on GPX1 activity of (A) 
C3A and (B) LX-2. C3A and LX-2 cells were incubated for 48 hours with LPON or 
separately its various components. Cells were then collected and GPX1 assessed as 
described in section 2.2.3.2. L=Lactate, P=Pyruvate, O=Octanoate, N= NH4Cl. Data 
represent the mean ± standard error (± SEM), n=3 for both A and B, each experiment 





























1. Triglyceride accumulation in LX2 or C3A cells can be achieved in vitro by using 
either LPON or oleate treatment. Both treatments could thus be regarded as candidate 
systems for an in vitro model of NAFLD.  
 
2.  LPON-loaded cells showed increased TR1 and GPX1 expression which might 
imply that such cells are under a marked degree of oxidative stress. It appeared that 
the component responsible for this effect in LPON was octanoate suggesting that -
oxidation of the fatty acid might be responsible for the oxidative stress. 
 
3. Oleate treatment produced the greatest degree of fat-loading but the fatty acid 
showed no effect on inducing TR1 or GPX1. This might imply that such cells were 
not under the same degree of oxidative stress as LPON treated cells. This may 





Fatty acids are commonly classified into saturated, e.g., palmitate, (C16:0) and 
octanoate (C8:0), mono-unsaturated, e.g., oleate (c18:1), or poly-unsaturated fatty 
acids, e.g. linoleic acid (C18:2). Palmitate, linoleic acid and oleate also can be 
classified as long-chain fatty acids, while octanoate is classified as a medium chain 
fatty acid.  
 
It is important to recognize that the oxidation and metabolism of  fatty acids  is 
related to their carbon chain length and degree of unsaturation (Pai and Yeh, 1996). 
Octanoate, as a medium chain fatty acid, can enter the hepatic mitochondria 
relatively independently of the acyl-carnitine transport system, and then  undergo β-
oxidation (Miele et al., 2003). Moreover, such medium chain fatty acids are oxidized 
much faster than  longer chain length fatty acids (Leyton et al., 1987). Other 
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evidence is suggestive that short and medium chain fatty acids enhance the 
uncoupling of oxidation in the mitochondria and subsequently provoke marked 
degrees of oxidative stress (Hird and Weidemann, 1966). 
 
Fat-loading and its relationship to insulin resistance and oxidative stress is unclear.  
We chose to use LPON (containing octanoate as a medium chain fatty acid) and 
compare it to a model using longer chain fatty acids alone, namely, oleate and 
palmitate to fat load C3A and LX-2 cells. . As shown in this chapter, LPON 
increased the triglyceride content of both C3A and LX-2 cells. Palmitate was more 
toxic to cells compared to oleate at the same concentration. 
 
Loading cells with oleate [0.25 mM] achieved a higher level of triglyceride 
accumulation as compared to cells exposed to a higher dose of octanoate [4 mM]. 
This would also tend to support other studies (Leyton et al., 1987) which suggest that 
oleate, compared to octanoate, needs regulated active transportation to allow it to 
enter the mitochondria (controlled metabolism). Therefore, most of the added oleate 
might eventually be converted to triglyceride and stored in cytoplasm as lipid 
droplets rather than be metabolized in the mitochondria through β-oxidation.  
 
Selenoenzymes are known to be induced in cases where cells  undergo  oxidative  
stress; this is regarded  as a protective mechanism (Moon et al., 2005). Although, 
LPON induced the selenoenzymes TR1 and GPX1 in both C3A and LX-2 cells, 
oleate or palmitate failed to show such an induction.  Dissecting the LPON 
components established that octanoate is the main component responsible for 
triglyceride accumulation, as well as TR1 and GPX1 induction. Octanoate undergoes   
β-oxidation following its unregulated entry into mitochondria. This would markedly 
increase oxidative stress leading to induction of antioxidant enzymes such as TR1 
and GPX1. In contrast, the mitochondrial metabolism of long chain fatty acids, such 
as oleate and palmitate, is controlled through regulation of entry into the organelle 
and, as such, these fatty acids are converted to triglyceride and deposited as lipid 




Initial experiments of LPON-treated cells were done in FBS-supplemented medium 
but subsequently it was shown that this medium could not provide a selenium-
deplete environment (chapter three). Therefore, it was important to confirm that 
LPON-treated cells in IT-supplemented medium (selenium-deficient medium) 
provide similar triglyceride, TR1 and GPX1 levels in as those cells grown in 10% 










































5 CHAPTER FIVE 
 
THE EFFECT OF SELENIUM AND OXIDATIVE 




Oxidative stress is commonly defined as an imbalance in the cell in which oxidant 
production exceeds the cell‟s antioxidant capacity to neutralize these oxidants (Sies, 
1997). This occurs because of either increased production rates of reactive oxygen 
species (ROS) or a decreased capacity of anti-oxidant systems to overcome the 
damaging effect of ROS (Sies, 1997). In turn, the decreased anti-oxidant capacity 
could be the result of either a disturbance of anti-oxidant production or of its 
distribution (Brenneisen et al., 2005).  
 
An overabundance of oxidants may occur from either endogenous or external 
environmental sources. Commonly, ROS are by-products of cellular respiration 
generated by electron leakage from mitochondrial electron carriers during oxidative 
phosphorylation. In normal physiological processes a steady state is maintained 
ensuring a balance between oxidants and anti-oxidants. However, if not properly 
regulated, excess ROS can damage cellular lipids, proteins or DNA leading to a 
disruption of normal cell function and signal transduction pathways (Brenneisen et 
al., 2005).  
 
Oxidative stress contributes to a range of major pathological situations and is thought 
to be involved in many liver disorders including alcoholic liver disease, hepatitis C 
and iron overload. Of particular interest with regard to liver pathology, oxidative 
stress has been implicated in the pathogenesis of NAFLD.  
 
The relationship between hepatic fat accumulation and oxidative damage is poorly 
understood. Steatosis may be due to dysfunction in fatty acid oxidation possibly 
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secondary to an oxidative stress-induced dysfunction of mitochondrial β-oxidation 
leading to the accumulation of fat (Jaeschke et al., 2002; Koteish and Diehl, 2001). 
Various studies suggest that, regardless of the mechanism, the fatty liver phenotype 
itself is also likely to contribute to oxidative stress. The oxidative metabolism of fatty 
acids in steatotic liver leads to increased ROS production and thereby predisposes the 
hepatocytes to oxidative stress (Pessayre et al., 2002). Some reports suggest that fat 
can also be directly  toxic to cells and induce apoptosis in hepatocytes (Schaffer, 
2003). Paradoxically, other studies suggest that fat accumulation has a protective 
rather than a damaging effect on the hepatocyte (Listenberger et al., 2003). The type 
of fat which accumulates in the hepatocytes appears also to modify the hepatocyte 
and its susceptibility to damage by oxidative stress (Ibrahim et al., 1997; Slim et al., 
1996).  
 
In this chapter I investigated the ability of liver cells to resist oxidative damage 
induced by t-butyl hydroxide when the cells were pre-exposed to a range of 
conditions designed to influence fat-loading and selenium status. I selected t-
butylhydroperoxide (t-BuOOH) as the agent to induce oxidative stress in-vitro 
because this agent that  induces oxidative stress in a manner which is similar to that 
induced in vivo by endogenous  lipid hydroperoxides  (Imberti et al., 1993; Masaki et 
al., 1989a). t-BuOOH  also damages mitochondrial and cellular membranes in 
cultured hepatocytes by peroxidation of membrane lipids (Masaki et al., 1989b).  
 
Anti-oxidants neutralize the effects of oxidants and can be categorized as enzymatic 
and non-enzymatic agents according to their mode of action andstructure. They can 
also be classified as preventive, interactive or reparative anti-oxidants according to 
their function (Sies, 1997). Non-enzymatic compounds with direct anti-oxidant 
actions include ascorbate, carotenes, flavonoids, glutathione, and tocopherols. The 
most common anti-oxidant enzymatic defense systems are superoxide dismutases, 
catalase, thioredoxin, thioredoxin reductases, and glutathione peroxidases (Sies, 
1997).  Because micronutrient elements such as selenium, zinc, manganese and 
copper are essential integral elements of many of the enzymes that have anti-oxidants 
action, there is much interest in the supply of these micronutrients in ant-oxidant 
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defense.  (Brenneisen et al., 2005). With specific reference to selenium, TR1, TR2 
and GPX1 are regarded as the most the important anti-oxidant selenoenzymes. 
 
Whether enzymatic or non-enzymatic, an anti-oxidant may have a protective, 
interventional and/or repair role (Sies, 1997). Examples of protective anti-oxidants 
are melanin which protects the skin from ultra-violet rays and cytochrome oxidase, 
which carries out cellular oxygen reduction with minimal release of superoxide or 
other radicals. Metal chelation is an additional major mechanism which limits lipid 
peroxidation and DNA damage (Sies, 1997).  
 
Humans acquire selenium mainly from grains, cereals and meat and an adequate 
supply of the trace element is required to ensure maximal synthesis of 
selenoenzymes (Prabhu et al., 2002). 
 
As I have observed in the previous chapter, selenium supplementation allows TR1 
and GPX1 to be expressed optimally in cultured C3A and LX2 cells. In this chapter I 
investigate whether selenium supplementation could protect cultured hepatocytes and 
stellate cells from an oxidative stress induced by t-BuOOH. In addition, the effect of 
fat-loading cells on their susceptibility to oxidative damage induced by t-BuOOH 























For the experiments in this chapter, C3A and LX-2 cells were seeded and maintained 
in DMEM containing 10 % FBS as described in sections 2.2.1. In order to modify the 
selenium status of the cells they were passaged and re-plated into 35 mm 6-well 
plates at a density of 100,000 cells per well and further culture was in IT medium, 
unless otherwise stated. After 24 hr incubation, treatments were started as described 
below. The LDH contents of cells and collected media were measured as described 
in section 2.2.4 to determine percentage LDH retention as a measure of cell 
damage/viability.  
 
Protocol 5.2.1: One group of cells was pre-treated with selenium [100 nM] for 48 
hours. C3A and LX-2 cells were then exposed to various doses of t-BuOOH (0-1000 
µM) for a further 24 hours. The LDH retention of cells were measured as described 
in section 2.2.4 
 
Protocol 5.2.2: C3A cells were pre-treated with selenium [100 nM], LPON (Lactate 
[20 mM], Pyruvate [1 mM], Octanoate [4 mM], NH4Cl [4 mM]) or selenium plus 
LPON for 48 hours. C3A cells were then exposed to various doses of t-BuOOH 
ranging from a sub-lethal dose of 200 µM rising to a toxic concentration of 1000 µM 
for a further 24 hours. In further experiments, oleate [0.25 mM], either with or 
without selenium [100 nM], was also added for 24 hours as a pre-treatment prior to 
addition of t-BuOOH. (These conditions are based upon results from appendix 
A4.1.2 which showed that an incubation time of 24 hours with oleate treatment was 
sufficient for triglyceride accumulation). 
 
Protocol 5.2.3: C3A cells were pre-treated with either lactate/pyruvate [20 mM] / [1 
mM], octanoate [4 mM], NH4Cl [4 mM], oleate [0.25 mM] plus or minus selenium 
[100 nM] for 48 hours. Various doses of t-BuOOH were added (200µM-3200µM) 




Protocol 5.2.4: C3A cells were pre-treated with either oleate [0.25 mM], octanoate 
[4 mM], LPOleateN (lactate/pyruvate [20 mM] /[1 mM] oleate [0.25 mM], NH4Cl [4 
mM]), or LPON. Experiments were carried out with or without selenium [100 nM] 
for 48 hours. T-BuOOH in various doses was added (200µM-3200µM) for a further 































5.3.1 The protective effect of selenium in C3A and LX-2 cells during t-
BuOOH-induced oxidative stress 
 
A preliminary experiment was conducted to determine the concentration of t-
BuOOH required to induce damage of C3A cells as assessed by LDH release from 
cells. The viability of cells was assessed by monitoring percentage LDH retention in 
these cells. It was concluded that concentrations of t-BuOOH between 0-3200 [µM] 
were able to induce various degrees of damage to C3A cells depending on their 
initial selenium status (data not shown). 
 
 
To investigate any protective effect of selenium on C3A and LX-2 cells undergoing 
t-BuOOH-induced oxidative stress, protocol 5.2.1 was followed.  
  
The susceptibility of both C3A and LX2 cells to damage by t-BuOOH was clearly 
dependent on their selenium status (figure 5.1). Selenium-supplemented LX2 and 




































































Figure 5.1: The effect of selenium on the viability of oxidatively stressed (A) C3A 
and (B) LX-2 cells: Both cell types were pre-treated with or without selenium for 48 
hours. Cells were then exposed to increasing concentrations of t-BuOOH for a 
further 24 hours. Data represent the mean ± standard error (± SEM), n=3 experiments 
for both C3A (A) and LX2 (B) cells. Each experiment was done using triplicate 
wells. * p<0.05, *** p<0.001 significant difference between Se- and Se+ cells. Two-
























5.3.2 The effects of selenium status and fat-loading on C3A cells viability 
during t-BuOOH-induced oxidative stress 
 
To investigate both the effects of selenium status and fat-loading on the ability of 
C3A cells to resist oxidative damage induced by t-BuOOH Protocol 5.2.2 was 
followed.  
 
Oleate was chosen to be part of the pre-treatment because LPON had been shown to 
increase the level of TR1 (see section 4.3.1.2) while oleate-treatment of cells failed 
to affect the level of TR1 suggesting oleate treated cells were not undergoing a 
marked oxidative stress.. It was hypothesized that different fatty acids might have 
different effect on hepatocyte function and their susceptibility to oxidant damage. 
 
As shown in figures 5.2A and figure 5.2B selenium pre-treated cells were highly 
resistant to damage induced by t-BuOOH when compared with selenium deficient 
cells. This protective effect was apparent irrespective of their fat loaded state using 
LPON (figure 5.1A) or oleate (figure 5.1B).  
 
 Panel 5.2C represent a combination of the data given in panel A and B together with 
data from selenium deficient or selenium supplemented cells that had not been 
treated with fatty acids. This allows a comparison of LPON and oleate treatments in 
selenium replete and selenium deficient states. There was no significant (p>0.05) 
effect of either oleate or LPON treatment on the susceptibility of the cells to t-
BuOOH-induced damage; this was true irrespective of the selenium status of the cell. 
However, it should be noted that there was a general trend for LPON and oleate-
treated cells to show more susceptibility to damage by t-BuOOH than cells that were 



































































Figure5.2:  The effect of selenium and fat loading on the viability of C3A cells 
exposed to t-BuOOH 
C3A cells were pre-treated with either (A) LPON for 48 hours (plus or minus 
selenium) (B) oleate for 24 hours (plus or minus selenium) (C) comparison of both 
pre-treatments to control (un-treated) cells. Cells were then exposed to different 
concentrations of t-BuOOH for further 24 hours and LDH retention assessed. Data 
represent the mean ± standard error (± SEM), n=3 experiments each experiment 
being done in triplicate. * p<0.05 compared to selenium deficient cells. Two-way 



















5.3.3 The effect of individual LPON components on C3A cell viability 
undergoing oxidative stress 
 
To determine if any of the LPON components may be harmful to C3A cells, protocol 
5.2.3 was followed. 
 
As shown in figure 5.3A and figure 5.3B there was no significant difference between 
various pre-treatments used irrespective of the selenium status. However, as in figure 
5.2C, there was a general trend for LPON treated cells to be more susceptible to 











































































































Figure 5.3: The effect of individual components of LPON on the viability of 
oxidatively stressed C3A cells in the (A) absence or (B) presence of selenium 
C3A cells were pre-treated with individual components of LPON and oleate in the 
(A) absence or (B) presence of selenium [100 nM] for 48 hours. The cells were then 
exposed to different doses of t-BuOOH for a further 24 hours. The LDH retention of 
cells was then assessed as described in section 2.2.4. Data represent the mean ± 
standard error (± SEM), n=3 experiments for both A and B, each experiment done 





















5.3.4 The effect of a medium combining lactate, pyruvate and 
ammonia with oleate (LPOleateN) on C3A cell viability 
undergoing oxidative stress induced by t-BuOOH. 
 
It was decided to investigate the effect of replacing octanoate with oleate as the fatty 
acid component of LPON.  For this purpose, protocol 5.2.4 was followed.  
 
As shown in figure 5.4A, in the absence of selenium, all pre-treatment regimens 
appeared to have no effect on the susceptibility of cells to t-BuOOH.   
 
When selenium-supplemented cells were used again no significant (p>.0.05) effect of 
any pre-treatment was apparent on cell viability following exposure to t-BuOOH. 
However it seems clear that again a general trend was apparent for each of the 
components of LPON and oleate to increase the susceptibility of these cells to 






































































































Figure 5.4: The effect of fatty acids and LPON on the susceptibility of C3A cells to 
damage from t-BuOOH in (A) absence or (B) presence of selenium. C3A cells were 
pre-treated with either oleate, octanoate, LPON or LPOleateN in the presence or 
absence of selenium [100 nM] for 48 hours. The cells were then exposed to different 
doses of t-BuOOH for a further 24 hours. The percentage LDH retention was then 
assessed as described in section 2.2.4. Data represent the mean ± standard error (± 




























Our findings provide support the following conclusions:- 
 
1. In culture, selenium supplementation can provide hepatocytes with marked 
protection from damage caused by oxidative stress induced by lipid hydroperoxides. 
From the work presented in chapter three, such protection is likely to be due to the 
induction of a range of selenoenzymes with antioxidant action including the families 
of GPX and TR. If this reflects the situation in vivo it suggests that low selenium 
status, possibly arising through relative lack of selenium in the diet, would 
predispose hepatic tissue to oxidative injury in humans.  
 
2. The data presented show that fat loading cells with either oleate or LPON provides 
no protection from oxidative stress induced by t-BuOOH.  
 
3. Whilst there was also no conclusive data to suggest that LPON predisposes cells to 
injury from t-BuOOH, the general trend in all experiments indicated that LPON 




Oxidative stress is a major destructive process involved in the pathogenesis of many 
disorders. The destructive process derives from an array of molecules produced 
during oxidative stress. Different molecules have different potential to damage other 
cellular components. The shorter the half life of a molecule, the more haphazard its 
action and the greater its destructive potential will be. For example, hydroxyl radicals 




and therefore a major destructive 
ability. On the other hand, lipid peroxidation products, such as 4-hydroxy-2,3-
nonenal (HNE) and 4-hydroxy-2,3-alkenals (HAK), have a longer half life and have 
less damaging potential (Parola and Robino, 2001). 
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The consequences of oxidative stress and production of ROS modify the binding of 
ligands to a range of membrane receptors and cause peroxidation of membrane lipids 
and DNA damage (Parola and Robino, 2001). Reports on the effect of mild oxidative 
stress include proteolysis of many proteins and enzymes involved in cell function, 
especially the activities of anti-oxidant enzymes including superoxide dismutase and 
glutathione peroxidases (Grune et al., 1995). Other studies suggest that cells undergo 
apoptosis at intermediate levels of oxidative stress whilst massive oxidative stress 
induces necrosis of the cells (Parola and Robino, 2001). Morphologically, the 
hepatocyte becomes swollen and the mitochondria suffer damage when subjected to 
an oxidative stress(Gonzalez-Flecha et al., 1993) and this is thought to be at least in 
part due to the production of   lipid hydroperoxides. On this basis, t-butyl 
hydroperoxide was used in our experiments because it is a lipid hydroperoxide that is 
widely used as an agent to induce a controlled oxidative stress in cultured cells 
(Imberti et al., 1993). 
Oxidative stress is a major pathogenic factor pathway in liver diseases including 
hepatitis C (Choi and James Ou, 2006). In fatty liver, oxidative stress is considered to 
promote the inflammatory process by enhancing the production and activities of 
chemokines and inflammatory cytokines to recruit infiltrating inflammatory cells 
(Dong et al., 1998).  
The findings of the experiments presented in this chapter demonstrate that in cultured 
hepatocytes (C3A cells) adequate selenium status provides a major protective 
element against oxidative stress induced by lipid hydroperoxides. Moreover, 
selenium can provide significant protection from oxidative stress to both normal and 
fat loaded C3A cells. These beneficial effects of selenium pre-treatment do not 
become apparent unless a prolonged (>24h) pre-treatment period with selenium is 
performed (Rafferty et al., 1998). This is because the ability of selenium to prevent 
oxidative damage requires the synthesis of selenoproteins. For this reason, in our 
experiments, cells were pre-treated with selenium for 48 hours to ensure 




Similar experiments were also conducted on LX-2 cells with findings similar to those 
found in C3A cells. This suggests that selenium-repletion might alleviate the effect 
of oxidative stress in liver tissue regardless of the cell type. This observation is 
important since antagonising the oxidative stress in multiple cells types is one of the 
key issues in protecting hepatic tissues from damage. The relationship between 
oxidative stress and fibrogenesis is complex and not fully understood. Several studies 
suggest that an indirect effect of oxidative stress on hepatocytes and other 
inflammatory cells, such as Kupffer cells and neutrophils, is the main regulator of 
activation of hepatic stellate cells (Giuliana et al., 1998). Other studies claim that 
direct effects of oxidative stress on stellate cells leads to their activation with release 
of collagen and progress to liver fibrosis (Houglum et al., 1997).  
 
It is clear that protecting the hepatocytes from the release of different inflammatory 
cytokines or protecting the stellate cells themselves are both potential mechanisms to 
moderate the fibrotic process. The key issue is the limitation of the fibrotic process in 
both hepatocytes and stellate cells and this is investigated in chapter six.  
 
We were unable to demonstrate any significant effect of fat loading on the ability of 
cells to resist damage by t-BuOOH. However it is worth noting that there was a clear 
trend for LPON-treated cells to be more susceptible to oxidative damage than 
untreated cells irrespective of the cell‟s selenium status.  Further dissection of the 
individual components of LPON revealed that each of the components of LPON may 
predispose cells to damage by t-BuOOH.  
 
A similar but less marked trend was also observed in oleate-treated cells. The failure 
to produce a significant effect of LPON or oleate pre-treatments in our experiments 
was in part due to the poor reproducibility of data between experiments (as illustrated 
by the large SEM of the data points in figures 5.3 and 5.4). Further experiments are 
required to investigate the effects of LPON and oleate on C3A cells, including direct 
measurement of oxidative stress in these systems. These trends might be explained 
by the fact that short chain fatty acids like octanoate can enter the hepatic 
mitochondria relatively independently of the carnitine transport system, and directly 
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undergo β-oxidation (Miele et al., 2003). Moreover, such medium chain fatty acids 
are oxidized much faster than other longer chain length fatty acids (Greenberger et 
al., 1966; Leyton et al., 1987) leading to a greater oxidative stress. Other evidence is 
suggestive that short and medium chain fatty acids enhance the uncoupling of 
oxidation in the mitochondria and subsequently provoke oxidative stress (Hird and 
Weidemann, 1966).  
 
It should be noted however that one study using HepG2 cells loaded with oleate 
and/or palmitate as a model for NAFLD, was unable to demonstrate increased 
oxidative stress following fat-loading (Gomez-Lechon et al., 2007). 
  
Finally the data presented here provide strong evidence for an important antioxidant 
role for selenium in hepatocytes and hepatic stellate cells. If this occurs in vivo it 
suggests that low selenium status, possibly arising through relative lack of selenium 
in the diet, would predispose hepatic tissue to oxidative injury in humans. As such, a 
low selenium status may be a contributory factor to the pathogenesis of both 


























6 CHAPTER SIX 
 
THE EFFECT OF SELENIUM ON α-1 PRO-COLLAGEN 




The hepatic stellate cell (HSC) is a major fibrogenic cell type that contributes to 
collagen accumulation during chronic liver disease. In healthy liver, hepatic stellate 
cells act as a reservoir of vitamin A and are believed to be responsible for the 
maintenance of a steady hepatic blood flow (Kershenobich Stal and Weissbrod, 
2003). The immortalized hepatic stellate cell line, LX-2, was chosen for this study 
because it has retained features of cytokine- and fibrogenesis-signalling which are 
similar to those seen in-vivo. LX-2 cells are thus widely regarded as a suitable model 
for cell culture-based studies that are designed to investigate human hepatic fibrosis 
(Xu et al., 2005). 
 
Various trials have been undertaken to try to inactivate hepatic stellate cells through 
various mechanisms, including apoptosis and causing reversion to an inactive 
phenotype. It is believed that such mechanisms are important in liver regeneration 
and resolution (Issa et al., 2001; Wright et al., 2001). One strategy focused on the 
direct antagonism of fibrosis gene expression by the use of agents such as 
halofuginone which inhibit collagen synthesis (Gnainsky et al., 2004). Other 
strategies have focused on moderating the oxidative stress associated with the 
activation process or relieving the effect of activating cytokines and/or associated 
signaling molecules. One important class of anti-oxidants, namely the 
selenoenzymes, have been largely ignored in relation to the pathogenesis of NAFLD 
and the associated fibrosis. .Selenium is very effective in preventing oxidative stress 
in several tissues (Kim et al., 2004; Santosh et al., 1999) through promoting the 
synthesis of  selenoenzymes (glutathione peroxidases and thioredoxin reductases) 
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that have powerful anti-oxidant functions. In this chapter I have examined the 
possibility that selenium may limit the fibrogenesis in NAFLD. 
 
The mechanism by which α-1 pro-collagen is released by hepatic stellate cells is not 
fully understood. Suggested factors affecting the production of α-1 pro-collagen are 
either a direct action of oxidative stress or stimulation of stellate cells by cytokines 
(released from nearby injured cells) which then can act in a paracrine fashion 
(Svegliati Baroni et al., 1998). In Chapter five it was found that selenium could 
prevent damage caused by oxidative stress both in the hepatocyte C3A cell line and 
the hepatic stellate LX-2 cell line. It was thus of interest to investigate if selenium 
status could modify, fibrogenesis and more specifically the expression of α-1 pro-
collagen in C3A and LX2 cells. To the best of our knowledge, no study has been 
reported on the effect of selenium status on the expression of α-1 pro-collagen. 
 
Although the literature stresses the importance of the hepatic stellate cells in liver 
fibrosis, the cell type(s) responsible for the fibrotic process remains controversial. 
For example, it is possible that the hepatic stellate cells might have a hepatocyte 
origin (epithelial phenotype). Moreover, the transition of epithelial cells to a 
myofibroblasts cell type is a well-described phenomenon in various fibrotic disorders 
in other tissues such as lung (Willis et al., 2006) and kidney (Vongwiwatana et al., 
2005; Zeisberg and Kalluri, 2004).  
 
The aims of the experiments reported in this chapter were  to study the expression of 
α-1 pro-collagen mRNA in both C3A and LX-2 cells and to investigate the effect of 
selenium status, conditioned medium or co-culture with C3A cells on the expression 














General Protocol: For the purpose of experiments reported in this chapter, C3A and 
LX-2 cells were seeded and maintained in DMEM containing 10 % FBS as described 
in section 2.2.1. The cells were passaged and re-plated into 6-well plates at a density 
of 100,000 cells per well. After a 24 hr incubation treatments were started as 




Optimization of the α-1 pro-collagen probe and primer concentrations for analysis on 
Taqman Real-Time PCR was dependent on two principal factors: 
 
1. The concentrations of primers and probe that would give the lowest CT value 
(most  sensitive to  detect low conc. of mRNA)  
2. The concentrations of primers and probe to give the least variance in 
triplicate results (i.e. best precision) 
 
I concluded from preliminary experiments that the best forward primer /reverse 
primer/ probe concentrations were 250/250/100 nM (final concentrations), 
respectively. 
 
Protocol 6.2.1: LX-2 cells were therefore incubated for 24 hours in either 0.2 
%BSA-supplemented medium or IT-supplemented medium. The two sets of cells 
were then treated with TGF-β1 [2.5 ng/ml] for 24 hours and the cellular mRNA 
collected from these cells was quantified as described in section 2.2.10. 
 
Protocol 6.2.2: LX-2 cells were incubated in IT-supplemented medium for 24 hours, 
and then pre-treated with selenium [100nM] or LPON for 48 hours. Tertiary-BuOOH 
[200 µM], TGF-β1 [2.5 ng/ml] and fresh treatments of selenium and LPON were 
then added to the cells for a further 24 hours. The cells were then collected and 




Protocol 6.2.3: C3A cells were incubated in IT medium for a preliminary period of 
24 hours. The cells were then treated with LPON and selenium [100 nM] for 48 
hours. C3A cells were subsequently recharged with fresh treatments of LPON, 
selenium, t-BuOOH [200 µM] and/or oleate [0.25 mM] for a further 24 hours. The 
cells were then washed twice and treated with IT medium for a further 24 hours. 
These various conditioned media from C3A cells were then collected for addition to 
LX-2 cells. TGF-β1 [2.5 ng/ml] and the various conditioned media were added to 
LX-2 cells for a final 24 hours. After this 24 hour period, LX-2 cells were then 
harvested and pro-collagen mRNA extracted and assessed as described in section 
2.2.10.  
 
Protocol 6.2.4: C3A cells were cultured in cell culture inserts and incubated in IT 
medium for a preliminary 24 hour period. The cells were then treated with LPON +/-
selenium [100 nM] for 48 hours before further treatment with IL-8 [500pg/ml], fresh 
amounts of LPON, oleate [0.25 mM] or t-BuOOH [200 µM] +/- selenium [100 nM] 
for a further 24 hours. The cells were then washed twice and treated with IT medium. 
Corresponding wells of LX-2 cells were ready to receive the cell culture inserts from 
the various C3A cell treatments. TGF-β1 [2.5 ng/ml], IL-8 [500pg/ml] and C3A cell 
culture inserts were then added to LX-2 cells for a final 24 hour incubation. LX-2 
cells were then harvested and α-1 pro-collagen mRNA extracted and measured as 
described in section 2.2.10. 
 
Protocol 6.2.5: C3A cells were divided into two groups, one group were cultured in 
IT medium and the second was cultured in ITS for 72 hours. Both groups were 
further divided into subgroups in order to allow treatment with LPON or oleate [0.25 
mM]. After 48 hours treatment, the respective media were replaced to allow 
treatment with TGF- β1 [2.5 ng/ml] for a further 24 hours. The cells were then 









6.3.1 The expression of α-1 pro-collagen mRNA in LX-2 cells: 
 
6.3.1.1 Optimization experiment 
6.3.1.1.1 Comparison of the expression of α-1 pro-collagen mRNA in LX-
2 cells in IT-medium versus 0.2% BSA-supplemented medium 
 
The majority of experiments conducted in this thesis were designed to investigate the 
effects of selenium status. To achieve a selenium-deficient state in cells that 
remained viable it was necessary to use IT medium as described in Chapter 3. Since 
many published studies have used cells cultured with 0.2% BSA rather than IT, a 
first step was to determine if cells grown in IT medium produced measurable 
amounts of α-1 pro-collagen mRNA and also determine if the levels were similar in 
IT versus BSA-treated cells. Also the effects of LPON and selenium addition on α-1 
pro-collagen mRNA were investigated according to protocol 6.2.1.  
 
As shown in figure 6.1, the expression of α-1 pro-collagen mRNA in LX-2 cells was 
similar in both settings (0.2%BSA versus IT-medium). Neither LPON nor selenium 
treatments had any effect on the α1- pro-collagen mRNA levels whether the cells 
were grown in 0.2%BSA-supplemented or IT-supplemented medium.  
 
The treatment of LX-2 cells with TGF-β1 for 24 hours gave a significant two-fold 
increase in expression of α 1-pro-collagen mRNA in both settings. 
 
Further experiments were done comparing shorter incubation period of TGF- β1 but 
it was only when incubated for 24 hours where a significant two-fold increase in 







































































































Figure 6.1: The effect of various treatments on the expression of α1-pro-collagen 
mRNA in (A) cells grown in 0.2% BSA or (B) cells grown in IT medium  
LX-2 cells were pre-treated where indicated with selenium [100 nM] or LPON for 48 
hours. TGF-β1 [2.5 ng/ml] was then added for further 24 hours. Panel A represents 
cells incubated in 0.2%BSA supplemented medium. Panel B represents cells 
incubated in IT supplemented medium. Data are the mean ± standard error (± SEM) 
for three experiments (n=3). Triplicate wells were used for each experiment. * 
p<0.05, ** p<0.01 compared to corresponding controls (CTRL) grown in either 




















6.3.1.2 Hypothesis-driven experiments 
6.3.1.2.1 The effect of selenium and TGF-β1 on the expression of α-1 pro-
collagen mRNA in LX-2 cells pre-treated with LPON or t-
BuOOH  
 
Because the role of oxidative stress in regulating the expression of α-1 pro-collagen 
is somewhat controversial, we investigated the effect of t-BuOOH, an agent known 
to induce oxidative stress, on α-1 pro-collagen mRNA production in LX-2 cells. The 
effect of t-BuOOH was compared with that of selenium and LPON addition 
according to protocol 6.2.2. 
As shown in figure 6.2A, neither selenium nor LPON had any effect on the basal 
expression of α-1 pro-collagen mRNA in LX-2 cells. This confirmed what was 
reported earlier (see figure 6.1). Surprisingly, t-BuOOH-treated cells showed a 
significant decrease in their α-1 pro-collagen mRNA levels, to about 10 % of that 
seen in control cells. Further experiments were done to dissect that effect and are 
shown in the appendix.. It was revealed that t-BuOOH showed a dose-dependent 
inhibition of α-1 pro-collagen mRNA (appendix A6.2.2). Furthermore, this effect of 
t-BuOOH was also observed on gene products that were both related (lysyl oxidase) 
and unrelated (steroid suphatase) to α-1 pro-collagen mRNA expression (appendix 
A6.2.2). 
TGF-β1-treated cells produced a two-fold increase of α-1 pro-collagen mRNA levels 
(figure 6.2B) in control cells but TGF- β1 was unable to initiate a stimulatory 
response on α-1 pro-collagen mRNA in the presence of t-BuOOH. Selenium 
appeared to ameliorate the effect of t-BuOOH, both in the absence (6.2A) or 














































































































































Figure 6.2: The effect of LPON and t-BuOOH pre-treated LX-2 cells on the 
expression of α-1 pro-collagen in the (A) absence or the (B) presence of TGF- β1    
LX-2 cells were pre-treated with selenium [100 nM], LPON for 48 hours. The cells 
were then treated with a sub-lethal dose of t-BuOOH [200 µM], together withTGF-
β1 [2.5 ng/ml] for a further 24 hours. The cells were then collected and assessed as 
described in section 2.2.10. Data are the mean ± standard error (± SEM) of three 
experiments (n=3), each experiment done in triplicate wells. ** p<0.01, *** p<0.001 






















6.3.1.2.2 The effect of conditioned media from C3A cells on the expression of α-
1 pro-collagen mRNA in LX-2 cells 
 
The pathogenesis of NAFLD most likely involves the interaction of different cell 
types. Thus an important mechanistic pathway underlying its pathophysiology may 
involve hepatocyte fat-loading, inflammation and/or injury affecting the activation of 
the hepatic stellate cells by a paracrine action. 
 
Increased expression of α-1 pro-collagen may be dependent on either a direct 
oxidative stress effect on hepatic stellate cells or an indirect one caused by cytokine   
release from adjacent stressed hepatocytes. We thus investigated whether 
conditioned media from C3A cells obtained after various states of fat-loading, 
oxidative stress or selenium treatment had an effect on α-1 pro-collagen mRNA 
levels in LX2 cells according to protocol 6.2.3. 
 
Conditioned medium from C3A cells treated with LPON and oleate had no 
significant effect on the α-1 pro-collagen expression in LX-2 cells (Fig 6.3A). 
Conditioned medium from selenium-supplemented C3A cells produced a small 
(about 25%) but significant (P<0.05) decrease in LX-2 α-1 pro-collagen mRNA 
levels when compared to control (conditioned LX-2 cells). This was true also of 
selenium replete C3A cells treated with oleate. Conditioned medium of selenium-
replete C3A cells treated with LPON or t-BuOOH had no effect on the expression of 


























































































































Figure 6.3: The effect of conditioned media from C3A cells on LX-2 cell expression 
of α-1 pro-collagen in the absence (A) or presence (B) of selenium.  C3A cells were 
treated with LPON, oleate [0.25 mM], t-BuOOH [200 µM] +/- selenium [100 nM] 
for 72 hours. The cells were then treated with fresh IT medium for a final 24 hours. 
The conditioned media were then collected and applied to LX-2 cells. TGF-β1 [2.5 
ng/ml] 24 hour-treated LX-2 cells were used as a positive control. Data represent the 
mean ± standard error (± SEM) of three experiments performed with triplicate 





















The cytokine contents of the conditioned media collected from the C3A cells in 
above experiment was also assessed (see section 6.3.1.2.2). These cytokines included 
TNF-α, IL-12, IL-6, IL-10, IL-1β and IL-8 and were kindly measured by Dr Suzanne 
Mackenzie as described in section 2.2.13 using a commercial cytometric bead assay. 
However, only IL-8 levels were found to be detectable in the culture medium using 
this assay.  
 
As shown in figure 6.4, selenium-treatment of C3A cells decreased the level of IL-8 
by about 50 %. Oleate-treated C3A cells showed an increased IL-8 level (~ 50 %) 
and selenium supplementation was able to reduce the IL-8 concentration in oleate 
treated cells also (~ 10 %).  
 
The effect of further treatments on IL-8 release was tested using t-BuOOH and 
LPON (data not shown). LPON treatment was of no effect on the IL-8 release 
regardless of the selenium status. Intriguingly, in selenium-deficient cells, t-BuOOH 
treatment reduced the IL-8 level by 50 %. Furthermore, t-BuOOH plus selenium 






































Figure 6.4: The effect of selenium status and  oleate loading  on the (IL-8) secretion 
by C3A cells. IL-8 levels of conditioned media from C3A cells treated with oleate 
[0.25 mM] plus or minus selenium [100nM] were assayed using a cytometric beads 
array kit. The experiment shown is a single experiment done in triplicate. * p<0.05, 




























6.3.1.2.3 The effect of co-culture of C3A and LX-2 cells on the LX-2 α-1 
pro-collagen mRNA expression 
 
Because an effect of conditioned medium was not clearly observed in the above 
experiments, it was necessary to conduct an experiment involving co-culture of LX-2 
cells with C3A cells that had previously been either  fat-loaded, treated with 
selenium, t-BuOOH or IL-8. For this purpose, the experiment was conducted 
according to protocol 6.2.4. 
 
As shown in figure 6.5A, only LX-2 cells co-cultured with C3A cells pre-treated 
with either selenium plus oleate or selenium plus t-BuOOH showed a small but 
significant difference compared to control (LX-2 cells not co-cultured). Co-cultured 
selenium deficient C3A cells treated with oleate or t-BuOOH had no significant 
effect on LX-2 α-1 pro-collagen mRNA expression.  
 
As shown in figure 6.5B, IL-8 treatment of LX-2 cells had no effect on α-1 pro-











































































































































Figure 6.5: The effect of co-culture of variously treated C3A cells on the LX-2 cells 
 mRNA expression of α-1 pro-collagen. C3A cells were treated with oleate  
[0.25 mM] or t-BuOOH [200 µM] (panel A), IL-8 [500pg/ml] or LPON (panel B) 
plus or minus selenium [100 nM] for 72 hours. C3A cells were then washed twice and 
cell culture inserts were then applied to LX-2 cells which had been treated with TGF-
β1 [2.5 ng/ml]) and also IL-8 [500 pg/ml] for 24 hours. Data represent the mean ± 
standard error (± SEM) for three experiments (n=3). Triplicate wells were used for 




















6.3.2 Expression of α-1 pro-collagen mRNA in C3A cells 
 
Because the hepatocyte may also be involved in the process of fibrogenesis in the 
healing and regeneration process, α-1 pro-collagen mRNA expression in C3A cells 
was also investigated.  
 
6.3.2.1 The effect of selenium on the TGF-β1-induced α-1 pro-collagen mRNA 
in C3A cells 
 
Preliminary experiments were carried out to determine the responsiveness of C3A 
cells to TGF-β1. It was found that 24 hours of incubation was sufficient to induce α-1 
pro-collagen mRNA expression in C3A cells (see appendix A6.2.3).  
 
Because C3A cells appeared highly responsive with respect to α-1 pro-collagen 
expression upon treatment with TGF-β1, the effect of selenium status on the 
expression of α-1 pro-collagen mRNA in C3A cells was also investigated according 
to protocol 6.2.5.  
 
As shown in figure 6.6, selenium supplementation was very effective (p<0.001) in 
reducing the expression of α-1 pro-collagen mRNA in response to TGF-β 1. This 
effect of selenium was seen in non-fat-loaded and oleate-loaded C3A cells such that. 
α-1 pro-collagen mRNA in selenium-treated cells was approximately only 25% of 
that found in selenium-deficient cells. Although there was a trend for selenium to 
reduce the expression of α-1 pro-collagen mRNA in LPON-loaded C3A cells, this 
did not reach statistical significance.  
 
Following TGF-β1 treatment, LPON plus TGF-β1-cotreated C3A cells had a 
significantly reduced level of α-1 pro-collagen mRNA compared to TGF-β1 treated 
cells that were not fat loaded (p<0.001). The level of α-1 pro-collagen mRNA in 
C3A cells was enhanced in oleate loaded cells compared to non-fat loaded cells 
(p<0.001). Treatment with IL-8 had no effect on the expression of α-1 pro-collagen 





































































Figure 6.6: The effect of selenium status on the expression of α-1 pro-collagen in 
C3A cells. C3A cells were divided into two groups, one being selenium-deficient and 
the second being selenium-replete. After 72 hours, both groups were treated with 
LPON or oleate [0.25mM] for 48 hours. The C3A cells were then treated with TGF-
β1 [2.5 ng/ml], LPON plus TGF-β1 [2.5 ng/ml] or oleate [0.25 mM] plus TGF-β1 
[2.5 ng/ml] for 24 hours. The cells were then collected and assessed for α-1 pro-
collagen mRNA as described in section 2.2.10. Data represent the mean ± standard 
error (± SEM) of three experiments n=3, each experiment done using triplicate wells. 
















6.4 Conclusion and Discussion 
 
Conclusion: 
In conclusion, my research revealed several important points: 
 
1. Neither direct oxidative stress nor indirect oxidative stress (through 
conditioned medium and co-culture) could promote α-1 pro-collagen 
expression in partially activated hepatic LX-2 stellate cells. Indeed, 
paradoxically, induction of oxidative stress via t-BuOOH or LPON treatment 
appeared to diminish the production of α-1 pro-collagen mRNA. LX-2 cells 
are known to be a partially activated cell and may be more than 80% 
activated in normal culture. Thus this cell model may have little reserve for 
any further induction of α-1 pro-collagen mRNA production in response to 
stimulation with a range of activators of fibrogenesis. LX-2 cells might not, 
therefore, be a good model to dissect the pathophysiology of α-1 pro-collagen 
expression in hepatic stellate cells unless a method is found to achieve a more 
quiescent state for these cells. 
 
2. LX-2 cells were responsive to an indirect effect of selenium through the use 
of conditioned medium and co-culture with C3A cells. This effect however 
was very small and is unlikely to represent an important phenomenon in vivo.  
 
3.  In C3A cells, α-1 pro-collagen expression could be induced some 10–fold in 
response to TGF-β1 treatment reaching levels of expression achieved in fully 
activated LX2 cells.  
 
4. Selenium supplementation was able to markedly reduce the expression of the 











In our study, selenium status had no significant effect on α-1 pro-collagen expression 
by LX-2 cells. This would be consistent with the possibility that the LX-2 cells are 
already highly activated and could not be de-activated by reducing the levels of 
oxidative stress following selenium supplementation. Surprisingly the use of t-
BuOOH to induce an oxidative stress down-regulated α-1 pro-collagen mRNA 
production. A possible explanation for this was that the cells‟ viability was 
significantly compromised in the presence of t-BuOOH such that the cells were no 
longer able to synthesise proteins for export (Figure 6.2). 
 
We then investigated if selenium could indirectly exert any effect on α-1 pro-
collagen mRNA production by LX-2 cells through modification of the paracrine 
actions of C3A cells. To investigate this phenomenon, conditioned media from 
control, fat-loaded, oxidatively stressed, or selenium-protected C3A cells were 
applied to LX-2 cells to mimic an in vivo paracrine effect. In this system selenium 
treatment of C3A cells had only a comparatively small effect on α-1 pro-collagen 
mRNA expression, in that selenium diminished α-1 pro-collagen mRNA levels by 
only 25% (figure 6.3).  
 
The cytokine contents of these conditioned media from C3A cells were also 
measured (figure 6.4). Although a number of candidate cytokines were assayed only 
IL-8 was present at detectable levels in these conditioned media. IL-8 is a neutrophil 
chemoattractant involved in provoking the inflammatory process (Joshi-Barve et al., 
2007). Selenium pre-treatment of C3A cells decreased the level of IL-8 of in non-fat-
loaded and oleate-loaded cells. IL-8 levels were unaltered by LPON or t-BuOOH 
treatments. Oleate pre-treated C3A cell produced higher levels of IL-8 compared to 
control cells. These data might suggest that hepatocytes fat-loaded with oleate are 
vulnerable to injury and the release of an inflammatory cytokine which would then 
signal wound repair.  
 
Because certain signals involved in cell to cell communication might be labile or 
transient, experiments involving co-culture of C3A and LX-2 cells were performed 
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to investigate further any possible paracrine actions of C3A cells on LX2 cells.  
These co-culture experiments showed that selenium pre-treatment of C3A cells gave 
a 50% inhibition of the expression of α-1 pro-collagen mRNA in LX-2 cells (Figure 
6.5). Although this effect of selenium on C3A cells was relatively small, this might 
suggest that hepatocytes, when well-protected from oxidative stress through optimal 
expression of selenoenzymes, may either fail to release paracrine factors that 
stimulate α-1 pro-collagen mRNA in LX-2 cells or alternatively selenium-loaded 
cells may secrete paracrine factors that prevent the synthesis of collagen by stellate 
cells.  
 
Although there was a trend for an increased expression of α-1 pro-collagen in LX-2 
cells treated with conditioned medium from C3A cells exposed to IL-8, such 
differences were not statistically significant. However, this might suggest that when 
C3A cells were pre-treated with IL-8, (a known neutrophil chemoattractant and 
inflammatory cytokine) they would release further chemical signals to hepatic 
stellate cells to increase the deposition of collagen. It seems reasonable to 
hypothesise that in cases of inflammation, different signals are released from the 
hepatocytes to induce inflammation and fibrosis. Since IL-8 had no direct effect on 
LX-2 cells this might suggest that IL-8 is not directly involved in the regulation of 
the α-1 pro-collagen but rather connected through inducing hepatocyte inflammation.  
 
There is growing evidence that TGF- β1 is the principal cytokine involved in the 
activation of stellate cells (Sato et al., 2003). In our LX-2 cell model these cells were 
already significantly activated and thus exposure of these cells to TGF-β1 could only 
up-regulate α-1 pro-collagen mRNA two-fold. Indeed, judging from comparison of 
respective real-time PCR cycle times (CT values) of C3A and LX-2 cells, the latter 
could be considered almost fully activated. C3A cells (hepatocytes) were also 
investigated since these cells may represent the epithelial origin of stellate cells. The 
expression of α-1 pro-collagen in the C3A cells was very low (CT values) but when 
treated with TGF-β1, the expression was increased markedly reaching levels similar 
to that found in LX-2 cells (Figure 6.6). These observations suggest that these 
epithelial hepatocytes can be activated and express α-1 pro-collagen to the level of a 
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highly activated hepatic stellate cell. It was of interest that oleate-loaded C3A cells 
gave enhanced production of α-1 pro-collagen mRNA when compared with control 
cells. If hepatocytes contribute to the pathogenesis of fibrosis, our observations are 
consistent with the view that fat-loaded hepatocytes are more fibrogenic than non-
fat-loaded hepatocytes. In contrast to the use of oleate, cells that were fat-loaded with 
LPON showed a diminished production of α-1 pro-collagen mRNA in response to 
TGF-β1. This highlights the importance of using an appropriate in vitro cell model 
for NAFLD. On the other hand, it is also possible that the hepatocytes produce 
collagen as part of the regeneration process to allow anchoring of new cells and 
eventual repair and not necessarily contribute significantly to the pool of hepatic 
stellate cells or liver fibrosis. 
 
In our study selenium supplementation significantly suppressed the expression of α-1 
pro-collagen mRNA in C3A cells in either the basal state, after stimulation with 
TGF-β1 or when fat-loaded with oleate. This effect of selenium is likely to be due to 
the induction of selenoenzymes including TR1 and GPX1 that have antioxidant 
action (Chapter three). This might suggest that these cells, when supplemented with 
selenium, become protected from oxidative stress and in turn prevents the activation 
of the pathways involved in α-1 pro-collagen production in the hepatocyte.  
 
These data provide evidence that selenium is an important protective factor for both 
oxidative stress and fibrogenesis in normal or fat-loaded C3A cells when exposed to 
a potent fibrogenic agent like TGF-β1. However, in the case of LX-2 this effect of 
selenium is difficult to observe given the fact that LX2 cells are already largely 
activated. Therefore, a quiescent phenotype of LX-2 cells might be a better model to 
investigate the factors that modify stellate cell production of α-1 pro-collagen gene 
expression in early stages of liver fibrosis. Selenium pre-treated cells may therefore 
be better protected from oxidative damage and fibrogenesis and limit the progress of 
liver fibrosis. The extent to which selenium contributes to reducing the fibrotic 
response to fat-loading of the liver in vivo merits further investigation, as well as the 
timescale of this protection (i.e. whether protection is early or late, or both, in the 
fibrotic process). With some agents that protect against fibrosis the protection 
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afforded may be limited to the earlier stages of fibrosis. An example of this is  
phosphatidylcholine which is only beneficial in the early stages of fibrosis and has no 
effect on later stages of the disease (Mato et al., 1999).  
 
In conclusion, this chapter highlights the potential ability of selenium to limit 
hepatocyte collagen production following exposure to TGF-β1. Given that 
hepatocytes are ten times more prevalent in the liver than stellate cells the selenium 
status of the hepatocyte may well influence the pathogenesis of fibrosis in NAFLD in 






































7 CHAPTER SEVEN 
  
ASSESSMENT OF SELENIUM AND SELENOENZYMES 






Selenium is an essential trace element for human health through the expression of a 
wide and growing range of selenoproteins which have important anti-oxidant roles. 
The current recommended daily allowance (RDA) for selenium is 75 µg in males and 
60 µg in females (Rayman, 2000). The highest intake of selenium that is regarded as 
being non-toxic is 400µg/day (Navarro-Alarcon and Lopez-Martinez, 2000). In 
subjects ingesting selenium in their diets at doses below the RDA, a strong 
correlation between the plasma selenium and the GPX1 expressed in red blood cells 
is found (Koller et al., 1984). Indeed the RDA for selenium is derived from the daily 
intake of selenium which is required to maximally express GPX1 in red blood cells. 
The plasma selenium concentration needed to optimize the expression of red cell 
GPX is approximately 95 μg/l (range 89–114 μg/l) (Rayman, 2000).  
 
The current average intake of selenium in the UK is in the order of ~30 μg/day 
(Rayman, 1997). The selenium intake in the UK and many parts of Europe has fallen 
over the last thirty years as a consequence of changes in the source of wheat 
consumed in many European countries (Rayman, 2000). Most of the dietary 
selenium consumed in Europe including the UK is in the form of bread and other 
wheat products. Prior to 1970 much of the wheat used in Europe was imported from 
areas of North America that had selenium-rich soil. As a consequence, wheat grown 
in such areas had a high selenium content. Because of this, the average daily intake 
of selenium at this time was in the order of 65 μg/day. However, after members of 
the European Community were encouraged to buy goods from within the Common 
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Market (members of the European community), much of the wheat consumed by 
Europeans had low selenium content because it was grown in areas where the 
selenium content of the soil was low. Currently the average selenium intake in the 
United Kingdom and many parts of Europe is thought to remain at only 
approximately 40% - 50% of the RDA. 
 
Many selenoproteins are enzymes that have antioxidant actions, and contain 
selenium in the form of selenocysteine at the active site. These selenoenzymes are 
involved in redox reactions and are capable of eliminating reactive oxygen species 
(ROS) and products formed during normal respiration. Two of the most important 
families of selenoproteins in this regard are the glutathione peroxidases (GPX) and 
thioredoxin reductases (TR).  
 
Because our hypothesis is that the pathogenesis of NAFLD involves insulin 
resistance and unopposed oxidative stress, the assessments of selenium and 
selenoenzyme status in patients at high risk of developing NAFLD may provide 
indirect evidence that selenium availability may affect the ability to resist oxidative 
stress and aid the development of NAFLD.  
 
Because obesity and type 2 diabetes are known to be risk factors for developing 
NAFLD we investigated if the selenium status of healthy subjects and patients with 
type 2 diabetes was associated with age, BMI, and the waist to hip ratio. 
 
 
The aims of this chapter are: 
 
 
1. To assess the selenium status of patients with type 2 diabetes (with or without 
NAFLD) as determined by plasma selenium concentrations and red cell 
GPX1 and TR1 expression.   










Patients attending the diabetic outpatient department of the Royal Infirmary of 
Edinburgh were considered for inclusion in the study. 
Patients who had any of the following criteria were excluded. 
 Alcohol consumption of more than 21 units weekly 
 Taking any medications that known to cause fatty liver or deranged liver 
function tests (LFTs)  
 Having other causes of fatty liver or abnormal LFT 
 Any co-existing major illness, e.g., malignancy 
 
Blood was collected from these 49 patients and serum, EDTA plasma and red cells 
were stored at –80
0
C until analysed. Normal liver function tests (bilirubin, ALT, 
alkaline phosphatase, gamma glutamyl transferase, albumin) were found in 30 of 
these patients although two of these patients had fatty change of the liver 
demonstrated by the ultrasonography. In the other 19 diabetic patients deranged 
LFTs were found.  
 
Healthy Control Subjects 
Samples were obtained from 133 healthy subjects from two studies. 44 subjects were 
taking part in the SELGEN study organised by the University of Newcastle (Meplan 
et al., 2007). The original purpose of this study was to assess whether genetic 
polymorphisms in the selenoprotein P gene had an effect on selenoprotein 
expression. These samples were collected from healthy volunteers in Newcastle, UK 
aged between 20-60 years old who did not have any cardiovascular, hepatic, 
gastrointestinal or thyroid disease. Also these volunteers were non-smokers, had an 
alcohol intake of less than 30 units/week, were not taking any selenium or 
multivitamin supplements nor on any anti-inflammatory medication (Meplan et al., 
2007). In addition, the healthy control group comprised 89 subjects from Aberdeen 
who were enrolled for a study of the effect of various diets on blood pressure. All 
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control subjects had been taking their “normal” diet prior to being enlisted and 





Selenium levels were kindly measured by Mr Gordon Marr (Combined Laboratories, 
Royal Infirmary of Edinburgh) using atomic absorption spectrophotometry (see 
section 2.2.11). 
 
All liver function tests (bilirubin, alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, albumin and gamma glutamyl transferase) 
were measured in serum using an Olympus 2700 analyser in routine use in the 
Clinical Biochemistry laboratory at the Royal Infirmary of Edinburgh. 
 
The BMI was measured from the height and body weight as follows  




With the co-operation of Professor Hayes group at the Royal Infirmary of Edinburgh, 
the collection of blood samples was carried out  by Dr Ann Lockman from the 
diabetic out-patient clinic and by Mrs Lesley McGregor from the liver out-patient 
clinic. 
 
The study had a full ethical approval. Blood samples were then sent to the clinical 
biochemistry research laboratory where I assessed the TR1 and GPX1 levels. Once 
received in our research lab, they were frozen and stored at –80
0
C until analysed.  
Samples were diluted 350 fold to assess the TR1 as described in section 2.2.8 and 










7.3.1 Plasma selenium concentrations in the healthy group and 
patients with type 2 diabetes mellitus  
 
It was found that 97.5% of the healthy group had plasma selenium concentrations 
which were below the recommended optimal selenium concentration (fig 7.1).  The 
recommended plasma selenium level to maximally express GPX1 is about 95 μg/l 
(range 89-114 μg/l) (Rayman, 2000). These observations are consistent with other 
evidence that indicates the selenium status in the UK is well below the levels needed 
for optimal GPX1 expression in healthy populations. Mean selenium was (63.73 ± 
0.99 µg/l) of all the recruited volunteers.            
 
The mean plasma selenium concentration in patients with type 2 diabetes mellitus  
was 58.81 ± 2.0 µg/l, N=49 which was significantly lower than the concentrations 
found in the healthy subjects 63.73 ± 0.99 µg/l, N=133 (figure 7.1), (p<0.01) (Mann 
Whitney test). The range of selenium concentrations found in the patients was also 
wider than seen in the healthy subjects. 
 














Figure 7.1: The plasma selenium levels in diabetes mellitus patients in comparison 
with healthy subjects (p<0.017). The red line represents the recommended selenium 
concentration to maximally express the GPX1 in red cells. Healthy group, n=133; 
diabetic group, n=49. 
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7.3.2 Correlation of plasma selenium, red cell TR1 and red cell GPX1 




The selenium concentrations were studied further to see if there were any 
associations with the various demographic and measured parameters which included: 
1. Age of the patient 
2. The duration of the diabetes mellitus 
3. Weight 
4. Waist to hip ratio 
5. Blood pressure  
6. Alanine aminotransferase (ALT) 
7. Aspartate aminotransferase (AST) 
8. Alkaline phosphatase (ALP) 
9. AST/ALT ratio 
10. AST/platelets 
11. Gamma glutamyl transferase (GGT) 
12. Bilirubin 
13. Albumin 
14. Fasting glucose 
15. HbA1c 
16. Total cholesterol 
17. Triglyceride level 
18. High density lipoprotein (HDL) 
19. Low density lipoprotein (LDL) 
 
There was no correlation between selenium levels and any of these parameters with 
the exception of BMI.  
 
As shown in figure 7.2A and B, there was a significant negative correlation (Pearson 
correlation) between selenium levels and Body Mass Index (BMI) of the healthy 
group (A) (p<0.0001; Pearson constant (r) =-0.28) and diabetic group (B) (p<0.005;  
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Pearson constant (r) = -0.39). However, there was no correlation between waist to 
hip ratio and the level of selenium in the diabetic group (data not shown, p= 0.1923). 
Waist-hip ratio data were not available for the control group. 
 
 




























Figure 7.2: Negative correlation between BMI and plasma selenium in (A) healthy 
























Correlation of plasma selenium with functional markers of selenium status, red 
cell GPX1 and TR1 in patients with type 2 diabetes mellitus 
 
A significant correlation was found between GPX1 activity in red blood cells and 
plasma selenium levels (Pearson correlation, r = 0.34) (Figure 7.2 A). However, there 
was no significant correlation (Pearson) between plasma selenium and red blood cell 
TR1 level (p= 0.40) (figure 7.2 B)  
  









































Figure 7.3: Correlation of red cell GPX1 activity (A) and red cell TR1 concentration 
(B) with plasma selenium concentrations in patients with type 2 diabetes mellitus. 




















Comparison of selenium status in type 2 diabetes patients with normal LFTs 
with those patients exhibiting abnormal liver function. 
 
Selenium status was compared in patient with abnormal liver function tests compared 
to those whom liver function tests were normal.  
 
As shown in figure 7.4A, there was no significant difference between plasma 
selenium in patients with normal LFTs (59.55 ± 2.67 µg/l, N=30) compared with 
patients exhibiting abnormal liver function (57.64 ± 3.1 µg/l, N=19). There were no 
significant differences between red cell GPX1 in patients with normal LFTs (9452 ± 
45 µg/l, N=30) compared with patients that had abnormal liver function (10040 ± 60 
µg/l, N=19) (figure 7.4 B). Similarly TR1 levels were no significantly different 
between the two groups. TR1 levels in normal LFTs group were (3787 ± 15 µg/l, 

































































Figure 7.4: Comparison of selenium GPX and TR1 levels between normal and 
abnormal LFTs groups of type 2 diabetes mellitus.  (A) Selenium level, (B) GPX1 












In this chapter I have presented data that show obesity leads to a diminution in 
functional selenium status in both plasma and at the tissue level (red blood cells). 
Obesity is a strong risk factor for the development of both insulin resistance and 
NAFLD. Thus the data are consistent with the following hypothesis which has been 
the theme throughout this thesis: namely, obesity leads to insulin resistance resulting 
in mobilisation of fatty acids to the liver where they exert an oxidative stress through 
β-oxidation in the mitochondria. Obesity also leads to a diminution in antioxidants 
including selenoenzymes. This in turn leads to unopposed oxidative stress with 
resultant oxidative damage and release of inflammatory cytokines and other 
chemokines. These chemokines promote steatohepatitis that activates hepatic stellate 
cells and leads to collagen production and fibrosis.  
 
This plausible hypothesis outlines the need for selenium supplementation 
intervention trials in human obese subjects to determine if such an intervention can 
prevent such patients from developing NAFLD. However the doses of selenium used 
for such a trial should be chosen with caution since there is some evidence to suggest 
that supplementing with 200 micrograms of selenium per day increases the risk of 





In our study, both the healthy subjects and patients with type 2 diabetes mellitus had 
plasma selenium levels that were considerably below that required to optimally 
express glutathione peroxidase (GPX) activity in red blood cells (range 89-114 μg/l) 
(Rayman, 2000). This highlights the desirability of selenium supplementation even in 
healthy UK residents. These findings on healthy control subjects confirmed previous 
studies in the UK, which suggest that selenium intake is only 40-50% of the 




In this chapter we have shown that patients with type 2 diabetics have significantly 
lower plasma selenium concentrations as compared to a healthy population. 
Furthermore, type 2 diabetics also have decreased stores of other anti-oxidants 
including GPX1 (Vericel et al., 2004). This would imply that this group of patients is 
more prone to the effect of oxidative stress (the second hit) and that they may be at 
an increased risk of developing NAFLD and particularly its progression from fatty 
liver to NASH and cirrhosis.  
 
The question arises as to whether type 2 diabetes leads to a lower selenium status or 
whether a deficiency in selenium status occurs before the onset of the disease. The 
control population used in this study were derived from the SELGEN study (Meplan 
et al., 2007) and from subjects who were enrolled for a study of the effect of various 
diets on blood pressure in Aberdeen. In these healthy subjects and in the patients 
with diabetes, a significant inverse correlation was found between BMI and plasma 
selenium. Obesity per se thus appears to lead to a diminution in selenium status prior 
to the onset of type 2 diabetes.  
 
In addition, the plasma selenium concentrations in the diabetic patients correlated 
significantly with their red cell GPX activities. This supports the possibility that the 
low plasma selenium concentrations lead to a functional selenium deficiency at the 
tissue level rather than the low plasma selenium being a result of changes in plasma 
selenium binding proteins and an acute phase reaction (Behne et al., 1996).  
    
Why selenium status is inversely correlated with BMI is unclear. Food intake in the 
obese would be high but if calories were predominantly taken as fat then this would 
not provide a suitable dietary source of selenium. Interestingly the use of the waist to 
hip ratio as a measure of obesity showed no inverse correlation with plasma 
selenium. The BMI represents the total body fat in contrast to the waist to hip ratio 
which reflects only the abdominal or visceral fat. The inverse correlation of BMI 
with selenium levels suggests that total body fat of type 2 diabetics is a more 




There was no correlation between TR1 and selenium levels in the type 2 diabetic 
patients despite a positive correlation between GPX1 and selenium being found. This 
is consistent with the hierarchical model of selenoprotein expression where, in 
selenium deficiency, GPX is the most sensitive of the selenoproteins to loss of 
expression in selenium deficiency (Hill et al., 1997a). TR falls above GPX in this 
hierarchy as demonstrated in Chapter three. Thus with the degree of selenium 
deficiency found in the UK, it appears TR1 expression can be maintained at maximal 
levels but GPX expression falls significantly below the maximum possible. 
 
There were no differences in plasma selenium, red cell GPX1 or red cell TR1 levels 
between diabetic patients with normal LFTs and those with abnormal LFTs 
(indicating active pathology of the liver). This observation might arise because LFTs 
do not accurately reflect the severity of liver  pathology given that patients with 
various stages of NAFLD may have normal ALT (Mofrad et al., 2003).  
 
In conclusion, in this chapter I have presented data that show obesity, a strong risk 
factor for the development of NAFLD, leads to a diminution in functional selenium 
status. If oxidative stress is involved in the pathogenesis of NAFLD it seems 
plausible that obesity and low selenium intake in the UK are risk factors for 
development and progression of NAFLD. This plausible hypothesis outlines the need 
for further studies and possibly a selenium supplementation intervention trial to be 
performed in obese subjects to determine if such an intervention can prevent such 
patients from developing NAFLD. However the doses of selenium used for such a 
trial should be chosen with caution since there is now evidence that supplementing 
with 200 micrograms of selenium per day increases the risk of developing type 2 












8 CHAPTER EIGHT 
 






The aim of this thesis was to test the hypothesis that selenium-deficiency is an 
important contributor to the pathogenesis of NAFLD and progression to NASH and 
fibrosis. The rationale for this hypothesis is that an inadequate dietary selenium 
supply (as occurs in the UK population) would lead to poor expression of 
selenoenzymes that have important antioxidant actions. This, in turn, would promote 
unopposed oxidative stress arising from fatty acid metabolism in the mitochondria of 
fat loaded hepatocytes and hepatic stellate cells. Subsequent oxidative damage to the 
hepatocyte and hepatic stellate cell would produce an inflammatory response that 
would activate the stellate cell resulting in the production of fibrogenic proteins. 
 
In order to test this hypothesis it was important to develop fat-loaded cell models that 
were viable in selenium-deficient culture medium. Such cells could then be used to 
assess the effect of selenium supplementation on fatty acid and lipid hydroperoxide 
toxicity, α-1 pro-collagen expression and selenoenzyme expression. 
 
 
Development of selenium-deficient cultured hepatic cell models (Chapter three) 
 
This thesis has established that both C3A and LX-2 cells, representative of human 
hepatocytes and hepatic stellate cells respectively, are capable of expressing key 
selenoenzymes whose expression can be modulated by selenium supply. In chapter 
three, it was revealed that IT-supplemented medium was a suitable selenium 
deficient medium which allowed good cell viability and subsequent induction of 




 To characterize which components of the IT-medium were required for maintenance 
of cell viability the individual components of the IT medium (i.e. insulin and 
transferrin) were evaluated. Transferrin (as a bulk protein) added alone failed to 
improve cell viability in both cell types, even at high concentrations. This suggests 
that C3A and LX-2 cells need more than simply added bulk protein for adequate 
viability. In contrast, insulin was clearly the factor in the IT-supplement which was 
required to maintain cell viability. It is thought that  insulin exerts a mitogenic effects 
on the cells through the expression of the insulin-like growth factor receptor, IGF-1 
receptor (Polychronakos et al., 1991).  ITS-supplement is commonly  used in cell 
culture to provide an ideal serum-free medium since it contains the iron-carrying 
protein (transferrin), growth factor (insulin) and the anti-oxidant factor (selenium) 
(Kisiday et al., 2005). By removing selenium from the ITS supplement we achieved 
cell viability under selenium-free conditions using IT medium alone. 
 
 It is likely that, FBS-supplemented medium contains insulin-like growth factors , 
which provide this growth-promoting function (Giacca et al., 1994) but, as shown in 
chapter three, FBS contains selenium that is accessible by some cell types. This 
makes FBS-containing medium unsuitable for studying the effects of selenium 
deficiency. 
 
 Insulin and transferrin added either singly or in combination, had no effect on the 
expression of TR1. This allowed IT-medium to be used to monitor selenoenzyme 
expression under different incubation conditions, including fat loading or selenium 
supplementation. In particular, selenium supplementation of these cells grown in IT-
medium (by addition of selenite to the medium) resulted in an increased expression 
of the selenoenzymes TR1 and GPX1 when compared with cells grown in insulin 
and transferrin alone (selenium-deficient cells). As these selenoenzymes are 
considered to be important intracellular anti-oxidants, this allowed me to pursue the 
central hypothesis of this thesis using these cell model systems in states of selenium 





Models of fat-loading using different fatty acids (Chapter four)  
 
Fat accumulation in the liver per se is considered by some to be physiological and 
does not necessarily occur following a hepatotoxic insult such as long-term excess 
alcohol intake. In some species, such as migratory birds, fat accumulation in the liver 
is considered a physiological process to help them undertake long journeys using the 
accumulated fat as the main source of energy (Bairlein, 2002; Jansen, 2004). 
Furthermore, a recent study suggests that fat accumulation inside the hepatocyte 
could serve as protective mechanism preventing liver damage following exposure to 
pro-oxidants and inflammatory cytokines (Damelin et al., 2007). One mechanism by 
which fat becomes hepato-protective is by directing fatty acids into  triglycerides 
thereby preventing free fatty acids becoming available for oxidation by the 
mitochondria; this in turn diminishes the accumulation of secondary lipid 
peroxidation products. In contrast, other reports consider fat accumulation in the 
hepatocyte as injurious and impairing the normal function of the hepatocytes (Day, 
2006).  
 
The complex relationship between triglyceride accumulation and cell injury is 
highlighted in a recent study using CHO cells. This study showed that triglyceride 
accumulation in these cells per-se was neither toxic nor made the cells more 
susceptible to injury (Listenberger et al., 2003) . Furthermore, oleate-treated cells 
accumulated triglyceride while palmitate-treated cells showed no accumulation of 
triglyceride. A combination of oleate and palmitate treatment showed some 
triglyceride accumulation. Oleate might therefore facilitate triglyceride 
accumulation, thereby protecting the cells from the apoptotic effect of palmitate 
(Listenberger et al., 2003). It could be therefore argued that these cells accumulate 
triglyceride as a protective mechanism to minimise injury. On the other hand, it is 
possible that after longer-term exposure to fatty acids, the cells have no further 
capacity to safely accumulate triglyceride and subsequent hydrolysis of the 
accumulated triglyceride occurs resulting in oxidation of the released fatty acids 




The more obese a patient is, the greater are the amounts of fatty acids that can be 
mobilized from adipose tissue to the liver following the development of peripheral 
insulin resistance. This large influx of fatty acids can potentially place a huge 
oxidative load on the hepatic mitochondria where the fatty acids undergo -
oxidation.  A secondary consequence of this increased oxidative metabolism 
(oxidative stress) in the mitochondria is the production of high levels of damaging 
lipid peroxides. The huge flux of fatty acids to the liver makes it difficult for the 
hepatocytes to function in a balanced manner and much of this fatty acid entering the 
hepatocyte then becomes esterified and accumulates as stored triglyceride (fat) in the 
cytoplasm. Although insulin resistance had been extensively studied, the mechanism 
of insulin resistance is not a straight forward process and may involve genetic 
polymorphisms and environmental factors that may promote obesity and other 
related diseases (Adams et al., 2005; Ong and Dunger, 2002).  
 
It is important to recognize that the oxidation and metabolism of different fatty acids 
are related to their carbon chain length and degree of unsaturation (Pai and Yeh, 
1996). Octanoate, as a medium chain fatty acid, can freely enter the hepatic 
mitochondria without need of the carnitine transport system. Once in the 
mitochondria octanoate undergoes -oxidation (Miele et al., 2003). Moreover, 
medium chain fatty acids such as octanoate are oxidized much faster than longer 
chain length fatty acids (Greenberger et al., 1966; Leyton et al., 1987). Other 
evidence is suggestive that short and medium chain fatty acids enhance the 
uncoupling of oxidation in the mitochondria and subsequently provoke oxidative 
stress (Hird and Weidemann, 1966).  
 
In contrast to octanoate, the requirement of oleate to enter the mitochondria only via 
the acyl-carnitine transporter allows a mechanism by which mitochondrial oleate 
oxidation is controlled. Therefore excess oleate entering the hepatocyte can be 
diverted to triglyceride rather than being metabolized in the mitochondria through β-
oxidation. Palmitate, a C16 saturated fatty acid, appears to be more toxic to the cell 
than oleate. Palmitate, but not oleate, induces cell death in pancreatic cells (Karaskov 
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et al., 2006). Furthermore, palmitate induces acute injury in the hepatocyte while 
oleate-induced cell damage only after chronic exposure (Gomez-Lechon et al., 2007). 
Other studies also suggest that saturated fatty acids predispose the hepatocytes to 
oxidative stress damage (Wang et al., 2006).  
 
Collectively, it is evident from various studies that different fatty acids have differing 
effects on the susceptibility of a cell to oxidative damage. For this reason two models 
of fat-loading were investigated in chapter four of this thesis, namely cells loaded 
with octanoate (as LPON) and ones loaded with oleate or palmitate. 
 
Under normal culture conditions C3A cells do not accumulate lipid and thus are not 
representative of the fat-loaded hepatocytes seen in vivo in patients with fatty liver. 
However, long-term culture of C3A cells in a medium containing  a cocktail  of 
lactate, pyruvate, octanoate and ammonium ion (LPON) not only increases  the 
functionality of C3A cells but also results  in the accumulation of fat-droplets, as 
visualised by electron microscopy (Filippi et al., 2004). The work presented in 
chapter four confirmed the observations of Filippi et al and also showed that the fat 
droplets were comprised largely of triglyceride and not cholesterol. Both C3A and 
LX-2 cells were successfully fat-loaded using LPON treatment and fat loading led to 
increased levels of TR1 and GPX1, expression, consistent with increased oxidative 
stress, possibly through an un-regulated metabolism of octanoic acid in 
mitochondria.  
 
The second model of fat-loading employed oleate and palmitate treatments and was 
based on an  earlier study describing the fat-loading of HEPG2 cells (Gomez-Lechon 
et al., 2007). Fat-loaded C3A and LX-2 cells after oleate or/and palmitate treatments 
were shown to have higher triglyceride accumulation compared to LPON-treated 
cells. These cells did not demonstrate increased levels of either TR1 or GPX1 
suggesting that this second model of fat-loading did not provoke the same degree of 
oxidative stress as that found in LPON treated cells. This may possible be due to the 
regulated entry of long-chain fatty acids into mitochondria. Because, under normal 
dietary conditions, fatty acids are predominantly ingested as long chain rather than 
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medium chain fatty acids it could be concluded that oleate-loaded cells provide a 
more physiologically relevant model. 
 
Since fat-loaded hepatic stellate cells in-vivo are believed to be quiescent cells, it was 
of value to explore the mechanism of stellate cell activation and its relation to fat  
loss during the process of activation, as this area is unclear. 
 
In chapter four appendix, the ability of LX2 cells to loose their triglyceride in case of 
activation (addition of TGF-β1) was tested. Although, this mechanism has been 
proposed as a hypothesis for activation (Friedman et al., 1993), it could not be 
confirmed in my experiments. This might suggest that the decrease in triglyceride per 
se is not involved in the activation process but rather that a unique cytokine such as  
PDGF is required for activation  (Friedman, 2003). There is very little information 
about the role of retinoids and the relationship of retinoid loss to the activation 
process. Furthermore, LX-2 cells seem to be largely activated cells in-vitro (80% 
activated) and fat loading these already activated cells might not render them 
quiescent. Indeed, fat loading LX2 cells had no effect on α-1 pro-collagen 
expression; implying fat loading had no effect on the activation state of these cells. 
 
 
The effect of selenium status and fat loading on the susceptibility of cultured 
liver cells to damage by oxidative stress induced by lipid hydroperoxides 
(Chapter five) 
Low plasma selenium levels in humans have been associated with many diseases 
including cardiovascular and neurodegenerative diseases (Castano et al., 1997; Kok 
et al., 1985). Selenium deficiency can result in an accumulation of fatty acid 
peroxides in the liver and lead to the formation of ROS products that enhance 
oxidative stress. Cells cultured under selenium-deficient conditions accumulate lipid 
hydroperoxides more rapidly under conditions of oxidative stress than selenium 
sufficient  cells, and die more rapidly (Geiger et al., 1993).  Selenium 
supplementation can prevent oxidative stress and hepatic cell damage induced by  
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lipopolysaccharide (LPS) treatment  (Kim et al., 2004)  and also cell damage induced 
by t-BuOOH treatment of cultured human endothelial cells (Campbell et al., 2007).  
 
The findings presented in chapter five show that selenium was a major protective 
element against oxidative stress induced by t-BuOOH in both C3A and LX2 cells. 
Moreover, selenium could provide this protection when C3A and LX2 cells were fat-
loaded.  Pre-treatment of cells with selenium for 48 hours was required for cells to 
acquire protection, suggestive that synthesis of selenoenzymes was required for 
selenium to exert its protective effect.  
 
The GPX and TR selenoenzymes  are powerful antioxidant enzymes in the cell 
cytoplasm (Sies, 1997). Both enzymes can  catalyses the reduction of a variety of 
hydroperoxides including hydrogen peroxide, t-BuOOH, and fatty acid 
hydroperoxides (Brigelius-Flohe et al., 2003; Rotruck et al., 1973). Several studies 
have shown  that GPX activity is increased in response selenium or to oxidative 
stress (Ibrahim et al., 1997; Kim et al., 2004) and, as shown in chapter four,  LPON 
and octanoate were able to induce these enzymes, though not oleate. 
 
It was not possible to show that LPON-treated cells were more sensitive to oxidative 
damage by t-BuOOH (a commonly used in vitro inducer of oxidative stress) than 
non-fat loaded cells. This was because of the high variability between the three 
experiments in the doses of t-BuOOH required to cause cell damage. However there 
was a clear trend in each individual experiment to show that LPON-treated cells were 
more susceptible to t-BuOOH toxicity than non-fat-loaded cells; this was true 
regardless of the selenium status of the cell. There was no evidence to suggest that 
oleate treatment had any protective or sensitising effect with regard to damage 
induced by t-BuOOH. It can be concluded that selenium can provide C3A and LX2 
cells with marked protection from oxidative stress induced by t-BuOOH and this 
occurs irrespective of whether such cells are fat-loaded. Although not conclusive, the 
data presented in chapter five strongly suggest that octanoate but not oleate induces a 




α-1 pro-collagen expression in C3A and LX-2 cells (Chapter six)   
 
Hepatic stellate cells are normally quiescent and store vitamin A. However, in liver 
injury, they undergo excessive cellular proliferation and transform into a highly 
contractile cell type known as the myofibroblast. The mechanism of hepatic stellate 
cell activation, described in several papers, has two stages: the first or initiation step 
renders the cells responsive to various arrays of cytokines released by nearby 
inflamed cells and the second or perpetuation stage is characterized by a series of 
events which lead eventually to matrix and fibrosis accumulation (Friedman, 2003). 
Different cytokines seems to be responsible for different events which occur during 
activation (Friedman, 2003). The activated phenotype is associated with a reduction 
of lipid droplets, loss of stored vitamin A (Friedman et al., 1993), increased 
proliferation, increased synthesis of collagen and alpha-smooth muscle actin, 
increased contractility and increased deposition of extracellular matrix components, 
including collagen, proteoglycans and adhesive glycoproteins (Friedman, 2000). 
Platelet-derived growth factor (PDGF) is responsible merely for the loss of retinoid 
and it may be a process unrelated to  activation itself (Friedman, 2003). The 
myofibroblasts migrate to the site of hepatic lesions and represent the principal cells 
involved in collagen production before the establishment and progression of hepatic 
fibrosis and cirrhosis.  
Several studies suggest that effects of oxidative stress on hepatocytes and  
inflammatory cells such as  Kupffer cells and neutrophils may be the main drivers of 
stellate cell activation (Giuliana Montosi, 1998). Other studies claim that  oxidative 
stress generated within the stellate cell can activate them and thus promote stellate 
cells  to release collagen, leading to liver fibrosis (Houglum et al., 1997). Most of the 
studies suggestive that oxidative stress could activate stellate cells directly were 
carried out in vivo. 
 
The regulation of α-1 pro-collagen expression in hepatic stellate cells remains 
controversial. Some studies suggest that the direct effect of injury and oxidative 
stress on the hepatic stellate cells is the main regulator of α-1 pro-collagen 
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expression (Lee et al., 2001). Furthermore, one study claimed that rat hepatic stellate 
cells transfected with cytochrome P4502E1 (CYP2E1), an obligatory essential 
producer of reactive oxygen species (ROS), could increase α-1 pro-collagen 
expression 4-fold compared to cells transfected with empty vector (Nieto et al., 
1999). In contrast, other studies indicate that α-1 pro-collagen regulation is related to 
paracrine effects of oxidatively stressed or injured adjacent cells (Svegliati Baroni et 
al., 1998). Paracrine inflammatory cytokines released from oxidatively stressed 
hepatocytes or Kupffer cells might therefore have a major role in the process of the 
activation of hepatic stellate cells (Reeves and Friedman, 2002).  
 
Although many studies suggest that apoptosis or reversion of cell type is the main 
fate of hepatic stellate cells in liver regeneration, it is not clear why these cells 
choose to differentiate one way or the other (Friedman, 2000). Furthermore, the 
regulation of cell reversion is not fully understood. Some studies attempted to drive 
the activated hepatic stellate cells to apoptosis (Issa et al., 2001; Wright et al., 2001). 
Others attempted to reverse the oxidative stress state using anti-oxidants such as 
vitamin E (Agarwal et al., 2005). Vitamin E was also found in inhibit the activation 
of hepatic stellate cells (Naziroglu et al., 1999). In contrast, another study on 
silymarin revealed no effect on the process of hepatic stellate cell activation (Pares et 
al., 1998). 
 
The question as to whether oxidative stress and resulting oxidative damage in LX-2 
or C3A cells might lead to the activation of hepatic stellate cells (i.e., LX-2 cells) 
was addressed in chapter six. We found that neither t-BuOOH, H2O2 nor menadione 
could induce α-1 pro-collagen expression in LX2 cells. This implied that a direct 
oxidative stress could not further affect these already activated stellate cells. 
However surprisingly, we found that t-BuOOH (a known inducer of oxidative stress) 
suppressed α-1 pro-collagen expression. This may be because t-BuOOH might 
induce a programmed cell death whereby the cell shuts down most of its gene 
expression entirely. This view was supported by the suppressive action of t-BuOOH 




As t-BuOOH was clearly inhibiting general gene expression in our LX2 experiments, 
the indirect effect (through conditioned medium and co-culture experiments) of this 
agent was therefore also investigated. Intriguingly, the use of conditioned medium or 
co-culture following t-BuOOH exposure had no effect on α-1 pro-collagen 
expression consistent with a direct toxic action of t-BuOOH on LX2 cells.  
 
In chapter six, cytokine production by C3A cells under a variety of conditions was 
studied. Only changes in IL-8 could be observed with the release of this cytokine 
increased by oleate-loading and diminished by selenium supplementation. Palmitate-
loaded human hepatocytes also release increased amounts  of  IL-8 (Joshi-Barve et 
al., 2007). The mechanism by which the IL-8 is released is believed to be related to 
the activation of nuclear factor kappaB (NF-kappaB) and c-Jun N-terminal 
kinase/activator protein-1 pathways (Joshi-Barve et al., 2007). Other studies also 
suggest that IL-8 is increased in inflamed alcoholic liver (Kershenobich Stal and 
Weissbrod, 2003).  
 
From chapter six, it is evident that conditioned medium and co-culture studies failed 
also to alter α-1 pro-collagen mRNA expression in the LX-2 stellate cell line. Thus 
neither direct nor indirect oxidative stress was found in our study to induce α-1 pro-
collagen mRNA expression in LX-2 cells. We postulate that this most probably arose 
because the LX-2 cells were already activated to a greater level than first believed 
(the original cells were described as „partially‟ activated).  
 
Various studies have indicated that activated hepatic stellate cells are the main 
producers of α-1 pro-collagen in liver fibrosis (Sato et al., 2003; Xu et al., 2005).  
Epithelial to myofibroblast transformation occurs in fibrogensis in various organs 
including kidney (Yang and Liu, 2002) and lung (Burgess et al., 2005; Willis et al., 
2006).Recent studies are also suggestive that this phenomenon could occur in liver 
fibrosis (Diaz et al., 2008; Zeisberg et al., 2007). The major cell type existing in 
healthy liver is the hepatocyte but the hepatic stellate cells become more abundant in 




When α-1 pro-collagen mRNA expression in C3A was investigated, a remarkable 
response of α-1 pro-collagen mRNA expression to TGF-β1 treatment was observed. 
The level of α-1 pro-collagen mRNA expression in TGF-β1-treated C3A cells almost 
reached the level of α-1 pro-collagen mRNA expressed in un-treated LX-2 cells. This 
also implied that C3A cells might have the potential to transform into myofibroblast-
like cells. 
 
Interestingly, selenium was effective in damping α-1 pro-collagen mRNA expression 
in TGF-1-treated C3A cells. This raised the possibility that selenium 
supplementation could be beneficial in the prevention of the transformation process 
and suppress α-1 pro-collagen mRNA expression in hepatocyte cells. In turn, this 
might be translated into a potential reduction in fibrosis associated with 
inflammatory liver disease. The observations given in chapter six are consistent with 
the hypothesis that there is an epithelial to mesenchymal transition in hepatocytes 
(C3A cells) following exposure to TGF-β1. 
 
LPON-treated C3A cells were found to exhibit a much lower level of α-1 pro-
collagen expression than oleate-loaded C3A cells when exposed to TGF-. Indeed 
since oleate-treated C3A cells showed a higher level of α-1 pro-collagen mRNA than 
LPON-treated cells, it might suggest that oleate-loaded C3A cells may be, from this 
one perspective, a better model of fatty liver. 
 
As shown in chapter five pre-treatment of cells with selenium (to optimize the 
expression of selenoenzymes) led to better protection from oxidative stress injury 
compared with cells which were not selenium-supplemented. Although, this seems to 
be the case for both cell types, the effect of selenium supplementation on α-1 pro-
collagen gene expression was more obvious in C3A cells than in LX-2 cells. 
 
Selenium and the UK population (Chapter seven) 
 
There have been a number of reports that highlight the problem of the low selenium 
status of the UK population with results similar to those found in our study. One 
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study of selenium levels in a healthy group of subjects recruited in Scotland found a 
plasma selenium concentration of 61 μg/l in males and  60 μg/l in females  (Shortt et 
al., 1997). In the same report, the authors concluded that only 2.5% of the samples 
collected had an optimum selenium level that would allow maximal expression of 
GPX and hence the possibility of greater protection from oxidant damage. These 
findings have potential significance in respect to cancer incidence and other diseases 
associated with selenium deficiency. A further report observed a low selenium level 
of 69  μg/l in British people aged between 4-18 years (Bates et al., 2002). Of 
relevance are the results from a recent study which found that persistently low 
selenium is associated with an increased risk of developing heart disease and cancer 
(Bleys et al., 2008).  
 
In our study, none of the samples had a selenium level above 130μg/l with most of 
them below falling below 75 μg/l. Furthermore, it is not only the UK population who 
have a  low selenium intake but also those in most of Europe are affected to a greater 
or lesser extent (Rayman, 2000). The average daily intake of selenium in the UK 
does not exceed 40 µg/day while the recommended intakes for males is 75 μg/l and 
55μg/l for females (Shortt et al., 1997). It is apparent that many European diets, 
including the UK diet, currently have an inadequate selenium content. 
 
 
Table 8.1: Selenium intake in the European countries (Rayman, 2000). 
 
This observations support the view that the lower selenium status found in diabetic 
patients is not the result of an acute phase response or diminished hepatic synthesis 
of plasma selenium-binding proteins due to disease. These data would suggest that 
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diabetic patients may benefit from selenium supplementation to optimize their 
antioxidant stores and thus diminish the harmful effects of oxidative stress.  
 
Finally, we found that selenium concentrations in the serum of our patients (type II 
diabetes mellitus) and healthy volunteers groups were well below the recommended 
level that is required to achieve optimal expression of selenoenzymes in tissues 
(chapter seven). Importantly we found that selenium status and the expression of red 
cell GPX1 was inversely proportional to the BMI of the study subjects. This implies 
that, in this UK population, obesity is linked to a diminution in selenium status and 
selenoprotein expression; this in turn may predispose such obese individuals to tissue 
damage from increased oxidative stress. Because obesity also leads to insulin 
resistance, which is a known risk factor for the development of NAFLD, one could 
argue that regimes designed to help patients lose weight and increase their selenium 
intake would be beneficial as regards preventing NAFLD.  
 
Conclusion  
In conclusion, I have shown that it is possible to use C3A and LX2 cells as model 
systems to investigate a potential role for selenium in anti-oxidant protection and in 
modulating the fibrotic response to oxidant injury. Both these cell types can be 
grown under selenium-deficient conditions and the effect of selenium 
supplementation on selenoenzyme expression demonstrated. These same cell types 
can also be fat-loaded using a number of fatty acid substrates and the ability of 
selenium to protect against oxidant damage under different conditions of fat-loading 
can then be studied.  In both cell types, selenium protects against oxidant damage 
caused by fat loading or t-BuOOH treatment. The same model systems were used to 
study α-1 pro-collagen mRNA expression. A novel finding was that C3A cells 
showed α-1 pro-collagen expression to be greatly stimulated by TGF-1 treatment 
(especially in oleate-loaded cells) with an ability of selenium to reduce α-1 pro-
collagen expression. LX2 cells appeared to be already extensively activated, with 
high basal levels of α-1 pro-collagen expression. The studies on diabetic subjects 
confirmed other work that the UK population is relatively selenium-deficient and 
also showed a significant negative association of selenium levels with BMI which 
could have important clinical implications. The work in this thesis raises important 
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questions as to the potential protective effect of selenium on hepatic injury and 




8.2 Future studies  
 
 
Further studies are suggested to pursue different aspects of this thesis, and are as 
follows: 
 
1. Studies on the relationship between α-1 pro-collagen expression in C3A cells 
and their transformation to myofibroblast-like cells should be performed. 
This should be addressed at the protein level to investigate the signalling 
pathways thought to be involved in the cell transformation. The influence of 
selenium on these signalling pathways should also be studied. 
 
2. Investigate the means by which it is possible to convert LX-2 cells to a 
quiescent state. This would allow the model to be used to look at the 
mechanism of activation of stellate cells and determine if selenium status 
could modify this, as is the case for C3A cells. 
 
3. Investigate the mechanism(s) by which t-BuOOH treatment decreases α-1 
pro-collagen expression in both C3A and LX-2 cells in relationship to 
oxidative stress and subsequent selenoenzyme expression. 
 
 
4. Establish a dietary selenium-supplementation trial in an at risk cohort of 
patients with obesity or type 2 diabetes to assess the effect of selenium 
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A3   (Chapter three appendix) 
  




For experiments in this chapter, C3A and LX-2 cells were seeded and maintained in 
DMEM containing 10 % FBS as described in section 2.2.1. The cells were passaged 
and re-plated into two 6-well (35 mm) or 12 well plates for each cell type. After 24 
hr incubation (i.e. at confluence) treatments was started as described below. 
 
Protocol A3.1.1: The medium was changed to a variety of different supplements in 
DMEM for 48 hours, including: 10 % FBS, BSA (ranging from 0-0.75% addition) or 
DMEM with insulin [10 µg/ml] plus transferrin [5 µg/ml]. After incubation for 48 
hours, 0.5 ml of conditioned medium from the wells was collected into a pre-labelled 
2 ml Eppendorff tube and centrifuged at 500 x g for 5 min to remove cells and cell 
debris. The LDH content of the medium was then measured as described in section 
2.2.4 as a measure of cell viability. 
 
Protocol A3.1.2: The medium was changed for a further 48 hours as follows: 10 % 
FBS-supplemented medium (as a positive control of maintenance of cell viability), 
medium with different combinations of added insulin/transferrin [0/0, 2.5/1.25, 5/2.5, 
10/5, 20/10µg/ml]. To assess cell viability, the medium and the cells were collected 
as described in section 2.2.2. LDH assays were carried out on both cells and media 
according to the method described in section 2.2.4 to calculate percentage LDH 
retention as a measure of cell viability. 
 
Protocol A3.1.3: The medium was changed to the following conditions for 48 hours: 
10 % FBS-supplemented DMEM medium (as a positive control to maintain cell 
viability), DMEM medium with insulin added at concentrations over the range0, 2.5, 
5, 10, 20 µg/ml and DMEM medium plus transferrin added over the concentration 
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range0, 1.25, 2.5, 5, µg/ml. Both cells and media were collected and cell viability 
assessed by LDH retention. 
 
Protocol A3.1.4: The medium was changed to the following supplementations: 10 % 
FBS-supplemented DMEM medium (positive control), DMEM medium with added 
transferrin at concentrations ranging from 0, 10, 50, 100, 500 µg/ml for 48 hours. 
 
Protocol A3.1.5: The medium was changed to the following supplementation: 
DMEM medium with added ‘in-house’ IT plus selenium (10 µg/ml (I) /5 µg/ml (T), 
58 nM (selenium)) and commercial ITS (10 µg/ml (I) /5 µg/ml (T), 58 nM 
(selenium)) for 72 hours. After incubation, cells were collected and thioredoxin 
reductase1 protein levels measured as described in sections 2.2.2 and 2.2.8 
































A3.2   Results 
A3.2.1  
A3.2.2  Effect of bovine serum albumin (BSA) supplementation on C3A cell 
viability: 
 
FBS-free medium is commonly supplemented with BSA to help maintain a protein 
balance for tissue culture. Another supplement frequently used to maintain cell 
viability is ITS (Insulin, Transferrin and Selenium). To assess whether either of these 
supplements aided the cell viability in the absence of FBS, protocol A3.1 was 
followed.  
 
The initial experiment was directed at the use of BSA supplementation because of a 
concern that the inclusion of insulin might confound later aspects of the study 
because of its association with fatty liver disease. Various concentrations of BSA 
supplementation were tested while IT was tested at its commercially recommended 
concentrations of insulin [10 µg/ml] plus transferrin [5 µg/ml]. As shown in figure 
A3.1, inclusion of BSA in the absence of IT had a minimal effect on maintaining cell 





































































Figure A3.1: The effect of bovine serum albumin (BSA) plus or minus insulin and 
transferrin on the LDH released from C3A cells. 
C3A cells were plated in FBS-supplemented medium and after 24 hours, medium 
was changed to FBS-supplemented medium, medium (minus FBS) with added BSA 
in various concentrations ranging from (0-0.75%) plus or minus insulin (10 µg/ml) 
and transferrin (5 µg/ml), respectively for 48 hours. Harvested media were assessed 






















A3.2.3 The effect of insulin and transferrin supplementation on the cell viability 
and thioredoxin reductase expression in C3A and LX-2 cells: 
Commercial ITS supplement is frequently used to maintain cell viability when 
serum-deficient medium is required. To assess whether insulin/transferrin alone (no 
BSA) is sufficient to maintain cell viability, preliminary experiments on C3A and 
LX-2 cells were carried out according to protocol A3.1.2.  
 
As shown in figures A3.2B and A3.3B, IT supplementation alone (i.e. without BSA) 
is capable of maintaining the viability of both cell types. However, the effect does 
not appear to alter with the different ratios of I/T used in this experiment. It was 
therefore necessary to determine which of the IT components (and at what 
concentration), was more effective in maintaining cell viability as described in 
protocol A3.1.3.  
 
As shown in figures A3.2C and A3.3C, transferrin had little effect on cell viability, 
whereas, insulin was effective at maintaining cell viability, even at the lowest 
concentration used [2.5 ug/l] (see figure A3.2A). 
  
Further experiments explored whether transferrin in higher doses was more effective 
in maintaining cell viability, as it is commonly believed that a high medium protein 
concentration is necessary to maintain cell membrane viability. Similar experiments 
to those described above were conducted as described in protocol A3.1.4,  
 
Figures A3.2D and A3.3D demonstrate that transferrin added alone at higher doses 
did not facilitate maintenance of cell viability. 
  
At this stage of the investigation, it was important, to verify that IT supplementation 
did not affect the thioredoxin reductase 1 expression. As shown in figures A3.4 and 
A3.5 there was no effect of IT supplementation on the level of thioredoxin reductase 




















































































Figure A3.2: The effect of (A) insulin, (B) insulin plus transferrin, (C) transferrin, 
low concentration range and (D) transferrin, high concentration range on the 
percentage of lactate dehydrogenase activity (%LDH) retained in C3A cells. Cells 
were cultured in FBS-supplemented medium and, after 24 hours, medium was 
changed to FBS-supplemented medium (positive control), medium with added 
insulin (A); medium with a combination of insulin and transferrin (B); medium with 
transferrin with a low (C) or high (D) concentration range. After 48 hours, cells and 
media were collected and assessed for LDH described in section 2.2.4. Data shown is 
for a single experiment with each data point determined with quadruplicate wells 





























































































Figure A3.3: The effect of (A) insulin, (B) insulin plus transferrin, (C) transferrin 
(low concentration range) and (D) transferrin (high concentration range) on the 
percentage lactate dehydrogenase activity (%LDH) retained in LX-2 cells.  The 
experimental conditions were as described for the C3A cells in figure A3.2 (mean ± 






























































































Figure A3.4: The effect of (A) insulin, (B) insulin plus transferrin, (C) transferrin, 
low concentration range and (D) transferrin, high concentration range on thioredoxin 
reductase 1 (TR1) in C3A cells. Cells were cultured in FBS-supplemented medium 
and after 24 hours, medium was changed to FBS-supplemented medium; (A) 
medium with added insulin; (B) combinations of insulin and transferrin; (C) 
transferrin (low concentration range); (D) transferrin (high concentration range). 
Cells were incubated for 48 hours. Data shown are from a single experiment with 
each data point analysed from determinations in quadruplicate wells (mean ± SEM). 
*** p<0.001 compared to 0 concentration of (A) insulin/transferrin, (B) insulin, (C), 












































































Figure A3.5:  The effect of (A) insulin, (B) insulin plus transferrin, (C) transferrin 
(low concentration range) and (D) transferrin (high concentration range) on 
thioredoxin reductase 1 (TR1) levels in LX-2 cells. The experimental conditions 
were as described in Figure A3.4. Data shown are from a single experiment with 
each data point arising from quadruplicate determinations (mean ± SEM). *** 
p<0.001, ** p<0.01 compared to 0 concentration of (A) insulin/transferrin, (B) 








A3.2.4 Comparison of the ‘in-house’ IT plus selenium with commercially 
sourced ITS: 
 
This experiment was conducted to compare the effect of ‘in-house’ prepared IT 
supplementation (with and without selenium) with commercially obtained ITS on 
TR1 expression according to protocol A3.1.5.   
 
As shown in figure A3.6, for C3A cells no significant difference in thioredoxin 

















































Figure A3.6: Comparison between the commercially available ITS supplement and 
IT plus selenium prepared ‘in house’. 
C3A cells were plated in DMEM medium containing 10 % FBS. After 24 hours, 
different supplements (as shown on the graph) were added for 72 hours. Cells were 
then harvested. TR1 level was measured as described.  IT+ Se refers to the ‘in-house’ 
selenium supplemented IT medium, while ITS refers to the commercially available 
supplement. This experiment was done once (each data point determined using 



























A4  (Chapter four appendix) 
 
A4.1   Methods 
 
General protocol: For experiments in this chapter, C3A and LX-2 cells were seeded 
and maintained in DMEM containing 10 % FBS as described in section 2.2.1. After 
24 hr incubation (i.e. at confluence) treatments was started as described below. 
 
 
Protocol A4.1.1: The cells were treated with oleate or palmitate at various 
concentrations [2 mM], [1 mM] or [0.5 mM] and then cultured for 24 hours. The 
percentage LDH retained was measured as described in section 2.2.4.   
 
Protocol A4.1.2: The medium was changed to IT-supplemented medium for a 
further 24 hours. Cells were then washed twice with HBSS before treatment with 
oleate [0.25 mM] or palmitate [0.125 mM] contained in IT-supplemented medium 
for different incubation periods of 24, 48 or 72 hours. Cells were then collected and 
triglyceride content assessed as described in section 2.2.6.  
 
Protocol A4.1.3: The medium was changed to IT-supplemented medium after 24 
hours of plating for a further 24 hours. Cells were washed twice with HBSS and then 
treated for 24 hours with combination of oleate/palmitate (2/1) ([0.166 mM]/[0.083 
mM]) and ([0.33 mM]/[0.166 mM]) at a total fatty acid concentration of [0.25 mM] 
and [0.5 mM] respectively contained in IT-supplemented medium. Cells were 
collected and their triglyceride content assessed as described in section 2.2.6.   
 
Protocol A4.1.4: The medium was changed to an IT-supplemented medium for 
further 24 hours. Cells were then washed twice with HBSS before treatment with 
lactate [20 mM], pyruvate [1 mM], octanoate [4 mM] or NH4Cl [4 mM] or LPON 
supplemented-IT medium for 48 hours. Cells were then collected and triglyceride 
content assessed as described in section 2.2.6. TR1 levels were assessed as described 
in section 2.2.8. GPX1 activity was assayed as described in section 2.2.3.2.   
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Protocol A4.1.5: The medium was changed to IT-supplemented medium (for 24 
hours) 24 hours after initial plating. Cells were then washed twice with HBSS 
followed by treatment with either oleate [0.25 mM] or palmitate [0.125 mM] for 24 
hours, or LPON for 48 hours. All treatments were in IT-supplemented medium. Cells 
were then collected and cholesterol content assessed as described in section 2.2.7. 
 
Protocol A4.1.6: The cells received IT-medium for 24 hours. After that, two groups 
of LX-2 cells were treated with oleate [0.25 mM] in IT-medium for 24 hours. Both 
groups of cells were then washed twice with HBSS and then one group was treated 
with TGF-β1 [2.5 ng/ml] for a further 24 hours in IT. The other group of cells 
(oleate-loaded cells only - as a positive control) received IT-supplemented medium 
for further 24 hours. Control cells also received IT-supplemented medium that was 
changed every 24 hours.  
 
Protocol A4.1.7: The corresponding experiment was conducted in the reverse order 
when cells were first treated by TGF-β1 [2.5 ng/ml] for 24 hours. 24 hours later, cells 
were treated with oleate [0.25 mM] for a further 24 hours. Control cells and oleate-
loaded cells were included, where control cells received IT-supplemented medium 
that was changed every 24 hours. Oleate-loaded cells received IT-supplemented 
medium for the first 24 hours followed by treatment with oleate [0.25 mM] for 24 
hours.  
 
Protocol A4.1.8: LX-2 cells were treated with both oleate [0.25 mM] and TGF-β1 
[2.5 ng/ml] simultaneously for 24 hours. Control cells and oleate-loaded cells were 
included, control cells receiving IT-supplemented medium that was changed every 
24 hours. Oleate-loaded cells were treated with oleate [0.25 mM] for 24 hours. Cells 
were washed twice with HBSS and then triglyceride content was assessed as 





A4.1.1  The effect of oleate and palmitate treatment on cell viability 
 
To determine the optimal dose of oleate or palmitate that could induce significant 
triglyceride accumulation in C3A and LX-2 cells without affecting their viability, 
protocol A4.1.1 was conducted.  
 
As shown in figure A4.1, both C3A and LX-2 cells were unable to survive at 
concentrations of 2 mM oleate. Unlike the C3A cells, LX-2 cells were able to 
accommodate 1 mM oleate. Although, 0.5 mM oleate appeared not to affect cell 
viability, it was decided that further experiments would be carried out using lower 
concentration of the fatty acid.  
 
As shown in figure A4.2, palmitate-loaded cells showed compromised viability with 
0.5 mM fatty acid addition. Thus, on a molar basis, palmitate is more toxic than 
oleate and may exert more acute injury to cells. This is in agreement with the 
findings of Gomez-Lechon et al (Gomez-Lechon et al., 2007). 
 
LX-2 cells appear to be more resistant to oleate and palmitate than C3A cells. 
Although, 1mM oleate or palmitate seems to be a toxic dose for C3A cells, this 
concentration had little effect on the viability of LX-2 cells. Both cell types were not 
able to survive at 2 mM oleate or palmitate. 
 
In subsequent experiments, 0.5mM and lower concentrations of oleate and 0.25 mM 





























































Figure A4.1:  The effect of oleate on the viability of (A) C3A and (B) LX-2. 
C3A and LX-2 cells were incubated with oleate at various concentrations for 24 
hours. Cells were harvested and media collected to assess the %LDH activity 
retained by cells. Data shown represent a single experiment carried out using 
triplicate wells (mean ± SEM). ** p<0.01, *** p<0.001 compared to 0 concentration 




















































































Figure A4.2:  The effect of palmitate on the viability of (A) C3A and (B) LX-2. 
C3A and LX-2 cells were incubated with palmitate at various concentrations for 24 
hours. Cells were harvested and media were collected to assess the %LDH activity 
retained in the cells. Data shown represent a single experiment conducted using 
triplicate wells (mean ± SEM). * p<0.05, ** p<0.01, *** p<0.001 compared to 0 




























A4.1.2  The effect of varying incubation time on oleate or palmitate fat-loading 
 
To further investigate and determine the optimal incubation period to observe 
triglyceride accumulation, protocol A4.1.2 was followed.  
 
As shown in figure A4.3, the maximal triglyceride accumulation in C3A and LX-2 













































































































































































Figure A4.3: Effect of incubation time on (A) C3A and (B) LX-2 after exposure to 
oleate or palmitate. C3A and LX-2 cells were incubated with either oleate [0.25 mM] 
or palmitate [0.125 mM] for 24, 48 or 72 hours. Cells were then harvested and 
triglyceride content was assessed as described in section 2.2.6. Data represent the 
mean ± standard error (± SEM) n=3 for both A and B, each experiment done in 






























The effect on triglyceride accumulation of the addition of both oleate and palmitate 
was also studied. The experiment was conducted as described in protocol A4.1.3.  
 
As shown in figure A4.4, both C3A and LX-2 responded to the addition of the fatty 
acid combination of oleate/palmitate (2/1) by accumulating triglyceride in a degree 
related to the total concentration of the supplemented fatty acids. Oleate was chosen 
to comprise two thirds of the final concentration of the combination because oleate 
was found to have less adverse effect on cell viability as compared to palmitate. 
Moreover, palmitate was claimed to induce acute injury whereas oleate treated cells 
















































































































Figure A4.4: Triglyceride content of (A) C3A and (B) LX-2  
C3A and LX-2 cells were incubated with combinations of oleate/palmitate (2/1) at a 
total concentrations of  [0.25 mM]/ [0.5 mM], respectively, contained in IT-
supplemented medium for 24 hours. Cells were then collected and triglyceride 
content was assessed according to the method described in section 2.2.6. Data 
represent the mean (± SEM) n=3 for both A and B, with each experiment done in 


























A4.1.4   Effect of LPON treatment of C3A and LX-2 cells in FBS- or IT-
supplemented medium 
 
After a suitable selenium-deficient medium was identified (i.e. IT-supplemented 
medium), it was important to examine the effect of marked selenium deprivation on 
triglyceride accumulation and selenoenzyme expression. For this purpose, protocol 
A4.1.4 was conducted.  
 
As illustrated in figures A4.5, A4.6 and A4.7, the triglyceride accumulation could be 
achieved in selenium-deficient medium (IT-medium). The triglyceride level was 
similar to the level obtained when these experiments were done in selenium replete 
(10% FBS-supplemented medium)( see figures 4.4, 4.5 and 4.6). This was true for 
both LX2 and C3A cells. This suggests that IT-supplemented medium could be used 
instead of FBS-supplemented medium when a fat-loading cell in a completely 
selenium-deficient environment is required, but without any compromise of cell 
viability.  
 
When comparing experiments done in selenium-deficient condition with the 
selenium-replete setting, the triglyceride levels of the control cells were very similar 
(25 ± 5 and  30 ± 5 nmole/mg protein, respectively). The triglyceride levels of cells 
treated with LPON or octanoate showed lower levels of triglyceride in a selenium 
deficient setting (reducing from 90 ± 6 to 65 ± 7 nmole/mg protein for C3A cells and 
from125 ± 5 to 55 ± 8 nmole/mg protein for LX-2 cells). Other components of 
LPON were not significantly different to control cells for both C3A and LX-2 cells. 
 
The TR1 levels (as expected) were lower in control cells grown in IT-medium 
compared to cells grown in 10 % FBS supplemented medium (reducing from 95 ± 6 
to 60 ± 10 ng/mg protein (C3A cells) and from 180 ± 12 to  85 ± 8 ng/mg protein 
(LX-2 cells). The TR1 response to LPON or octanoate was also different in a 
selenium-deficient setting compared to a selenium-replete condition, reducing from 
about 150 % to about 160 % of control cells for C3A cells and from about 200 % to 
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about 134% for LX-2 cells. Lactate/pyruvate or ammonium components of LPON 
were not significantly different to control cells in both C3A and LX-2 cells. 
 
The GPX1 level (also as expected) were lower in control cells grown in selenium 
deficient conditions compared to cells grown under selenium replete conditions 
(reducing from  25 ± 4 to 2.5 ± 0.2 mU/mg protein for C3A cells and from  30 ± 5 to 
2.5 ± 0.3 mU/mg protein for LX-2 cells). Although, lower levels of GPX1 were 
observed in all treatments compared to the selenium replete situation, the GPX1 
response to LPON or octanoate was higher compared to selenium-repletion condition 
(increasing by about 160% in selenium replete conditions as compared to 480% in 
selenium deficiency for C3A cells and from about 160% in selenium replete 
conditions to about 370% in selenium deplete conditions for LX-2 cells this is 
confused). Lactate/pyruvate or ammonium components of LPON were not 









































































Figure A4.5: The effect of LPON and its separate components on triglyceride content 
of (A) C3A and (B) LX-2 in IT-supplemented medium. C3A and LX-2 cells were 
pre-incubated in IT-supplemented medium for 24 hours. Cells were then incubated 
for 48 hours with LPON and its separate components (contained in IT-supplemented 
medium). Cells were then collected and triglyceride content assessed as described in 
section 2.2.6. Data represent one experiment done in triplicate. L=Lactate, 
P=Pyruvate, O=Octanoate, N= ammonium chloride (NH4CL). Data represent the 
mean ± standard error (± SEM), ** p<0.01, *** p<0.001 compared to CTRL (no 









































































Figure A4.6: The effect of LPON and its various components on TR1 levels  in IT-
supplemented media setting of (A) C3A and (B) LX-2. C3A and LX-2 cells were 
pre-incubated in IT-supplemented medium for 24 hours. Cells were then incubated 
for 48 hours with LPON or its separate components (contained in IT-supplemented 
medium). Cells were then collected and TR1 assessed as described in section 2.2.8. 
Data represent one experiment done in triplicate. L=Lactate, P=Pyruvate, 
O=Octanoate, N= ammonium chloride (NH4CL). Data represent the mean ± standard 
error (± SEM) for 3 wells, ** p<0.01, *** p<0.001 compared CTRL (no addition of 






















































































Figure A4.7: The effect of LPON and its various components on GPX1 activity of 
(A) C3A and (B) LX-2 in IT-supplemented medium. C3A and LX-2 cells were pre-
incubated in IT-supplemented medium for 24 hours. Cells were then incubated for 48 
hours with LPON or its separate components (contained in IT-supplemented 
medium). Cells were then collected and GPX1 assessed as described in section 
2.2.3.2. Data represent one experiment done in triplicate. L=Lactate, P=Pyruvate, 
O=Octanoate, N= ammonium chloride (NH4CL). Data represent the mean ± standard 






















A4.1.5   Cholesterol levels of fat-loaded cells  
 
To further explore the composition of lipid accumulated in C3A and LX-2 cells after 
treatment with LPON, oleate or palmitate, a pilot experiment was conducted 
according to protocol A4.1.5.  
 
As shown in figure A4.8, the cholesterol content of cells did not change in contrast to 
their cellular triglyceride content.  
 
 
This suggests that the lipids accumulating in LX-2 cells were mainly triglyceride 









































Figure A4.8: Cholesterol content of LX-2 cells treated with various fatty acids. 
LX-2 cells were incubated with oleate or palmitate for 24 hours and LPON for 48 
hours. Cells were then collected and their cholesterol content assessed according to 





























A4.1.6  Loss of fat by TGF-β1-activated stellate cells 
 
Hepatic stellate cells are normally quiescent and store vitamin A. However, in liver 
injury, they undergo increased cellular proliferation and phenotypically transform 
into a highly contractile cell type known as the myofibroblast. The activated 
phenotype is associated with loss of stored vitamin A (Friedman et al., 1993), 
increased synthesis of collagen and alpha-smooth muscle actin, increased 
contractility and increased deposition of extracellular matrix components (Friedman, 
2000). Because LX-2 cells could be successfully fat-loaded, we proceeded to 
examine whether fat-loaded LX-2 cells might exhibit the loss of these fat droplets 
upon activation, as seen in vivo.   
 
A4.1.6.1 The effect of TGF-β1 on the triglyceride content of normal and fat-
loaded LX-2 cells: 
 
Because the mechanism of stellate cell activation is poorly understood, I explored the 
activation process in relation to fat droplet loss, in three ways. Firstly, LX-2 cells 
were fat-loaded (perhaps achieving a quiescent status) and then cells were treated 
with the potent stellate cell activator cytokine, TGF-β1. Secondly, LX-2 cells were 
initially activated by TGF-β1, and then fat-loaded. Thirdly, LX-2 cells were 
simultaneously fat-loaded and treated with TGF-β1 for 24 hours according to 
protocols A4.1.6, A4.1.7 and A4.1.8 respectively. 
 
Since oleate was less toxic and accumulated relatively more triglyceride than 
palmitate (see sections A4.1.2), oleate was chosen to fat-load hepatic stellate cells in 
these experiments.  
 
As shown in figure A4.9, there was no change in the triglyceride content of LX-2 






Further experiments were conducted in various different ways to try to demonstrate a 
loss of fat upon activation. Different fatty acids were used such as octanoate, 
palmitate and retinol, as well as different doses of TGF-β1 with concentration as high 
as [20 ng/ml]. Different incubation times with TGF-β1, ranging from 4, 8, 24, 48 
hours, were also selected.  
 
None of these experiments showed any evidence of loss of fat droplet in LX-2 cells 

























































































Figure A4.9: The effect of TGF-β1 on the triglyceride levels of control and fat-
loaded LX-2   (A) LX-2 cells were fat-loaded with oleate [0.25mM] for 24 hours. 
TGF-β1 [2.5 ng/ml] were then added in the corresponding wells for another 24 
hours. (B) LX-2 cells were treated with TGF- β1 [2.5 ng/ml] for 24 hours and then 
cells were washed and treated with oleate [0.25mM] for 24 hours. (C) In this setting, 
both oleate [0.25mM] and TGF- β1 [2.5 ng/ml] were added at the same time for 24 





















A6   (Chapter six appendix) 
 
A6.1   Methods 
 
General protocol: For experiments in this chapter, C3A and LX-2 cells were seeded 
and maintained in DMEM containing 10 % FBS as described in section 2.2.1. After 
24 hr incubation (i.e. at confluence) treatments was started as described below. α-1 
Pro-collagen mRNA was measured as described in section 2.2.10. 
 
 
Protocol A6.1.1: LX-2 cells were incubated in IT medium for 24 hours before 
treatment with TGF-β1 [2.5 ng/ml]. The α-1 pro-collagen mRNA production in these 
cells exposed to TGF-β1 was then measured at 4, 8 and 20 hours to follow the time 
course of its effect.  
 
Protocol A6.1.2: LX-2 cells were treated with various doses of t-BuOOH [0, 5, 10, 
50, 100, 200 µM] for 24 hours and mRNA expression of α-1 pro-collagen, lysyl 
oxidase (LOX) and steroid sulphatase (STS) was assessed.  
  
Protocol A6.1.3: C3A cells were incubated in IT medium for 24 hours prior to 














A6.2  Results  
 
 
A6.2.1  The temporal effect of TGF-β1 treatment on α-1 pro-
collagen mRNA in LX-2 cells:   
 
 
Because TGF-β1 is an important cytokine and can have a rapid effect within 4 hours 
on many cells, experiment was conducted according to protocol A6.1.1. 
 
As shown in figure A6.1, the expression of α-1 pro-collagen mRNA in LX-2 cells 
showed a significant two-fold increase, but this required a 20 hour treatment period. 
 
 





































Figure A6.1: The temporal effect of TGF-β1 on the expression of α-1 pro-collagen 
mRNA in LX-2 cells LX-2 cells were treated with TGF-β1 [2.5 ng/ml] for 0, 4, 8 and 
24 hours. The cells were then collected to measure the α-1 pro-collagen mRNA 
levels. Data are the mean ± standard error (± SEM) for three experiments (n=3), each 




A6.2.2  Dose response of t-BuOOH treatment on other LX-2 gene 
products (lysyl oxidase, steroid suphatase) 
 
Because t-BuOOH decreased the level of α-1 pro-collagen mRNA expression, it was 
essential to explore further this effect by clarifying whether this effect was specific to 
the expression of α-1 pro-collagen or an effect on other collagen pathway genes (e.g. 
lysyl oxidase), or a general effect which extended to non-collagen pathway genes 
(e.g. steroid sulphatase). For this purpose, an experiment was conducted according to 
protocol A6.1.2. 
 Lysyl oxidase (LOX) is a gene that expresses a copper-dependent protein that is 
involved in the cross-linking of collagens and elastin. Furthermore, LOX is increased 
in many fibrotic diseases (Smith-Mungo and Kagan, 1998).  
Steroid sulfatase (STS) is responsible for the regulation of the formation of 
biologically active steroids. The enzyme has a pivotal role in hormone-dependent 
tumours including breast and prostate cancers and is found to be at increased levels 
in aggressive tumours and indeed is of prognostic value in these pathologies (Reed et 
al., 2005). STS has no link with collagen synthesis. 
As shown in figure A6.2, t-BuOOH decreased the level of α-1 pro-collagen mRNA 
expressed by LX-2 cells in a clear dose-dependent manner. A concentration of 100 
µM t-BuOOH decreased the mRNA level by about 60-70% while 200µM t-BuOOH 
decreased the mRNA level by 80-90%. Notably, no significant enhancement of α-1 












































Figure A6.2: the dose-dependant effect of t-BuOOH on the expression of α-1 pro-
collagen.  LX-2 cells were treated with various doses of t-BuOOH [0-200 µM] for 24 
hours. The cells were then collected and assessed as described in section 2.2.10. Data 
are the mean ± standard error (± SEM) from three experiments (n=3), each 
experiment done using triplicate well. * p<0.05, ** p<0.01 compared to CTRL (0 
concentration of t-BuOOH). 
 
 
As shown in figure A6.3, t-BuOOH significantly inhibited the expression of both 
STS and LOX genes. The inhibition by t-BuOOH on STS and LOX was 65%, 75% 
respectively compared to a 90% inhibition of α-1 pro-collagen gene expression. It 
was therefore concluded that t-BuOOH treatment affected the level of expression of 
a number of genes both within and outwith the collagen pathways.  
 
Because t-BuOOH appeared to be a non-specific inhibitor of gene expression, it was 
necessary to establish whether other inducers of oxidative stress such as H2O2 and 
menadione also affected α-1 pro-collagen expression. However, neither H2O2 nor 
menadione affected α-1 pro-collagen expression in LX-2 cells (data not shown),  

































































Figure A6.3: The effect of t-BuOOH on the (A) LOX and (B) STS mRNA 
expression LX-2 cells were exposed to t-BuOOH for 24 hours. LOX and STS gene 
expression was then assessed. The graph shown is a single experiment done using 
triplicate wells. * p<0.05, ** p<0.01, *** p<0.001 compared to CTRL (0 





























A6.2.3  The temporal effect of TGF-β1 on α-1 pro-collagen mRNA in C3A 
cells: 
 
A pilot experiment to establish α-1 pro-collagen mRNA levels in C3A cells revealed 
that these cells were also responsive to TGF-β1 [2.5 ng/ml] (data not shown). A 
temporal study of the effect of TGF-β1 on C3A α-1 pro-collagen mRNA expression 
was therefore conducted. For this purpose, the experiment was conducted according 
to protocol A6.1.3. 
 
As shown in figure A6.4, the expression of α-1 pro-collagen in C3A cells was 
significantly increased after TGF-β1 treatment reaching up to about 35 fold increase 
after 20 hours of treatment comparing the 20 hr exposure to time 0 hr. 
 
The CT value of the α-1 pro-collagen gene expression on C3A cells after 20 hours of 
TGF-β1 treatment was (30.28 ± 0.53). This was not significantly different from the 

















































Figure A6.4: The temporal effect of TGF-β1 on the expression of α-1 pro-collagen 
mRNA in C3A cells C3A cells were incubated with TGF-β1 [2.5 ng/ml] for 0, 4, 8 
and 20 hours. Cells were then collected to measure the level of α-1 pro-collagen 
mRNA. Data represent the mean ± standard error (± SEM) of three experiments, 
each experiment done using triplicate wells. *** p<0.001 compared to CTRL (0 
time). 
 
 
 
 
 
 
 
 
 
